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ABSTRACT 
 
Antimalarial drugs remain as one of the most powerful tools in the fight against 
malaria with artemisinin derivatives now standing as the cornerstone of anti-
malarial drug therapy. Unfortunately, evidence of delayed in vivo parasite clearance 
after artemisinin treatment is accumulating on the Thai-Cambodian border and in 
nearby countries. A better understanding of the mechanisms of artemisinin (ART) 
resistance may contribute to the development and validation of new tools for the 
surveillance of resistance.  
One promising approach to identifying candidate genetic markers of ART 
resistance is genetic analysis of drug-pressured mutants of the rodent malaria 
parasite Plasmodium chabaudi. This experimental system has identified a number 
of genetic mutations in parasites artificially selected for resistance to ART 
derivatives. These mutations encode alterations in a de-ubiquitinating enzyme 
(UBP-1) and in a 26S proteasome subunit (26SPS), both involved in the 
ubiquitin-proteasome pathway, responsible for protein turnover through selective 
degradation. An additional mutation was found to have occurred in a gene 
encoding the “mu” chain of the AP2 adaptor protein complex, a component of the 
endocytic machinery. 
The importance of the above mentioned markers in modulating susceptibility to 
different drugs in the human malaria parasite remains unclear. In that context, the 
hypothesis to be tested in this thesis is that the three loci implicated in ART 
resistance in experimentally selected in P. chabaudi will similarly modify ART 
response in natural parasite populations of P. falciparum. 
Increased artemisinin resistance in a P. chabaudi parasite derived from a 
chloroquine resistant parasite after prolonged and progressive artemisinin selection 
was phenotypic and genetically characterized. The whole genome sequencing 
identified a mutation in a gene encoding the mu chain of the AP2 adaptor protein 
complex. To explore the genetic variability of the ap2-mu gene in P. falciparum and 
its associations with artemisinin in vitro responses we sequenced field isolates from 
Brazil, São Tomé and Rwanda. Analysis of P. falciparum field isolates showed a 
weak association between a Ser160Asn mutation and in vitro dihydroartemisinin 
responses. 
To investigate the correlation between polymorphisms in pfubp-1 and pfap2-mu 
and in vivo parasite susceptibility to ART we genetically characterized samples from 
an ACT clinical trial carried out in Kenya. Previously work done on the same ACT 
clinical trial samples described sub-microscopic persistent parasites on day 3 post-
treatment samples. These parasites were only detected by qPCR but the children 
carrying these parasites had a higher transmission potential and were far more 
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likely to go on to classical treatment failure at day 28 or day 42 post-treatment. The 
molecular work carried out here demonstrates that a Ser160Asn/Thr mutation in 
the pfap2-mu gene and an E1528D mutation in the pfubp-1 gene might be 
associated with in vivo responses to artemisinin derivatives.  
Polymorphisms on the pfubp-1 gene and pfap2-mu genes were further studied 
using field isolates from an ACT clinical trial in Burkina-Faso which were also tested 
in vitro for their response to dihydroartemisinin and several other antimalarial 
drugs. Using these samples, we also investigate the genetic polymorphisms of the 
pf26S-protSU, another drug resistant candidate gene identified in the studies of P. 
chabaudi. Data revealed that polymorphisms in pfubp1 and pf26S-protSU, can 
modulate in vitro responses to lumefantrine. However, this work did not reveal any 
significant association between polymorphisms in pfubp-1 and pfap2-mu genes and 
in vitro artemisinin susceptibilities or treatment outcomes.  
In order to validate the pfap2-mu candidate marker as an important modulator 
of parasite sensitivity to artemisinins and to improve understanding of the 
biological mechanisms of resistance to this class of drugs we further performed 
gene functional characterization using transfection techniques. Transgenic parasites 
carrying the 160Asn allele of pfap2-mu were significantly less sensitive to 
dihydroartemisinin using a standard in vitro test. Sensitivity to chloroquine and 
quinine were also reduced. Localization studies of pfap2-mu were performed by 
transfection of fluorescent-tagged gene construct into P. falciparum and expression 
of fluorescent fusion protein in parasites was observed using a confocal 
microscope. 
The findings from this study provide the first in vivo evidence that 
polymorphisms in the pfap2-mu and pfubp-1 genes modulate P. falciparum 
responses to artemisinins. Additionally, transgenic laboratory lines of P. falciparum 
carrying the 160Asn mutation in pfap2-mu gene have altered in vitro responses to 
dihydroartemisinin, quinine and chloroquine. We therefore propose these genes 
should be evaluated further as potential molecular markers of artemisinin 
resistance. 
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THESIS OUTLINE 
 
This PhD thesis is compiled in the “research paper style” format, as approved by the 
London School of Hygiene and Tropical Medicine. Therefore, the main body of the thesis 
will be presented as various manuscripts that have already been published in an 
international peer-review journal, are currently in submission or have been prepared for 
publication. 
The Introduction chapter (Chapter 1) provides a review of the relevant literature 
background, in a more comprehensive approach than that presented in the various 
manuscripts. The aim and the specific objectives of the thesis are stated on Chapter 2 and a 
detailed description of the materials and methods used in the thesis is given in Chapter 3. 
Chapters 4, 5, 6, 7 and 8 contain the key findings of the thesis in the form of research 
papers that are already published or will be submitted. 
 
This thesis focus on two fulcral issues in antimalarial drug resistance: 
 
Section 1 
Polymorphisms in the genes of interest in parasites treated in vivo 
* 
In Chapter 4 we have identified a unique mutation in a gene encoding the µ-chain of the 
AP2-adaptor complex in a Plasmodium chabaudi parasite that presents a high level of 
artemisinin resistance. Allelic variations of the Plasmodium falciparum orthologue gene 
were investigated in field samples from Africa and South America. The association between 
the allelic variations and the in vitro responses to artemisinin derivatives were also 
evaluated in these samples (data not included in the published manuscript). 
Chapter 5 reports the genotype of the recently described sub-microscopic parasites that 
persist after artemisinin combination treatment, in Kenyan children. In this chapter, the 
DNA sequences of resistance associated parasite loci (pfcrt, pfmdr1, pfubp-1 and pfap2-mu) 
were determined in pre- and post-treatment isolates. 
Chapter 6 describes the genotype of the three candidate markers studied on this thesis 
(pfubp-1, pfap2-mu and pf26S-protSU), using field isolates from an Artemisinin 
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Combination Therapy trial conducted in Burkina Faso. The correlation between the 
polymorphisms found and the in vitro responses profiles to artemisinin derivatives and 
other antimalarial drugs was also assessed. 
 
Section 2 
Functional analysis of the pfap2-mu gene in vitro 
* 
Chapter 7 describes the generation of two transgenic parasites lines carrying and extra 
copy of either the wild-type (WT) copy of pfap2-mu or the 160Asn form, in addition to their 
endogenous WT pfap2-mu gene. The in vitro susceptibility of these parasites to several 
antimalarial drugs was evaluated. 
The generation of a transgenic parasite stably expressing GFP-fused pfap2-mu and 
subsequent cellular localization of the GFP-fused protein is reported on Chapter 8. 
 
Chapter 9 summarizes and discusses the study as a whole, incorporating all five 
manuscripts, as well as the data presented in the additional unpublished section. The final 
chapter (Chapter 10) focus on the future perspectives in relation to the main findings of 
this thesis. 
The references for the manuscripts are provided for each paper, whereas the references 
for the Introduction, Materials and Methods and Discussion chapters are presented at the 
end of the thesis. 
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Chapter 1 – Introduction 
1.1.MALARIA BURDEN 
Despite considerable scientific advances and the development of modern drugs, malaria 
remains a major public health concern. Globally around 3.4 billion people live in areas at 
risk of malaria, resulting in 207 million clinical cases in 2012. Although it is disseminated 
throughout more than 100 countries, the bulk of this burden falls on sub-Saharan Africa 
with approximately 80% of all malaria cases and 90% of related deaths in young children 
(WHO 2013f)(Figure 1.1). 
 
Figure 1.1 The spatial distribution of Plasmodium falciparum malaria transmission in 2010 (adapted 
from Gething et al., 2011 (Gething et al. 2011). Areas of no risk, with unstable risk (PfAPI < 0.1%) and 
with stable risk (PfAPI ≥ 0.1%) are shown. 
 
The number of deaths due to malaria decreased substantially between 2000 and 2012, 
more than 45% globally and by 49% in African countries, resulting in an estimated 3.3 
million malaria deaths prevented over this period (WHO 2013f). Nevertheless, the effect of 
malaria extends far beyond this direct measure of mortality since morbidity in endemic 
countries leads to major socio-economic losses. Acute febrile illness, anaemia, chronic 
debilitation, complications in the course and outcome of pregnancy, school and 
Chapter 1 – Introduction 
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employment absences and delays in cognitive and physical development contribute to a 
heavy public-health burden, which has a negative impact on the social and economic 
development of affected countries (Sachs and Malaney 2002; Bloland 2003; Chima et al. 
2003; Breman et al. 2004; Malaney et al. 2004; Barnes and White 2005; Okorosobo et al. 
2011). The disease contributes to an approximately 1.3% annual reduction in economic 
growth in countries with high levels of transmission (WHO 2011b). 
 
1.2.PLASMODIUM 
Malaria is caused by protozoan parasites of the genus Plasmodium, which are 
inoculated into humans by biting female Anopheles mosquitoes. The genus contains more 
than 100 species of which six are found in natural infections in humans: Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale curtisi, P. ovale 
wallikeri and, in parts of South-East Asia, the simian malaria parasite Plasmodium knowlesi 
(Singh et al. 2004; Cox-Singh et al. 2008; Sutherland et al. 2010; WHO 2013c).  
These species differ morphologically, immunologically, in their geographical distribution, 
in their ability to relapse and in their response to drugs. By far, the most virulent species is 
P. falciparum, which causes the majority of severe malaria morbidity and mortality 
(Greenwood et al. 2005) 
 
1.3.LIFE CYCLE OF PLASMODIUM FALCIPARUM 
The P. falciparum life cycle comprises numerous transition stages and occurs between 
two separate hosts (definitive and intermediate) (Figure 1.2). The cycle begins when 
haploid sporozoites are injected into the intermediate human host by an infected female 
mosquito of the genus Anopheles during a blood meal. These motile forms of the parasite 
rapidly access the blood stream and then migrate to the liver. There, each sporozoite 
traverses a few hepatocytes, before finally establishing in one of them. The sporozoite, 
differentiates and undergoes asexual multiplication resulting in tens of thousands of 
merozoites, which burst from the hepatoctye (hepatic stage). One P. falciparum sporozoite 
develops into approximately 40,000 merozoites in a liver cell over 6 days. Upon release 
Chapter 1 – Introduction 
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from the liver, individual merozoites invade red blood cells (erythrocytes). Once inside the 
erythrocyte and during a 48h cycle (erythrocytic stage), P. falciparum develops into a ring 
stage/early trophozoite and then into a highly metabolically active late stage trophozoite. 
Finally, trophozoites develop into schizonts and asexual replication occurs. In the latter, 
new merozoites (8-32 daughter cells) are formed within the schizont and are released to 
the bloodstream when the erythrocyte bursts. The clinical manifestations of malaria (such 
as a spiking fever) are associated with the synchronous rupture of infected erythrocytes. 
The free merozoites immediately invade new erythrocytes. Although the majority of 
invading merozoites will go on to develop into schizonts and continue the asexual cycle, a 
small proportion enter the sexual phase of the life cycle by differentiating into haploid male 
or female gametocytes. These are the only forms that are transmissible to the mosquito.  
For transmission to occur, when an infectious host is bitten by a female anopheline 
mosquito, both male and female gametocytes must be taken up during the blood meal. 
Inside the mosquito midgut, gametocytes develop into gametes and sexual reproduction 
takes place, whereby 8 flagellated microgametes are released from a male gametocyte. 
These fertilize the female macrogamete to form a diploid zygote that converts into an 
motile ookinete. After penetrating a cell wall in the midgut epithelium, the ookinete 
subsequently develops into an oocyst. Each oocyst produces haploid sporozoites by asexual 
reproduction. The oocyst finally ruptures to release a large number of sporozoites into the 
haemolymph of the mosquito, from where they travel to the salivary glands. The 
sporozoites remain here, ready to be inoculated into the next host and begin a new cycle of 
infection when the female mosquito takes a further blood meal (Figure 1.2). 
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Figure 1.2. The life cycle of P. falciparum, the most virulent human malaria parasite (adapted from 
(Rosenthal 2008)). The malaria parasite uses both an anopheline mosquito and a human host. Sexual 
reproduction occurs in the mosquito and asexual reproduction takes place in the human. 
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1.4. MALARIA CONTROL 
Political commitment and important increase in international funding has led to 
remarkable improvements in malaria control in the past decade, resulting in major 
reductions in the burden of malaria caused by P. falciparum. Globally, the estimated 
incidence of malaria has been reduced by 29% and the mortality rates have declined by 
45 % (WHO 2013f). These reductions are partly due to improved vector control, diagnostic 
testing and better access to artemisinin combination treatment (O'Meara et al. 2010; WHO 
2012b). 
Three living entities are involved in the malarial infection; parasite, host and vector. In 
order to reduce the burden of malaria, interventions can be designed to target several 
stages of the parasite lifecycle. For example, the parasite can be targeted in the host either 
directly with drugs, or indirectly with vaccines. Similarly, strategies that reduce vector 
contact with the host or increase vector mortality can be employed to reduce the number 
of new infections (Greenwood 2008).  
 
 Vector control 
There are two key approaches to malaria prevention by vector control: the use of long 
lasting insecticide –treated nets (LLINs) and indoor residual spraying (IRS). LLINs are factory 
pyrethroid insecticide treated mosquito nets, which do not require any re-treatment during 
their expected lifespan (generally 2–3 years). These nets have a high degree of protection 
for the individual sleeping under the net and have an effect at the community level as well, 
by killing the mosquitoes that contact the net (WHO 2007). IRS is a method used to kill 
mosquitoes by spraying of a long-lasting residual insecticide on to potential malaria vector 
resting surfaces (internal walls and ceilings). IRS repels the mosquitoes from entering the 
houses and kills the female mosquitoes that rest inside them, having a large effect on 
reducing transmission at community level (WHO 2013b). 
These central interventions may be complemented by other methods such as larval 
control or environmental management, which aims to reduce mosquito breeding sites 
(WHO 2006; 2008). 
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 Vaccines 
Despite decades of intensive research, there is no licensed malaria vaccine to date 
(Girard et al. 2007; Matuschewski and Mueller 2007; Hill 2011), however a recent phase III 
clinical trial with the RTS,S vaccine showed promising results, with 55% reduction in the 
incidence of clinical malaria among young children and 33% among infants. The efficacy 
against severe malaria was 47% among young children and 37% against infants (Agnandji et 
al. 2011; Agnandji et al. 2012). The full trial results will be available at the end of 2014 and 
a World Health Organization (WHO) recommendation for use may occur in 2015 (WHO 
2013c). The available data suggest that this vaccine is likely to be implemented as an 
addition to, not a replacement for, existing preventive, diagnostic and treatment measures.  
 
Measures aimed against the parasite still need to be based on the use of drugs either as 
treatment or as prophylaxis. Medication reduces morbidity and mortality by terminating a 
malaria infection in a patient and restricts malaria transmission by diminishing the parasite 
reservoir (WHO 2013c). Antimalarial drugs are also used as a preventive measure, as 
chemoprophylaxis for travellers to malaria endemic areas, for intermittent preventive 
treatment (IPT) in areas of high transmission in specific high-risk groups such as pregnant 
women and infants and for seasonal malaria chemoprevention in children in the Sahel sub-
Region of Africa (WHO 2013d). 
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1.5.ANTIMALARIAL DRUGS 
This section will give an introduction to the most historically important antimalarial 
drugs with a focus on those used as partner drugs in artemisinin combination therapy. The 
chemical structures of these antimalarial drugs are summarized in Figure 1.3. 
 
Figure 1.3. Chemical structures of commonly used antimalarial drugs with a focus on those used as 
partner drugs in artemisinin combination therapy. 
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 Quinolines and related compounds 
Quinine 
Western medicine has relied on the medical properties of quinine (QN) and related 
alkaloids since the early 17th century (WHO 1986; Meshnick and Dobson 2001). QN is the 
most abundant alkaloid in the bark of the cinchona tree (originally found in South America) 
and was first isolated in 1820, by the French chemists Pierre Pelletier and Joseph Caventou 
(Siegel and Poynter 1962; Greenwood 1992; Foley and Tilley 1998; Meshnick and Dobson 
2001). 
QN has rapid schizonticidal action against intra-erythrocytic malaria parasites and its 
half-life ranges between 11-18 hours (White et al. 1983; Jamaludin et al. 1988). QN has 
long been the basis for treatment of severe malaria although following the results of the 
SEAQUAMAT and AQUAMAT trials (Dondorp et al. 2005; Dondorp et al. 2010), WHO 
approved the replacement of QN with artesunate as treatment of choice for severe 
malaria, with QN still recommended where artesunate is not available (WHO 2010b). 
The need to treat soldiers for malaria infection during the World War I promoted the 
chemical research on antimalarial discovery and the attempt to synthesize quinine led to 
the development of methylene blue and the dye industry. The first synthetic drug was the 
8-aminoquinoline pamaquine (also called plasmoquine). Pamaquine was synthesized in 
1920 by German scientists and has anti-relapse activity (kills hypnozoites, the persistent 
liver stage parasites of P. vivax and P. ovale) but was later found to be too toxic and not 
used for long (Greenwood 1995; Sa et al. 2011). 
 
Chloroquine and Amodiaquine 
In 1934, Andersag in the German programme developed a 4-aminoquinoline compound 
named resochin (resoquine), but the drug was ignored for a decade due to toxicity 
concerns. During World War II, the interest in resoquine was renewed, when sontoquine 
the slightly modified compound, was captured from the Germans in North Africa. 
Resoquine was renamed as chloroquine (CQ) and was introduced in 1946 (Loeb 1946). CQ 
is considered to be one of the most successful drugs ever produced. CQ was efficacious 
against all blood stage malaria parasites, well tolerated, easily administered, inexpensive 
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and therefore the most widely used antimalarial drug (WHO 1986; Meshnick and Dobson 
2001; Sa et al. 2011) until the 1990s when parasite resistance led to its replacement with 
other regimens (White 1998a). CQ combined with primaquine is still recommended for 
treatment of P. vivax infections, because resistance has not fully developed (Price et al. 
2009; WHO 2010b). 
CQ was one of many antimalarials resulting from scientific advances made during World 
War II. A massive antimalarial screening programme coordinated by American scientists led 
to the discovery of amodiaquine, another 4-aminoquinoline (Greenwood 1995; Meshnick 
and Dobson 2001). However, in the 1980s its use was discouraged due to serious problems 
of hepatotoxicity after long term prophylaxis (Taylor and White 2004). After the 
development of CQ resistance in the 1990s, the use of amodiaquine was reviewed and 
nowadays is commonly used in combination with artesunate as first-line treatment. It is 
assumed that the serious toxic effects do not occur in shorter therapeutic treatments 
(Olliaro et al. 1996). 
 
Pyronaridine 
Pyronaridine is structurally related to chloroquine and was synthesized in the Chinese 
Institute of Parasitic Diseases in 1970 (Zheng et al. 1979; Zheng et al. 1982). It has potent in 
vitro activity against erythrocytic stages of P. falciparum (Ringwald et al. 1996; Vivas et al. 
2008) and it has been used in China for treatment of malaria for more than 30 years (Croft 
et al. 2012). Clinical studies have demonstrated that pyronaridine is safer and less toxic 
than chloroquine (Chang et al. 1992). Additionally, pyronaridine is reported to be highly 
effective in cases of chloroquine resistance (Ringwald et al. 1996) and has been recently 
combined with artesunate as a new combination therapy (Croft et al. 2012; Kayentao et al. 
2012; Rueangweerayut et al. 2012). 
 
Primaquine 
Attempts to search for alternative drugs with characteristics similar to pamaquine, in 
particular, the ability to prevent relapse led to the discovery of primaquine. Primaquine 
became available during the Korean War and remains in use today (Greenwood 1995; Baird 
and Hoffman 2004). Primaquine is used in the treatment of Plasmodium vivax and 
Plasmodium ovale hypnozoites and for malaria prophylaxis in endemic regions (Hill et al. 
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2006; Vale et al. 2009). However, primaquine causes haemolysis in patients who have a 
deficiency in the glucose-6-phosphate dehydrogenase (G6PD) enzyme, a common 
deficiency in malaria endemic regions of the world (Howes et al. 2013). 
Primaquine is also currently the only fully effective gametocytocidal drug and recently 
the WHO recommended a single low-dose of primaquine (0.25 mg base/kg, dose that is 
unlikely to cause serious toxicity problems in G6PD deficient patients) for patients with 
uncomplicated P. falciparum malaria, in addition to an artemisinin based combination 
therapy (WHO 2012a). 
 
Piperaquine 
In the face of increasing drug resistant malaria infections, other quinoline based 
compounds have been synthesized and studied. Piperaquine was first synthesized in the 
1960s in France and developed in China, where it was used for prophylaxis and treatment 
for the next 20 years (O’Neill et al. 2012a). Piperaquine includes two 4-aminoquinoline 
moieties and has shown high effectiveness against CQ resistant P. falciparum, is well 
tolerated, relatively inexpensive, has a long elimination half-life, and is thus considered a 
good partner drug in combination therapy. Thus dihydroartemisinin-piperaquine is 
recommended for artemisinin combination therapy by WHO (Davis et al. 2005; WHO 
2010b). 
 
Mefloquine 
The U.S. Army Antimalarial Drug Development Program, initiated during the Vietnam 
War, was responsible for the discovery of new chemical groups that later served as 
prototypes for the development of other antimalarials compounds (Kitchen et al. 2006). 
One such compound is mefloquine, like quinine a 4-quinolinemethanol, which was 
introduced in the mid-1970s (WHO 1986; Shanks 1994). Mefloquine was approved for use 
in 1989 and is still currently prescribed as prophylaxis, due to a long half-life that requires 
only a once-weekly dosing, and in combination with artesunate as first line treatment 
(WHO 2010b; Biamonte et al. 2013). However, emergence of resistance and fears about 
neurotoxicity are limiting its use, in favor of safer and better tolerated antimalarial drugs 
(Overbosch et al. 2001; Croft 2007). 
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Lumefantrine 
Lumefantrine (originally called benflumetol) was synthesized in the 1970s by the Beijing 
Academy of Military Medical Sciences (Basco, Bickii, et al. 1998). Studies on the 
combination of artemether and lumefantrine  were also performed at the same Academy 
and the results indicated high efficacy and synergistic activity of the two antimalarial drugs 
(Hassan et al. 1999). The artemether-lumefantrine(AL) combination was the first fixed-dose 
artemisinin-based combination therapy recommended and pre-qualified by WHO for the 
treatment of P. falciparum uncomplicated malaria (Nosten and White 2007). Lumefantrine, 
has never been used as monotherapy prior to its combination with artemether, so the risk 
of resistance to this compound may be lower when compared with other partner drugs 
used in artemisinin based therapies (Premji 2009).  
 
Atovaquone 
Another chemical group developed were the 2-hydroxynaphthoquinones, which 
provided the basis for the discovery of atovaquone (WHO 1986; Meshnick and Dobson 
2001). Atovaquone is now being used in combination with proguanil (Malarone) for 
treating patients with uncomplicated malaria or employed as prophylaxis in travelers due 
to its ability to clear liver schizonts (Hudson 1993; Biamonte et al. 2013). 
 
 Antifolates 
Antifolate drugs were first developed as antibacterial agents but a number were also 
found to have activity against malaria parasites (Curd et al. 1945). During the II World War 
British chemists synthesized a group of compounds, derivatives of pyrimidine, designated 
as antifolates, which target the folate metabolism (WHO 1986; Schlitzer 2007). Proguanil is 
one of these compounds. The discovery of proguanil encouraged further investigation on 
antifolates in the early 1950s (WHO 1986; Nzila 2006) and in 1951 Falco and colleagues 
found that pyrimethamine was active against blood forms of malaria (Falco et al. 1951). 
Other antifolates include the sulfa drugs; the most important are the sulphonamide, 
sulfadoxine and the sulfone, dapsone. Although these drugs have antimalarial activity when 
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used alone, when used in combination they exhibit a synergistic effect. A combination of 
two antifolate compounds, pyrimethamine and sulfadoxine (FansidarTM) was one of the 
first combination therapies in malaria treatment and became available in 1971 (Shanks et 
al. 1989). Sulfadoxine-pyrimethamine (SP) is effective, cheap and is considered a drug with 
good compliance, tolerance and safety and has the advantage of a single-dose therapy with 
a long half-life (Basco, Tahar, et al. 1998). After its introduction as a new antimalarial drug 
SP replaced CQ in many countries, due to the emergence and spread of CQ resistance 
(White 2004).  
Resistance to SP emerged rapidly in the Amazon Basin of South America (WHO 2001c; 
Gregson and Plowe 2005) and most areas of South East Asia and forced countries to change 
to more effective artemisinin combination therapies (ACTs) (WHO 2001c). SP plus 
artesunate is currently recommended as first line treatment for uncomplicated P. 
falciparum malaria (WHO 2010b) and SP alone continues to be widely used for treatment 
where ACT is not available (Thriemer et al. 2006; Mkulama et al. 2008). Furthermore, due 
to its safety and good tolerance SP is still used for malaria prevention during pregnancy and 
in children in IPT programmes in African areas with moderate-to-high malaria transmission 
and low drug resistance (WHO 2001d; Peters et al. 2007; WHO 2013e). It is also used in 
combination with amodiaquine as seasonal malaria chemoprevention (SMC) in children to 
reduce morbidity and mortality of malaria in Sahel sub-Region of Africa (WHO 2013d). SMC 
is not recommended elsewhere, due to known hig levels of resistance to amodiaquine and 
SP in eastern and southern Africa. 
 
 Antibiotics 
Animal studies in the late 1940s demonstrated that some antibiotics possess 
antimalarial properties. Interestingly, when treated with antibiotics the parasites in the 
initially exposed host cells are not damaged. However, after these daughter cells invade a 
new host cell, division is slowed and no further progeny are produced (Goodman and 
McFadden 2013).This phenotype is known as “delayed death” and it is the cause for the 
longer parasite clearance times and prolonged symptoms. Therefore, most antibiotics 
should be combined with a more rapidly acting drug to treat malaria, such as artemisinin or 
quinine (Dahl and Rosenthal 2008) or used in monotherapy as antimalarial prophylaxis in 
travellers. 
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WHO recommends the use of tetracycline or doxycycline or clindamycin in combination 
with artesunate or QN as second line treatment of falciparum malaria (WHO 2010b) and 
doxycycline alone is recommended for prophylaxis in many malaria endemic areas (Tan et 
al. 2011). Azithromycin is also a slow acting antimalarial but in combination with CQ was 
shown to be synergistic against CQ resistant strains and both drugs have demonstrated 
safety in children and pregnant woman and can be used in intermittent preventive 
treatments (Chico et al. 2008).  
 
 Artemisinin compounds 
The therapeutic benefits of the qinghao plant (Artemisia annua) were documented in 
China two thousand years before the isolation of active component, artemisinin (Peters 
1987; Hsu 2006; Cui and Su 2009). In the 1970s the sesquiterpene lactone artemisinin was 
isolated and characterized by Chinese scientists in search of new antimalarial drugs against 
CQ resistant malaria (Meshnick and Dobson 2001; White 2008).  
Artemisinin (ART) chemical modifications carried out by the original Chinese developers 
improved solubility and absorption, resulting in the water soluble derivative artesunate and 
the more active oil-soluble dihydroartemisinin (DHA) and artemether (Cui and Su 2009). 
ART and its derivatives are currently the most important class of antimalarial drugs, 
presenting many advantages over other compounds. These advantages include several 
possible routes of administration, suitability for treating severe malaria, thus replacing QN 
and avoiding its side effects (Dondorp et al. 2010). This class of compounds possesses 
several important pharmacological characteristics. Firstly, ART can reduce the number of 
parasites faster than any other class of antimalarial drug and thus provide rapid clinical 
relief (Hien and White 1993; White 1997). Additionally, ARTs are active against early ring 
forms as well as the usual targets of chloroquine and quinine, trophozoites, blood 
schizonts, early gametocytes and later ring forms (Krishna et al. 2004a). This latter property 
may help diminish transmission rates at a population level (Price et al. 1996) since attacking 
early ring forms, can impair gametocyte development. Altogether, ART derivatives when 
used appropriately can, reduce the incidence of malaria and reduce drug use, and thus may 
contribute to slowing the evolution of drug resistance (Price et al. 1996; White 1999).  
The use of ART as monotherapy over short periods (less than 5 days) is associated with 
high treatment failure rates (recrudescence) because of the short plasma half-lives of these 
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drugs (Giao et al. 2001). Clearance of parasitaemia is only temporary in up to 50% of 
patients (WHO 1998). Higher efficacy can be obtained with prolonged regimens however, 7 
days of ART monotherapy still only cures 80-90% of uncomplicated falciparum infections 
(Woodrow et al. 2005). For this reason, and to avoid resistance development, ART is only 
used in combination therapy, as will be further discussed.  
 
1.6.ARTEMISININ-BASED COMBINATION THERAPY 
To optimize ACT treatment, the combination of an ART derivative with another 
structurally unrelated antimalarial, has been proposed as the best therapeutic strategy 
(WHO 2010b) in order to improve treatment efficacy and slow down the development of 
resistance to the individual drugs in the combination (WHO 2001a). The concept that 
combination treatment, using drugs with different targets, decreases the chance of a 
natural resistant strain to emerge was first developed in the treatment of tuberculosis and 
has been adopted widely for the treatment of the human immunodeficiency virus (HIV) and 
cancer (White 1999). The underlying principle for the impact of combination therapy on 
drug resistance is based on the assumption that drug resistance essentially depends on 
DNA mutation. Provided that the constituent drugs administered in the combination have 
independent modes of action, the probability of a parasite developing resistance to both 
drugs simultaneously is significantly reduced compared to developing resistance to one 
drug (White et al. 1999). 
ART and its derivatives are highly potent and rapid acting, with a parasite reduction rate 
of 10 000 parasites per erythrocytic cycle (48h) (White 1997). However these compounds 
have extremely short half-lives (Table 1.1), the active metabolite of the ART compounds, 
DHA, is eliminated with a half-life of ~1 h (White 2008). For this reason, the administration 
of ARTs with longer-acting agents is required (Nyunt and Plowe 2007). In an ACT, the ART 
derivative kills most of the parasites rapidly and those that remain are eliminated by a high 
concentration of the longer-lasting partner drug (Table 1.1), after the short-lived ART has 
dropped below therapeutic levels (White 2008). In this way the ART derivative should 
protect its partner drug. If the treatment is successful, the partner drug also protects the 
ART derivative by removing all the remaining parasites that were initially exposed to the 
ART. Consequently the probability that mutant parasites survive and emerge after 
treatment with these two drugs is lower (White 1997; Nosten and White 2007). However, it 
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is now accepted that a mismatch in elimination half-lives may not be as advantageous as 
previously assumed (Peters 1985; Hastings and Watkins 2006). The underlying reason is 
that, after the rapidly elimination of the ART derivative from the organism, the long-lasting 
drug remains in the blood stream in sub-therapeutic levels, strongly selecting for the 
evolution of tolerance and, ultimately, resistance to the longer-lived drug (Bloland et al. 
2000; Hastings and Watkins 2006). Additionally, it was been recently suggested that post-
treatment anti-malarial activity drug profiles should be considered when designing new 
drug combination therapies, rather than simply the drugs half-lives (Hastings and Hodel 
2014). 
 
Table 1.1 – Half-lives of antimalarials (Ashley et al. 2007; WHO 2010b; Croft et al. 2012).  
Compound Half-life 
Artemisinin derivatives 
Artemisinin 1 h 
Dihydroartemisinin 45 min 
Artemether 1h 
Artesunate 45 min 
ACT partner drugs 
Lumefantrine 3 days 
Pyrimethamine 4 days 
Sulfadoxine 4-9 days 
Amodiaquine 
(Monodesethylamodiaquine*) 
3 h 
(9-18 days) 
Mefloquine 21 days 
Piperaquine 5 weeks 
Pyronaridine 13 days 
Other antimalarials 
Quinine 11-18 h 
Chloroquine 1-2 months 
Primaquine 3-6 h 
Atovaquone 60-70 h 
Tetracycline 8 h 
Doxycycline 10-24 h 
Clindamycin 2-3 h 
* Monodesethylamodiaquine – amodiaquine primary active metabolite 
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Fixed-dose ACTs aree now the gold standard treatment with six recommended for 
first-line treatment of uncomplicated malaria in adults and children (WHO 2010b; EMA 
2012): 
 Artemether-lumefantrine – Coartem (Novartis/ Chinese Academy of Medical 
Military Sciences/MMV); 
 Artesunate-amodiaquine - Coarsucam (Sanofi-Aventis/DNDi/MMV); 
 Artesunate-mefloquine – ASMQ (Farmanguinhos/DNDi/Cipla); 
 Artesunate + sulfadoxine-pyrimethamine - AS+SP; 
 Dihydroartemisinin-piperaquine – Eurartesim (Sigma-Tau/MMV/Pfizer); 
 Artesunate-pyronaridine - Pyramax (Shin Poong Pharamaceuticals). 
 
1.7.ANTIMALARIAL DRUG RESISTANCE 
Antimalarial drugs remain as one of the most powerful tools in the fight against malaria 
and the development of resistance to these compounds is probably the greatest problem 
faced by malaria control programmes. 
The emergence of CQ resistance was considered responsible for a dramatic increase in 
child mortality and morbidity in Africa in the 1980’s and 90’s (Trape 2001) and nowadays, 
resistance to nearly all established antimalarial compounds has been reported. 
In the last decade, first line treatment with ACTs has played a major role in reducing 
malaria burden (Dondorp et al. 2011). Currently no alternative antimalarial treatment 
offers the same level of efficacy and tolerability as ACTs (WHO 2013a). Therefore, the 
emergence and spread of ART resistance would be a serious threat to the 
elimination/eradication efforts. 
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1.7.1. EMERGENCE OF DRUG RESISTANCE 
The development of genetically determined resistance in a pathogen under drug 
pressure is a two step process; 1) de-novo emergence of the new genotype, 2) subsequent 
spread through the pathogen population. Resistance arises through spontaneous point 
mutations or gene duplications, mainly during asexual reproduction. A single genetic event 
may be all that is required, or multiple independent events may be necessary. The ‘de-novo 
mutation’  emergence is a rare event in malaria and is thought to be independent of drug 
selection pressure (White and Pongtavornpinyo 2003). In the presence of the drug, these 
mutants can survive and expand in numbers to generate gametocyte densities sufficient for 
subsequent spread (White and Pongtavornpinyo 2003; Barnes and White 2005; Hastings 
2006). The drug pressure provides a selective advantage to resistant parasites and their 
frequency in the population increases (Olliaro and Taylor 2004). The resistant parasites are 
then transmitted in the human population by the mosquitoes. Genetic recombination 
occurs after fertilization in the mosquito stages consequently if one mosquito bites two 
people carrying different gametocytes or bites one person carrying more than one parasite 
genotype, the recombination with the formation or breakdown of multigenic resistance can 
occur (Barnes and White 2005). The parasites carrying the mutant alleles are selected if 
antimalarial drug concentrations are sufficient to suppress the development of susceptible 
parasites but insufficient to inhibit the newly arisen mutants, a phenomenon known as 
"drug selection" (White 1998b). Once drug resistant parasites have emerged and are 
selected over sensitive ones it is difficult to avoid the spread of resistance.  
Advances in the understanding of the mechanisms of drug action during the last two 
decades have led to the identification of the putative drug resistance molecular targets, for 
some antimalarial drugs. The genetic basis of parasite resistance, which in some cases does 
not involve the molecular target, was also identified in some antimalarial drugs. The 
genetic events that confer antimalarial drug resistance include single point mutations in or 
changes of copy numbers of genes encoding drug targets, such as important enzymes, or in 
genes encoding pumps that affect intraparasitic drug concentrations. These mechanisms 
will be discussed in detail in the next section.  
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1.7.2. DEFINITION OF ANTIMALARIAL DRUG RESISTANCE 
Antimalarial drug resistance has been defined as the “ability of a parasite strain to 
survive and/or multiply despite the administration and absorption of a drug given in doses 
equal to or higher than those usually recommended but within tolerance of the subject”. 
This definition was later modified to specify that the drug in question must “gain access to 
the parasite or the infected red blood cell for the duration of the time necessary for its 
normal action” (Bruce-Chwatt 1986; WHO 2010a). 
Due to the particular mode of action of ARTs, the definition of artemisinin resistance has 
been a controversial issue. According to the WHO (WHO 2014), in vivo ART resistance is 
suspected when an increased parasite clearance time is observed (as evidenced by ≥10% of 
cases with parasites detectable by microscopy on day 3 after ACT treatment). Resistance is 
confirmed when treatment failure happens after treatment with an oral ART based 
monotherapy with adequate antimalarial blood concentration, as evidenced by persisting 
parasitaemia on day 7 post-infection, or the presence of parasites on day 3 and 
recrudescence within 28/42 days (WHO 2011a). 
 
1.7.3. ASSESSMENT AND MONITORING OF RESISTANCE IN P. FALCIPARUM 
The emergence of resistant mutants has resulted in reduced efficacy of several drugs 
and drug combinations in some regions. Drug efficacy surveillance is necessary to ensure 
the correct management of clinical cases and early detection of changing patterns of 
resistance. This monitoring is needed to inform treatment policies in malaria-endemic 
countries allowing the deployment of effective antimalarial drugs (WHO 2003). Three 
approaches have been used to evaluate the efficacy of an antimalarial drug in a given 
setting: clinical in vivo studies (also known as therapeutic efficacy testing), in vitro 
susceptibility testing, and more recently, molecular markers (WHO 2003). There are 
advantages and disadvantages with each of these assays.  
 
In discussing these different approaches, it is fundamental to differentiate intrinsic 
parasite resistance from treatment failure, which is the inability to clear parasitaemia 
and/or resolve clynical symptoms after treatment. Parasite intrinsic susceptibility is only 
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one of several factors that can determine the outcome of the treatment; treatment failure 
can also be caused by incorrect drug dosing, poor drug quality and poor treatment 
compliance, interactions with other drugs or inadequate drug absortion (Laufer 2009). 
 
  IN VIVO TESTS  
Susceptibility of P. falciparum to antimalarial drugs is commonly assessed by therapeutic 
response (in vivo testing) (WHO 2003). One of the key characteristics of these tests is the 
ability to evaluate the actual clinical and epidemiological responses. Those responses 
involve a complex interaction between the drugs, the parasites, and the host (i.e. the 
therapeutic response of currently circulating parasites infecting the current population in 
which the drug will be used), while in vitro tests measure only the interaction between the 
blood stage parasites and the drugs (Talisuna et al. 2004).  
In vivo tests involve the treatment of symptomatic P. falciparum infected patients with a 
standard dose of an antimalarial drug and subsequent follow-up of clinical and 
parasitological outcomes of treatment during 28-day, or even 42-day, follow-ups 
(Stepniewska et al. 2004), where the patient’s clinical and parasitological response is 
categorized as “early treatment failure”, “late clinical failure”, “late parasitological failure” 
or “adequate clinical and parasitological response”. This procedure allows the detection of 
any reappearance of symptoms or signs of clinical malaria and the detection of parasites in 
the blood as an indication of reduced sensitivity to a particular drug (WHO 2003). 
Due to the influence of factors such as patient’s immunity, variations in drug absorption 
and metabolism, and possible misclassification of new infections as recrudescence, the 
results of a therapeutic efficacy test do not necessarily reflect the real level of antimalarial 
drug resistance (Marfurt et al. 2010). These studies include other drawbacks: the long 
duration of patient monitoring that may result in high loss to follow-up; treatment 
administration must be supervised; the quality of the drugs has to be verified and the 
assessment of resistance to one drug regimen only (Laufer 2009). 
However, these tests provide decision-makers with a simple, readily comprehensible 
indicator of the efficacy of an antimalarial drug with reduced requirement for equipment 
and supplies, when compared with in vitro tests (WHO 2003). 
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  IN VITRO TESTS 
The in vivo method has helped the inference of treatment failure thresholds that are 
critical for adjusting antimalarial drug policies, but it is not considered enough on its own to 
confirm drug resistance (WHO 2003). 
To support the evidence of a failing antimalarial regimen, a dose-response (in vitro) test 
can provide a more precise measure of drug sensitivity under controlled experimental 
environment, which removes variables such as patient immunity, initial parasite load, 
re-infection and pharmacokinetics. In vitro tests allow a more objective approach to 
parasite resistance, since in these studies the parasite will be in direct contact with 
incremental drug concentrations. Furthermore, several tests can be carried out with the 
same sample, and several drugs can be assessed simultaneasly, including drugs that are still 
at the experimental stage (WHO 2003).  
There are several in vitro readout methods, which differ with respect to the measured 
effect and the duration of exposure to the test compound. These include microscopic 
examination of blood films for the WHO mark III test (inhibition of maturation or 
replication; Giemsa-stained), the radioisotopic test (incorporation of hypoxanthine), the 
enzyme-linked immunosorbent assay (ELISA) with antibodies directed against Plasmodium 
lactate dehydrogenase or histidine-rich protein II (Noedl et al. 2002; Olliaro 2005) and 
fluorometric assays with DNA biding fluorescent dyes (Noedl et al. 2003; Corbett et al. 
2004). These assays turn out to be more important with the increasing use of combination 
therapy, since they can be used to monitor susceptibility to each drug in a combination 
(Vestergaard and Ringwald 2007). 
The in vitro drug sensitivity assays are very useful but they have significant 
disadvantages. These methods are very costly and time consuming, requiring very well 
trained personnel with access to advanced laboratory facilities capable of performing 
parasite culture (Basco and Ringwald 2000). Even when provided with such facilities some 
aspects of the parasite might be lost during long term adaptation to ideal conditions 
(LeRoux et al. 2009). Moreover, in part because these tests remove the host factors, the 
correlation of in vitro response with clinical response is not always reliable and is not well 
understood. The requirement of some prodrugs to be metabolized in vivo is also a 
drawback of in vitro tests. 
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In vitro drug sensitivity data may provide early evidence of increasing drug tolerance 
prior to parasitological/clinical resistance. Conversely, it may give misleading indications if 
the changes in sensitivity do not ultimately translate into parasitological/clinical resistance 
(Hastings et al. 2007). 
 
Once the genetic changes associated with resistance are identified, drug resistance can 
be confirmed with molecular techniques. 
 
 MOLECULAR MARKERS 
Molecular markers for drug resistant malaria offer promising advantages to the 
methods described above and are essential public heath surveillance tools (Plowe et al. 
2007). Examination of molecular markers allow the assessment of a large number of 
samples and is less expensive compared with clinical studies involving more patient care 
and follow-up (Ekland and Fidock 2008). Sample collection, storage and transport of 
specimens for subsequent molecular analysis is far easier than for in vitro tests (WHO 
2003). In the era of combination therapies, molecular markers of resistance can 
discriminate associations between individual mutations and the response to each drug 
(Picot et al. 2009). Furthermore, monitoring of molecular markers may also help in tracking 
the rates of resistance in a certain area after withdrawal of an antimalarial drug, where it 
would be unethical to conduct in vivo tests (Kublin et al. 2003). 
Molecular markers for drug resistant malaria are based on genetic changes that confer 
parasite resistance to drugs. These genetic mechanisms of P. falciparum drug resistance 
have not been completely elucidated in every case. However, relatively well defined 
molecular markers of resistance have been established for the principal chemical families 
of antimalarials in current use. Multiple mutations in the P. falciparum chloroquine 
resistance transporter (PfCRT) confer resistance to CQ (Ecker, Lehane, Clain, et al. 2012). 
Mutations in the P-glycoprotein homologue (Pgh1) encoded by pfmdr1 (P. falciparum 
multidrug resistance gene 1) may further modulate the extent of CQ resistance (Fidock et 
al. 2000; Reed et al. 2000). Polymorphisms and/or amplification of pfmdr1 have also been 
shown to affect the susceptibility to structurally unrelated antimalarial drugs, including 
mefloquine, artesunate, lumefantrine and QN (Price et al. 1996; Sidhu et al. 2005). 
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Resistance to SP is conferred by mutations in the dihydropteroate synthase (pfdhps) and 
dihydrofolate reductase (pfdhfr) genes, respectively (Gregson and Plowe 2005; Muller and 
Hyde 2013). Atovaquone resistance is linked to mutations on the cytochrome b gene. The 
pfnhe-1 gene, which encodes a putative Na+/H+ exchanger has been associated with QN 
resistance, but additional studies are needed to validate this marker (WHO 2010a). 
Disadvantages of the molecular surveillance include the need for sophisticated 
equipment and well trained personnel and the fact that only a limited number of genes 
involved or potentially involved in P. falciparum antimalarial drug resistance have been 
identified. Similar to the limitations of in vitro tests, the presence of particular molecular 
marker does not necessarily directly predict treatment outcome, especially when 
resistance involves more than one gene locus and/or multiple mutations (Sidhu et al. 
2002). The presence of mutations in the above genes contributes to drug failure but the 
final outcome is not certain: some patients with “resistant” alleles clear the infection, and 
some patients with “sensitive” alleles failed treatment. Consequently we should consider 
that mutations increase the probability of drug failure that ultimately depends on factors 
such as host immune response, the drug dose taken, and variation in drug absorption and 
metabolism (Hastings 2007). 
These methods should be considered as complementary rather than competing 
sources of information about drug resistance, with critical treatment strategy implications. 
 
1.8.MODES OF ACTION AND MECHANISMS OF PARASITE RESISTANCE  
Several studies on the underlying mechanisms of drug resistance have shown that 
parasite survival can be achieved by one or more of the following mechanisms:  
Alterations in the drug target -The parasite can eliminate the drug target, inducing an 
alternative pathway; can alter the target’s affinity for the drug, by the introduction of 
mutations in the target gene, or can overexpress the drug target (gene amplification); 
Drug target unchanged - The parasite can alter the intracellular drug levels by the 
development of drug transporters that modulate the uptake or export of the drug; 
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Dormancy - Parasites can go into a state of quiescence where they are protected from 
the drug lethal effects, but are able to recover at a later stage and resume normal growth, 
after cessation of therapy; 
Overexpression of biological mechanisms to handle the drug effects - overexpression 
of genes involved in the DNA repair mechanism or in the oxidative stress response. 
 
Current knowledge on the mechanism of action, resistance and on the molecular 
markers of resistance is summarized below. 
 
 Quinolines and related compounds 
All quinolines, with the exception of primaquine, are thought to exert an antimalarial 
action by interfering with the formation of haemozoin, within the parasite’s digestive 
vacuole (Muller and Hyde 2010). During the intraerythrocytic development, P. falciparum 
digests 60-80% of the erythrocyte haemoglobin content to obtain a major source of its 
amino acid requirements and to avoid the erythrocyte premature rupture (Krugliak et al. 
2002; Lew et al. 2003). A byproduct of haemoglobin digestion is free haem that is toxic to 
the parasite, as it causes lethal changes to membranes and proteins. To avoid haem toxicity 
the parasite converts it into an insoluble form called haemozoin (Bray, Ward, et al. 2005). 
 
Quinine 
The mode of action of QN is only partially understood. QN shares some common 
characteristics with other quinoline antimalarial drugs such as CQ. QN, like CQ, accumulates 
in the parasite’s digestive vacuole and can interact with haem, but binds to it with lower 
affinity than CQ (Sullivan et al. 1998; Sanchez et al. 2008). For that reason, it was 
hypothesized that QN also acts through haem detoxification inhibition (Foley and Tilley 
1997; Fitch 2004). However is not clear whether haem is the only or even the major target 
for QN.  
Despite the widespread use of QN in the nineteenth century, high level resistance to the 
drug has been very slow to develop. The first documented reports of QN resistance are 
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from 1910 (Peters 1982; Mwangi and Ranford-Cartwright 2013). However, high levels of 
resistance are rare and limited (Wongsrichanalai et al. 2002; Okombo et al. 2011). The slow 
development and spread of QN resistance was possibly a result of a multigenic response of 
the parasite (Ferdig et al. 2004; Nkrumah et al. 2009). In fact, the genetic basis for 
resistance to QN has been associated with several genes, probably working synergistically. 
Currently, 4 genes have been identified: P. falciparum chloroquine resistance transporter 
gene (pfcrt) (Cooper et al. 2002; Cooper et al. 2007), the multidrug resistance transporter 1 
gene (pfmdr1) (Reed et al. 2000; Sidhu et al. 2006) and more recently the resistance 
protein gene (pfmrp) (Mu et al. 2003) and the sodium/proton exchanger 1 (pfnhe1) (Ferdig 
et al. 2004).  
 
Chloroquine and Amodiaquine 
Despite years of research, the exact mechanism of CQ remains a controversial area. CQ 
is a diprotic weak base and diffuses freely between the extracellular matrix and the acidic 
digestive vacuole of the parasite. After diffusing to the vacuole, CQ becomes protonated 
and since membranes are not permeable to charged species, CQ becomes trapped 
(Homewood et al. 1972; Ferrari and Cutler 1991). This ion-trapping mechanism leads to CQ 
accumulation inside the digestive vacuole (Hawley et al. 1996). In the digestive vacuole, CQ 
binds to haem, which prevents its polymerization into haemozoin. This leads to 
accumulation of the toxic free haem and later on to oxidative stress and membrane 
damage within the parasite (Sullivan et al. 1998; Warhurst et al. 2007; Roepe 2009)  
CQ was a victim of improper use. In the early 1960s, CQ was included in table salt and 
used in population based prophylaxis regimens in an effort to eradicate malaria (Peters 
1987). Unfortunately, shortly afterwards, the first cases of CQ resistance emerged in the 
same areas where chloroquinized salt was distributed (Foley and Tilley 1998). Regardless of 
the extensive use of the drug, there was nearly a 20 year lag between the introduction of 
CQ in 1950s and the widespread occurrence of resistance, suggesting a complex 
mechanism of resistance implicating multiple mutations or several genes. The first cases of 
CQ resistant parasites came from South America (Columbia, Brazil and Venezuela) in 1960 
(Wernsdorfer 1991) and these were followed soon afterwards by sporadic reports of 
resistance in Southeast Asia (Thailand and Kampuchea) in 1961 (Wernsdorfer 1991). By 
1973 CQ resistance was widespread in South America and Asia. Molecular epidemiological 
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studies suggest that resistance then spread from Southeast Asia to Africa in the late 1970s, 
when its emergence was first reported in Kenya and Tanzania (Campbell et al. 1979; Fogh 
et al. 1979).  
CQ resistant parasites accumulate less CQ in the digestive vacuole than sensitive strains, 
consequently keeping the drug concentration below toxic levels (Saliba et al. 1998; Bray, 
Ward, et al. 2005). Studies of a genetic cross between HB3 (CQ sensitive) and Dd2 (CQ 
resistant) strains have shown that resistance is mainly determined by the selection of a 
mutant form of PfCRT protein (Wellems et al. 1991; Su et al. 1997; Fidock et al. 2000). 
PfCRT, has since been shown to localize in the parasite’s digestive vacuole (Fidock et al. 
2000; Cooper et al. 2002), where it can control the access of CQ to haem. Furthermore, 
bioinformatic analyses predict PfCRT to be a member of the “drug/metabolite transporter” 
superfamily (Martin and Kirk 2004). The normal physiological function of PfCRT is still 
poorly understood and at the moment there are two main theories proposed; PfCRT can 
act as either a channel (allowing protonated CQ to exit the digestive vacuole) or as an 
active transporter protein (Warhurst et al. 2002; Bray et al. 2006; Sanchez et al. 2007). 
Linkage studies demonstrated an association between an amino acid substitution at 
position 76 from lysine to threonine (K76T) and CQ resistance in culture adapted isolates 
from different geographic areas (Fidock et al. 2000). The importance of the K76T mutations 
appears to be due to the loss of positive charge within the channel. This mutation is 
predicted to alter the selectivity of the protein such that it is able to transport the positively 
charged CQ allowing its exit from the digestive vacuole, and therefore away from its site of 
action (Warhurst et al. 2002; Lehane and Kirk 2008). 
Genetic sequencing has revealed that other changes occur in combination with K76T 
which have different geographic distributions and different drug resistant phenotypes 
(Bray, Martin, et al. 2005; Sa et al. 2009). These extra mutations are possibly compensatory 
mutations for unfavorable changes in the normal function of PfCRT (Hyde 2007). CQ 
resistant forms are classified by the amino acid positions 72-76: CVMNK is the sensitive 
haplotype; the SVMNT and CVIET are the resistant haplotypes, although there are many 
other rarer haplotypes at these residues found in the field (Cooper et al. 2005; Summers et 
al. 2012). CVIET is by far the most dominant mutant haplotype in Africa and also found in 
Southeast Asia and South America, while SVMNT haplotype had been reported mainly in 
South America (Fidock et al. 2000; Cooper et al. 2005; Gama et al. 2010), Papua New 
Guinea (Mehlotra et al. 2001) and in the Philippines (Chen et al. 2005). 
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Another gene associated with CQ resistance is pfmdr1. Pfmdr1 encodes a homologue of 
mammalian multidrug resistance gene (mdr1) called P-glycoprotein homolog 1 (Pgh1) 
(Foote et al. 1990). When mutant PfCRT is present mutations on pfmdr1 have been found 
to modulate the degree of CQ sensitivity, particularly mutations at codon positions 86, 184, 
1034, 1042 and 1246 (Sa et al. 2011; Ecker, Lehane, Clain, et al. 2012). Interestingly 
amplification of wild type form of this gene has been implicated in increased CQ sensitivity 
(Price et al. 2004; Sa et al. 2011). On the contrary, parasites with multiple copies of pfmdr1 
appear to be less sensitive to mefloquine, QN and ARTs (Sidhu et al. 2005). 
 
Amodiaquine is an important ACT partner drug, since artesunate-amodiaquine is 
presently the second most commonly used ACT in the world (Zwang et al. 2014). 
Amodiaquine is structurally related to CQ and is rapidly metabolised in vivo into 
monodesethylamodiaquine, its primary metabolite. Based on structural similarity, 
amodiaquine is hypothesized to act also by inhibiting haem detoxification. Furthermore, 
like CQ, amodiaquine has been shown to accumulate within the digestive vacuole, bind to 
haem and to inhibit haem polymerization in vitro, with a similar efficiency to CQ (Foley and 
Tilley 1998; Hayeshi et al. 2008). 
Cross resistance between CQ and amodiaquine has been reported however, strains of P. 
falciparum resistant to CQ are not necessarily also resistant to amodiaquine (Sa et al. 
2009). Resistance to amodiaquine has been associated with the 76T mutation in pfcrt 
(Ochong et al. 2003). Furthermore, the strongest association with amodiaquine in vitro 
resistance has been found with the pfcrt SVMNT haplotype. The SVMNT haplotype is 
associated with high levels of amodiaquine resistance, but only moderately resistance to 
CQ, whereas the CVIET haplotype is linked to greater resistance to CQ and moderate 
resistance to amodiaquine (Sa et al. 2009). This association was also establish in vivo by 
Beshir et al., who described that the presence of the SVMNT haplotype is enough to confer 
amodiaquine resistance (Beshir, Sutherland, et al. 2010). The effects of the pfcrt haplotypes 
in amodiaquine resistance is further modulated by mutations in pfmdr1 (Sa et al. 2009). 
The pfmdr1 polymorphisms 86Y, 184Y and 1246Y (YYY haplotype) were found to be 
selected after treatment with amodiaquine monotherapy or artesunate-amodiaquine 
combination therapy in East Africa (Holmgren et al. 2007; Humphreys et al. 2007; Nsobya 
et al. 2007)  
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Pyronaridine 
Pyronaridine is highly active against erythrocytic stages of malaria parasites but its 
mechanism of action is not yet understood. Some studies suggested that pyronaridine can 
interfere with the food vacuole of the parasite (Croft et al. 2012) while other studies 
reported that pyronaridine inhibits the decatenation activity of P. falciparum 
topoisomerase II (Chavalitshewinkoon et al. 1993). Pyronaridine is also thought to target β-
hematin formation. Additionally, it can interfere with a glutathione-dependent heme 
degradation process by forming a drug-haematin complex and inducing the lysis of the red 
blood cells (Auparakkitanon et al. 2006). 
There are conflicting reports on in vitro cross resistance between pyronaridine and CQ. 
In some studies pyronaridine does not appear to show cross-resistance with CQ (Basco and 
Le Bras 1992; Chang et al. 1992; Ringwald et al. 1996) although in other studies evidence of 
cross resistance between the two drugs is found (Schildbach et al. 1990; Pradines et al. 
1998; Caramello et al. 2005). On the other hand, clinical trials have shown that 
pyronaridine has good efficacy against CQ resistant strains (Looareesuwan et al. 1996; 
Ringwald et al. 1996; Ringwald et al. 1998).  
The use of pyronaridine has been limited to China therefore it is expected that 
resistance will be slow to develop across other regions with malaria. However, in vitro 
studies indicate that the sensitivity to this drug decreased in China between 1988 and 1995 
(Yang et al. 1997). These data suggest that the resistance to pyronaridine may have already 
developed but the molecular mechanism is unknown.  
 
Primaquine 
Primaquine (probably as its metabolites) is active against gametocyte and hypnozoite 
stages and its mode of action appears to be quite distinct from all the other quinolines. 
However, the precise mechanism of action is still unknown. Treatment with primaquine 
causes swelling and thickening of the mitochondria of tissue stage parasites suggesting that 
it exerts its activity by disrupting the metabolic processes of parasite mitochondria. Possibly 
by interference with the ubiquinone function (Vale et al. 2009), in a similar way to 
atovaquone, which has been shown to inhibit the cytochrome bc1 complex of the 
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mitochondrial respiratory chain and collapse the mitochondrial membrane potential (see 
atovaquone section for more details) (Foley and Tilley 1998). 
The activity of primaquine against gametocytes and dormant stages has been attributed 
to the inability of these stages to repair damaged mitochondria (Warhurst 1984) and the 
damage is possibly caused by the primaquine-induced production of highly reactive 
metabolites that generate toxic intracellular oxidative potentials (Hill et al. 2006). 
Resistance to primaquine is rarely reported (White 2004; Vale et al. 2009) and the 
possible mechanism of resistance is unknown. 
 
Piperaquine 
Due to structural similarities with CQ, it was postulated that piperaquine and CQ share a 
similar mode of action. Studies have shown that piperaquine concentrates in the digestive 
vacuole and that it is a potent inhibitor of haem polymerization (Raynes 1999; Warhurst et 
al. 2007) however, the exact mechanism of action of piperaquine is still unknown. 
Resistance to piperaquine is known to have developed in China where this drug was 
used intensively in the late 1970s (Tran et al. 2004) resulting in the subsequent decline in 
its use (Davis et al. 2005). There are high rates of piperaquine resistance in China but the 
genetic determinant has not yet been identified (Hao et al. 2013).  
In vivo studies on African P. falciparum isolates have demonstrated that piperaquine 
does not exhibit cross-resistance with CQ and that modulation of piperaquine resistance is 
not modulated by mutations in the pfcrt gene (Pascual et al. 2013). Moreover, piperaquine 
has excellent activity against CQ resistant parasites indicating that these two drugs have 
different resistant mechanisms. This characteristic can be explained by the fact that 
piperaquine has four positive charges and may be more efficiently trapped inside the 
digestive vacuole or by its steric bulk (the amount of space that the piperaquine molecule 
occupies), which prevents it from fitting into the binding site of PfCRT (O’Neill et al. 2012b). 
Recently, studies have suggested that a copy number variation on chromosome 5 (not 
pfmdr1) is associated with piperaquine resistance in vitro (Eastman et al. 2011). 
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Mefloquine 
Mefloquine competitively inhibits CQ accumulation, and vice-versa, suggesting that they 
share the same mechanisms of accumulation (Foley and Tilley 1998). However, mefloquine 
interacts weakly with free haem with corresponding less effect on haem polymerization, 
when compared with CQ (Dorn et al. 1998). Mefloquine is a much weaker base than CQ 
and should accumulate less well, in the acidic digestive vacuole. Nevertheless, is a more 
potent inhibitor of the growth of drug-sensitive strains than CQ (Foley and Tilley 1998). 
Therefore, these observations suggest that these drugs interact at different points within 
the haemoglobin degradation pathway or that other targets are implicated in the 
mefloquine mode of action (Foote and Cowman 1994; Foley and Tilley 1998). 
Mefloquine resistance was reported from the Thai-Myanmar and the Thai-Cambodian 
borders in 1982, where mefloquine was used intensively as treatment for uncomplicated 
malaria (Wongsrichanalai et al. 2001; White 2004). Resistance is not widespread and 
mefloquine is still effective outside SE Asia and in some regions of South America.  
The exact mechanism of mefloquine resistance is still unclear, although studies 
conducted in the Greater Mekong subregion (Cambodia and Thailand) report that 
mefloquine resistance is associated with an increase in the parasite pfmdr1 copy number 
(Price et al. 2004). Furthermore, in vitro susceptibility to mefloquine and QN increased 
when the parasites carried pfmdr1 mutations (S1034C/N1042D/D1246Y) and decreased 
when the wild-type pfmdr1 copy number was increased (Sidhu et al. 2005; Sidhu et al. 
2006; Chaijaroenkul et al. 2010).  
One interesting observation is that there seems to be an inverse relation between 
mefloquine and CQ sensitivity. Thus, the selection for high levels of mefloquine resistance 
and the presence of increased pfmdr1 copy number are often associated with increased 
sensitivity to CQ and vice versa (Hayton and Su 2004). The MDR1-Pgh1protein is localized 
on the digestive vacuole membrane (Cowman et al. 1991), where it functions as a 
transporter (Rohrbach et al. 2006), and has been identified as a possible modulator of 
resistance to a diverse range of antimalarial drugs probably by directly or indirectly 
removing the drugs from their sites of action (Rubio and Cowman 1996). It is believed that 
the site of action of CQ is the digestive vacuole, consequently concentrating the drug in this 
compartment may be prejudicial for the parasite; on the contrary, the accumulation of 
mefloquine (and artemisinin) in the digestive vacuole may be advantageous to the parasite 
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if the drug has a different target site. Alternatively, it has been suggested that Pgh1 may be 
the molecular target of mefloquine (Rubio and Cowman 1996; Gavigan et al. 2007). 
 
Lumefantrine 
The mechanism of action of lumefantrine is not known. Lumefantrine inhibits 
haemozoin formation suggesting that lumefantrine, like CQ, interferes with haemoglobin 
detoxification (Combrinck et al. 2013). This might be one but not the only mechanism of 
action of lumefantrine. In fact, a recent study suggests that lumefantrine exerts its 
antimalarial action by interfering with membrane phospholipids (Mwai et al. 2012). 
Lumefantrine has never been used as monotherapy and resistance to lumefantrine in 
field isolates has not yet been convincingly demonstrated (Kokwaro et al. 2007). However, 
lumefantrine tolerant parasites were reported in isolates from Tanzania after treatment 
with artemether-lumefantrine. This phenotype was associated with polymorphisms in 
PfMDR1, particularly the wild type variant N86 (Sisowath et al. 2007) and with 
amplifications in PfMDR1 (Price et al. 2006; Sisowath et al. 2007). Additionally, parasites 
with the wild type PfCRT show reduced susceptibility to lumefantrine (Sisowath et al. 2009; 
Eyase et al. 2013). 
More recently, lumefantrine tolerance in vitro was associated with changes in gene 
expression profiles on 184 P. falciparum genes, detected using microarray assays. Among 
those are known and putative transporters, including the pfmdr1 gene and the multidrug 
resistance associated protein and the V-type H+ pumping pyrophosphatase 2 (pfvp2) 
although, further validation is needed to confirm the role of these genes on lumefantrine 
resistance (Mwai et al. 2012). 
 
Atovaquone 
Atovaquone is a structural analogue of protozoan ubiquinone (also called coenzyme Q), 
a vitamin like substance involved in electron transport in the mitochondria (Baggish and Hill 
2002). Atovaquone binds irreversibly to the mitochondrial cytochrome bc1 complex of P. 
falciparum inhibiting the natural function of ubiquinone. Ubiquinone participates in 
mitochondrial membrane electron transport by accepting electrons from a number of 
dehydrogenase enzymes and passing them to the cytochromes. Since blockage of the 
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electron transport chain means that dihydroorotate dehydrogenase, a key enzyme in 
pyrimidine biosynthesis, is unable to transfer electrons to ubiquinone, blockage of the 
electron transport chain ultimately inhibits de novo pyrimidine biosynthesis. The inhibition 
of electron transfer in the mitochondrion not only results in inhibition of pyrimidine 
biosynthesis but also collapses the parasite mitochondrial membrane electrochemical 
potential, two essential processes that contribute to parasite death (Srivastava et al. 1997; 
Baggish and Hill 2002; Biagini et al. 2006). Atovaquone acts on all growing stages of the life 
cycle due to its antimitochondrial activity, but does not affect hypnozoites. 
Within only a few years of application in the field atovaquone resistance was observed 
with point mutations in the cytochrome b gene, principally affecting position 268, either 
exchanging a tyrosine for a serine (Y268S) (Korsinczky et al. 2000; David et al. 2003; Farnert 
et al. 2003; Schwobel et al. 2003; Legrand et al. 2007; Musset et al. 2007) or less frequently 
for asparagine (Y268N) (Fivelman et al. 2002) or for cysteine (Musset et al. 2007; 
Sutherland et al. 2008), associated with drastic reductions in parasite susceptibility to the 
drug. 
 
 Antifolate-resistance 
The malaria parasite is unable to consume pyrimidines already synthesized by the host 
and for that reason must produce its own (Le Bras and Durand 2003). Pyrimethamine is a 
potent inhibitor of the dihydrofolate reductase (DHFR) enzyme which is encoded by the 
dhfr gene that exists as a bifunctional enzyme together with thymidylate synthase (TS) 
(Ivanetich and Santi 1990), while sulfadoxine targets the dihydropteroate synthetase 
(DHPS) domain of the bifunctional 7,8-dihydro-6-hydroxymethylpterin pyrophosphokinase-
DHPS enzyme, encoded by the dhps-pppk gene (Brooks et al. 1994). Both enzymes are part 
of the parasite folate synthetic pathway and the inhibition of these enzymes leads to 
interruption of the DNA synthesis and nuclear division. Unfortunately, falciparum parasites 
are able to quickly accumulate multiple genetic mutations producing enzymes resistant to 
such drugs (Sibley et al. 2001) (Hyde et al., 2007). 
Resistance to pyrimethamine occurred soon after its deployment as antimalarial 
(Petersen 1987) and resistance to the SP combination was reported rapidly after its 
introduction in both Southeast Asia and the Amazon basin in the mid-1970s (White 1992; 
Anderson and Roper 2005). The expansion of SP resistance did not happened as quickly as 
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the expansion to CQ resistance, in Africa the emergence of SP resistance was only reported 
in the 1990s, in Tanzania (Ronn et al. 1996). Even nowadays, SP treatment failure due to 
high-level parasite resistance is widespread in South America and Asia and is common in 
East Africa, although SP retains some efficacy in West Africa (WHO 2010a). 
The mechanism of resistance is attributed to mutations in the encode drug targets (dhfr 
and dhps genes) of P. falciparum. Both the dhfr and dhps gene mutations occur in a 
progressive stepwise manner, with higher levels of resistance occurring in the presence of 
multiple mutations. A point mutation at position 108, changing a serine to an asparagine 
(S108N), in the dhfr gene product is the first step for acquiring increased resistance to 
pyrimethamine. Addition of subsequent mutations at positions 50, 51, 59, and 164 
increases the level of pyrimethamine resistance (Peterson et al. 1988; Snewin et al. 1989). 
Mutations at amino acid positions 436, 437, 540, 581 and 613 in DHPS decrease this 
enzyme’s affinity for sulfadoxine. Like DHFR, the increasing of in vitro resistance to 
sulfadoxine is generally associated with the number of amino acid substitutions in the DHPS 
enzyme. An alanine to glycine substitution at position 437 (A437G) has been proposed as 
the first step to sulfadoxine resistance (Wernsdorfer and Noedl 2003). 
These mutations reduce the binding affinity of the drugs to their targets while still 
enabling the parasite to manipulate the folic acid synthesis pathway for its own benefit 
(Snewin et al. 1989; Wernsdorfer and Noedl 2003). 
 
 Antibiotics 
The mechanism of action of antibiotics against malaria parasites is unclear however they 
are thought to act against the parasite by inhibiting protein synthesis, as they do in bacteria 
(Warhurst 1986). Tetracyclines (tetracycline and doxycycline) and lincosamides 
(clindamycin) antibiotics exert their antibacterial effects by interfering with 70S ribosomes 
(Clough and Wilson 2001). In P. falciparum, tetracyclines have been reported to inhibit 
mitochondrial proteins, decrease dihydrooroate dehydrogenase activity, an enzyme of the 
pyrimidine pathway (Briolant et al. 2010). In addition, it was shown that clindamycin, 
doxycycline and azithromycin, cause “delayed death” by disruption of apicoplast function 
(Dahl et al. 2006; Dahl and Rosenthal 2007), though the precise mechanism remains 
uncertain. Studies in a mouse model revealed that the antibiotics inhibit apicoplast 
biogenesis in the liver stage. These drugs do not prevent the maturations of the merozoites 
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in the liver, but the produced daughter cells cannot establish a viable red blood cell 
infection. For this reason, the antibiotics are being investigated for a new vaccination 
strategy against malaria (Friesen et al. 2010). 
No clinical malaria failure with the tetracycline doxycycline have been reported yet, 
however different phenotypes of susceptibility to doxycycline have been identified among 
P. falciparum clinical isolates (Briolant et al. 2009). These different phenotypes have been 
associated with pfmdt (a putative drug/metabolite transporter gene) and pftetQ (a 
putative tetQ family GTPase gene) copy number variations (Gaillard et al. 2013). 
Clindamycin, like tetracyclines, inhibits prokaryotic protein translation, but in this case 
by binding to the 50S ribosomal subunit (comprising the 23S rRNA and the 5S rRNA and 
ribosomal proteins. Data on P. falciparum clindamycin resistance have been reported in 
2010 and have been associated with point mutations on the apicoplast 23S rRNA. 
Mutations on this gene have been also associated with clindamycin resistance in bacteria 
(Ecker, Lehane and Fidock 2012). 
 
 Artemisinins 
ART is a sesquierpene trioxane lactone that contains an endoperoxide bridge (C-O-O-C; 
Figure 1.3) that provides a structure very different from any of the previously known 
antimalarial drugs (i.e., quinolines and antifolates) (Klayman 1985; Hien and White 1993; 
Barradell and Fitton 1995). Despite several years of research, the molecular mechanism of 
action of ARTs remains uncertain although most studies agree that their antimalarial 
activity is dependent on the reactivity of the endoperoxide bridge (Avery et al. 1993; 
Meshnick et al. 1996; Golenser et al. 2006). ARTs are considered prodrugs that need to be 
activated before it becomes effective (Krishna et al. 2004b) but the mechanism responsible 
for ARTs activation is unclear. Early studies done by the Meshnick group (Meshnick et al. 
1991; Meshnick 1994b) suggested that ART is activated by iron (II) to produce free toxic 
activated oxygen. After that two different mechanisms have been proposed that differ by 
their dependency on iron and contribution of carbon centred radicals. In the reductive 
scission model, the peroxide bridge is cleaved by low-valent transition irons (ferrous haem 
or nonhaem, exogenous divalent Fe2+), producing oxygen centred radicals that rearrange to 
produce carbon centred radicals (Posner et al. 1995; O'Neill et al. 2000; Jefford 2001; 
Olliaro et al. 2001). Alternatively, the open peroxide model, suggests that the peroxide ring 
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is opened by protonation (H+) or by complex formation with a metal iron (Fe2+). This 
mechanism has the potential of producing reactive oxygen species (Haynes et al. 2007; 
O'Neill et al. 2010).  
Once activated ARTs were hypothesized to cause damage to different cellular targets 
present in the surrounding environment. They can impair the haem detoxification pathway 
by alkylating intracellular haem and inhibiting its polymerization to non toxic haemozoin 
(Meshnick et al. 1991; Robert et al. 2005; Creek et al. 2008). The free radicals generated by 
the ARTs activation may interfere with the proper function of key parasite proteins 
(Meshnick 2002; Wu et al. 2003) such as proteases involved in haemoglobin degradation 
and the translationally controlled tumor protein, a protein that binds haem (Bhisutthibhan 
and Meshnick 2001; Haynes et al. 2007; O'Neill et al. 2010).  
Alternative views propose the sarcoplasmic endoplasmic reticulum calcium ATPase 
(PfATP6 or PfSERCA) gene of Plasmodium as a possible parasite specific target. This is based 
on structural similarity between ARTs and thapsigargin (another sesquiterpene lactone), an 
inhibitor of human sarco-endoplasmic reticulum calcium dependent ATPase (SERCA) 
(Eckstein-Ludwig et al. 2003). PfATP6 is thought to be critical for parasite survival 
(Vennerstrom et al. 2004) and studies suggested that mutations on this enzyme modulate 
the affinity of ART for the protein (Eckstein-Ludwig et al. 2003; Uhlemann et al. 2005). In 
fact, ART can inhibit the activity of ATPase6 in transfected Xenopus laevis oocytes (Eckstein-
Ludwig et al. 2003), and a single amino acid substitution in ATPase6 (L263E) is enough to 
prevent ART’s inhibitory effects (Uhlemann et al. 2005). Since this work was published 
there have been several studies which contradict this hypothesis. A subsequent study 
showed no antagonism between thapsigargin and artemisinin, contradicting the original 
work (del Pilar Crespo et al. 2008). The use of P. falciparum transgenic parasites carrying 
the L263E mutation showed a barely significant small reduction in the susceptibilities to 
ART and dihydroartemisinin, but not to artesunate when compared with the wild-type 
strain (Valderramos et al. 2010). 
ART has also been shown to inhibit the respiratory chain of the mitochondria (Wang et 
al. 2010). Using a yeast model the authors proposed a dual role of mitochondria on ART 
mode of action: the ART is activated by the electron transport chain which generates free 
radicals that damage the mitochondria (Li et al. 2005; Wang et al. 2010). Furthermore, 
Hartwig and colleagues have shown that ARTs accumulate within neutral lipids and can 
damage the membranes of the parasite (Hartwig et al. 2009). 
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The first signs of suspected ART resistance were reported near the Thailand-Cambodian 
border (Vijaykadga et al. 2006) following artesunate-mefloquine, but was not possible to 
confirm if the ACT clinical failure was due to artesunate or the partner drug. Subsequent 
studies in western Cambodia and northwestern Thailand confirmed artesunate tolerance 
characterized by delayed clearance times after artesunate monotherapy (Noedl et al. 2008; 
Dondorp et al. 2009). 
For now, the resistance appears to be confined to the Greater Mekong subregion and 
early signs of ART resistance were confirmed in at least 16 sites in Cambodia, Laos, 
Myanmar, Thailand and Viet Nam (WHO 2014). However, a recent study from Kenya 
suggested a reduced sensitivity to ART derivatives (Borrmann et al. 2011). 
Many genes have been implicated in resistance to this class of compounds. Uhlemann 
and colleagues suggested that resistance to ARTs may depend on a single nucleotide 
polymorphism in the drug’s putative chemotherapeutic target, the pfatpase6 gene 
(Uhlemann et al. 2005). A subsequent study report that P. falciparum parasites from French 
Guiana harbouring mutant forms of the pfATPase6 gene (S769N) displayed significantly 
increased IC50s to ARTs, suggesting its role in ART resistance (Jambou et al. 2005). However, 
mutations in this gene are not associated with resistance in field isolates from elsewhere 
(Dahlstrom et al. 2008; Jambou et al. 2010). Causal unequivocal association between 
mutations in the pfATPase6 gene and resistance to ARTs has not yet been established 
though. 
Amplification of PfMDR1 has been linked to the parasite’s ability to modulate ART in 
vitro responses in previous work (Duraisingh et al. 2000; Reed et al. 2000; Price et al. 2004). 
In an attempt to clarify the role of pfmdr1 amplification in this phenotype, Sidhu et al. 
(Sidhu et al. 2006) genetically abolished one of the two copies of the gene in the multi-drug 
parasite P. falciparum line FCB. In vitro assessment of the resulting knock-out mutant 
harboring a single gene copy revealed that its sensitivity to ART had approximately halved, 
providing the first direct evidence as to the ability of pfmdr1 copy number to modulate this 
phenotype.  
However, no correlation was found between pfATPase6 or pfmdr1 genes and in vivo 
resistance to ARTs in the first confirmed cases of resistance along the Thai/Cambodian 
border (Imwong et al. 2010).  
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It has since been shown that ART resistance is a heritable trait (Anderson et al. 2010) 
and different genome wide association studies have proposed several candidate genomic 
regions/genes associated with the Cambodian ART resistance phenotype, including a region 
on chromosome 13 (containing seven candidate genes) (Cheeseman et al. 2012), and point 
mutations on chromosomes 10, 13 and 14 (Takala-Harrison et al. 2013). However, the role 
in ART resistance of these new candidates needs further genetic evaluation, as do 
additional chromosome regions implicated in unusual population structure observed in 
western Cambodia, which may be linked to ART sensitivity (Miotto et al. 2013). 
Mutations on the kelch propeller domain gene (“K13-propeller”) have recently been 
proposed as a molecular marker of ART resistance. Using a Tanzanian laboratory adapted 
strain, selected to survive high doses of ART, Ariey and colleagues found an association 
between mutations in seven genes and ART resistance in vitro (measured on small rings 
with only 3 hrs exposure to drug), with one of them being the K13-propeller gene (pfk13). 
Subsequently they investigated the role of these candidate genes in ART resistance, using 
parasite lines from Cambodia. They demonstrated that Y493H, R539T and C580Y mutations 
on the K13-propeller were correlated with the in vivo delayed parasite clearance 
phenotype followed by ART treatment and Y493H, I543T, R539T, and C580Y mutations 
were associated with a prolonged parasite ex vivo survival (Ariey et al. 2014). Additional 
studies have confirmed the association between clinical slow clearance phenotype from 
other Southeast Asian populations (Vietnam, Myanmar, Laos and Thailand) and different 
polymorphisms in the propeller region of pfk13 (Amaratunga et al. 2014; Ashley et al. 
2014). The polymorphisms associated with artemisinin resistance in Southeast Asia were 
not detected in other countries in Africa (Ashley et al. 2014; Taylor et al. 2015). However, 
other non-synonymous SNPs were identified in African samples with unclear phenotype 
(Taylor et al. 2015). 
Recently, two independent transfection based studies have now confirmed this 
association. The mutation C580Y was introduced in the genome of a P. falciparum strain 
susceptible to artemisinin using the CRISPR-Cas9 system, and consequently increased the 
ring-stage parasite survival in presence of artemisinin (Ghorbal et al. 2014). In addition, 
parasites engineered to express K13 mutations have shown incresed in vitro resistance in 
the RSA0-3h ring-stage survival assay, as well as a loss of resistance in parasites whose 
mutant K13 gene was reverted back to the wild-type sequence (Straimer et al. 2015). 
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1.9.PLASMODIUM CHABAUDI MODEL SYSTEM 
Field studies of human malaria parasites provide a very limited amount of information 
about the mechanisms underlying drug resistance. Consequently, the genetic basis of 
drug resistance in malaria must be investigated by other ways .  
An alternative approach that has been used to identify the mechanism of ART resistance 
is the selection of the rodent malaria parasite Plasmodium chabaudi under sustained drug 
pressure in vivo. One of the most appropriate ways is to use genetically stable 
resistant mutants selected through drug pressure from cloned sensitive parasite 
lines. In this way, drug sensitive and drug resistant parasites are genetically 
identical (isogenic) except for the mutation involved in resistance; such mutations 
can then be identified using different approaches like genetic linkage analysis or 
whole genome sequencing.  In vitro studies with human malaria parasites present several 
limitations, the selection of in vitro resistance can be extremely laborious and it is very 
difficult to generate a stable drug resistant strain (Nzila and Mwai 2010). Identification of 
causative mutations requires controlled in vivo laboratory experiments, which are simply 
not feasible with human malarias. Therefore rodent malaria parasites have been 
widely used to study the mechanisms of drug resistance in vivo (Walker et al. 
2000; Cravo et al. 2003; Ferrer-Rodriguez et al. 2004; Afonso et al. 2006a; Hunt et 
al. 2010; Rodrigues et al. 2010; Borges et al. 2011). 
Plasmodium chabaudi chabaudi is a malaria parasite of murine rodents and it has 
been used as a model to study various aspects of parasite biology and disease which are 
difficult to investigate using human malaria parasites. There are many reasons why P. 
chabaudi is considered to be a good model for the human malaria parasite, especially in 
studies on drug resistance. This species shares a number of similarities in its basic biology 
with P. falciparum, including preferential invasion of mature erythrocytes, the synchronicity 
of their asexual blood form, sequestration of schizont-infected erythrocytes, and 
gametocyte development late in the infection (Carlton et al. 2001).  
There are many different strains of Plasmodium chabaudi however, the AS strain has 
been historically used in the experimental evolution of drug resistance, resulting in a series 
of isogenic parasites which are resistant to many different drugs (AS lineage). These 
parasites were obtained over successive generations through exposure to different 
antimalarials (Figure 1.4 and Table 1.2). As a consequence, these parasites should have the 
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same genetic background, with mutation in genes involved in resistance to the drug used 
for the selection of each clone.  
The AS isolate was originally taken from naturally infected thicket-rats (Thamnomys 
rutilans) from the Central African Republic (Carter and Diggs 1977), inoculated into 
laboratory mice and cloned by limiting dilution (Carter and Walliker 1975). The AS-SENS 
was then exposed to 75 mg/kg of pyrimethamine daily for 4 days and parasites that 
recrudesced after treatment were cloned and designated AS-PYR (Walliker et al. 1975). The 
AS-PYR parasite is resisistant to pyrimethamine and showed the substitution of a serine to 
an asparagine in position 106 (S106N) in the orthologue of P. falciparum’s pfdhfr, the 
pcdhfr gene (Cowman and Lew 1990). 
AS-PYR was then selected for resistance to chloroquine by treatment with low doses of 
chloroquine over 15 mouse passages and a line resistant to low doses of chloroquine was 
obtained (Rosario 1976). Serial passages to maintain the parasites were carried out by 
intraperitoneal inoculation of normal mice with parasitized red blood cells from a donor 
mouse. Each passage was repeated every 4-7 days, depending on the development of the 
parasite in the mice (Rosario, 1976). This line was cloned, denoted AS-3CQ and then 
subjected to further stepwise increases of chloroquine over 40 mouse passages, producing 
a line capable of surviving intermediate doses of CQ (Padua 1981). These parasites, named 
AS-15CQ did not represent a clonal population, and, furthermore, underwent mosquito 
passaging, resulting in genetic recombination among the various parasites of the 
population. The AS-15CQ was subject to further increments in chloroquine pressure to 
select parasites resistant to high levels of CQ (Padua 1981; Carlton et al. 1998). This clone 
was denominated AS-30CQ and was subsequently used for the generation of AS-ART by 
stepwise increasing doses of artemisinin during 15 passages. These parasites had a 15-fold 
increase in the minimum curative dose to artemisinin (Afonso et al. 2006b). Finally, the AS-
15CQ clone, served as progenitor for the generation of a second clone, AS-ATN. This clone 
was selected by treatment with stepwise increasing doses of artesunate during 14 passages 
and had a 6-fold increase in the minimum curative dose to artesunate (Afonso et al. 
2006b). 
The sensitive and resistant phenotypes are defined by in vivo growth recovery assays. 
These assays monitor the growth of parasites from an intraperitoneal inoculation under 
selection of a dose of drug. The time taken for parasites appearance is used as a measure 
of degree of resistance (Carlton et al., 1998, Hunt et al., 2004; Hunt et al., 2007). 
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Table 1.2 – Stable drug resistant mutants of Plasmodium chabaudi produced by drug selection. 
 
Clone Drug selection 
Drug response 
Genetic marker Refs 
Pyrimethamine Chloroquine Artemisinin 
AS-SENS None Sensitive Sensitive Sensitive / (Carter and Diggs 1977) 
AS-PYR 75mg/kg pyrimethamine 
(4 days) 
Resistant to 10 mg/kg 
pyrimethamine for 4 days 
Sensitive Sensitive Pcdhfr S106N 
(analogous to the 
Pfdhfr S108N) 
(Walliker et al. 1975; Cowman 
and Lew 1990; Cheng and Saul 
1994) 
AS-3CQ Increasing doses of CQ 
(±2 months) 
Resistant  Low resistance 
(resistant to 3 mg/kg of CQ 
for 6 days) 
Sensitive Pcaat1 (aminoacid 
transporter) A173E 
(Rosario 1976; Carlton et al. 
1998; Hunt et al. 2004; Kinga 
Modrzynska et al. 2012) 
AS-15CQ Increasing doses of CQ 
(±4 months) 
Resistant Intermediate resistance 
(resistant to 15 mg/kg of 
CQ for 6 days) 
/ This line is uncloned 
(has a mix genotype) 
(Padua 1981) 
AS-30CQ Increasing doses of CQ 
(±6 months) 
Resistant High resistance 
(resistant to 30 mg/kg of 
CQ for 6 days) 
Resistant to 100 mg/kg 
of artemisinin for 3 
days 
PCHAS_031370 
(transporter on 
chr03) T719N; Pcubp1 
V2728F 
(Padua 1981; Hunt et al. 2007) 
AS-ART Increasing doses of artemisinin 
(±4 months) 
Resistant Resistant Resistant to 300 mg/kg 
of artemisinin for 6 
days 
Pcubp1 V2728F; 
pcap2-mu I568T 
(Afonso et al. 2006a; Hunt et al. 
2007; Hunt et al. 2010); (see 
chapter 4; Henriques et al., 2013) 
AS-ATN Increasing doses of artesunate 
(±4 months) 
Resistant Resistant Resistant to 60 mg/kg 
of artesunate for 6 days 
Pcubp1 V2697F; 
pf26S-protSU E738K 
(Afonso et al. 2006a; Hunt et al. 
2007; Hunt et al. 2010); 
(Rodrigues et al., in preparation) 
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Figure 1.4. ART phenotypes and ubp-1, ap2-mu and 26S-protSU genotypes in the Plasmodium 
chabaudi (AS lineage). Parasites were selected by passage in presence of drugs (pyrimethamine, CQ, 
artesunate or ART). The appearance of mutations in the pcubp-1 gene is coincident with the 
evolution of ART-resistance phenotype during CQ selection. The AS-ART clone has a higher degree of 
resistance to ART relative to its progenitor, AS-30CQ [see Chapter 4 (Henriques et al. 2013).  
 
Research performed in the laboratories of Pedro Cravo and Paul Hunt have determined 
the genetic basis of drug resistance in some of the drug resistant AS clones, using advanced 
technology like Linkage Group Selection (LGS) and Solexa (second generation sequencing 
technology). LGS allows the identification of areas of the whole genome associated with 
drug resistant phenotypes, using the uncloned, recombinant progeny of genetic crosses 
(Culleton et al. 2005) and Solexa permits the rapid and accurate sequencing of whole 
parasite genomes and thus the identification of any mutation occurring within drug 
resistant clones by comparison with genetic related clones lacking the phenotype of 
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interest (Bentley 2006). These studies lead to the identification of three genes (Figure 1.2) 
that could potentially mediate ART resistance: a de-ubiquitinating enzyme (ubp1) (Hunt et 
al. 2007; Hunt et al. 2010), a gene encoding the mu (µ) chain of the AP2 adaptor protein 
complex (ap2-mu) (Henriques et al. 2013), and the 26S Proteasome regulatory subunit 
(26S-protSU) (Rodrigues et al., in preparation). However, the importance of the above 
mentioned markers in modulating susceptibility to the ART derivatives in the human 
malaria parasite has not yet been assessed. 
This thesis sets out to test the hypothesis that the three loci that mediate ART resistance 
in experimentally selected in P. chabaudi will similarly modify ART response in natural 
parasite populations of P. falciparum. To test this hypothesis, I will examine field isolates 
from Rwanda, Democratic Republic of São Tomé & Principe (São Tomé) Brasil and Burkina 
Faso which were fresly collected and tested in vitro for their response to ART derivatives 
and other antimalarial drugs. I will also evaluate pre- and post-treatment samples from two 
in vivo ACT trials, one carried out in Burkina Faso and the other one in Kenya. In these 
samples I will investigate the association between the presence of mutations in the pfubp1, 
pfap2-mu and pf26S-protSU genes and the in vitro responses to ART derivatives. 
Additionally, I will also investigate the association between polymorphisms on these genes 
with various measured endpoints in the two trials that might indicate a drug resistant 
parasite phenotype. If any such associations are found, a further aim will be to assess the 
functional basis of the mutation on the resulting protein, using molecular and biochemical 
techniques in an in vitro P. falciparum parasite model, and attempt to strengthen the 
evidence of a causal association with drug resistance. 
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Chapter 2 - Aims 
 
The main objective of this project is to identify and characterize the genetic 
determinants responsible for the artemisinin resistant phenotype observed in a lineage of 
P. chabaudi drug-pressured parasites and evaluate the importance of these newly 
described genes in natural parasite populations of P. falciparum. 
 
The specific objectives are as follows: 
 
Chapter 4: To genetically identify and characterize a P. chabaudi parasite that presents a 
high level of artemisinin resistance. To explore the genetic variability of the ap2-mu gene 
(identified as the genetic determinant responsible for the artemisinin resistant phenotype 
in P. chabaudi) and its associantion with in vitro P. falciparum responses against 
artemisinins. 
 
Chapter 5: To identify polymorphisms in pfubp-1 and pfap2-mu and investigate potential 
associations between the identified polymorphisms and treatment outcomes using pre- 
and post-treatment samples from an in vivo ACT clinical trial conducted in Kenya. 
 
Chapter 6: To identify polymorphisms in pfubp-1, pfap2-mu and pf26S-protSU genes and 
investigate the association between the polymorphism and in vitro response profiles to ART 
and other antimalarial drugs. 
 
Chapter 7: To characterize the role of pfap2-mu variants in mediating the in vitro 
antimalarial drug response of P. falciparum by generating transgenic parasites.  
 
Chapter 8: To determine temporal and spatial expression patterns of AP2-mu protein 
during the P. falciparum life cycle. 
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Chapter 3 – Materials and Methods 
 
3.1.PLASMODIUM FALCIPARUM ISOLATES 
In this thesis it was intended to investigate the genetic variation and possible 
contribution of mutations in the P. falciparum ubp-1, ap2-mu and 26S-protSU genes to 
artemisinin resistance in natural infections. We investigate a collection of isolates of P. 
falciparum from Rwanda, the Democratic Republic of São Tomé & Principe (São Tomé), 
Brazil, Kenya and Burkina-Faso, as described below: 
 
 Rwanda, São Tomé and Brazil 
In chapter 4 180 isolates of P. falciparum that were previously collected and tested in 
vitro for their response to several artemisinin derivatives were analyzed. Blood samples 
were collected in Rwanda during November and December 2003 (Tinto et al. 2006), in Sao 
Tomé during February 2004 (Ferreira et al. 2007) and in Brazil during September 2005 
(Ferreira et al. 2008). 
São Tomé and Brazil isolates were tested for their in vitro susceptibility to different 
antimalarial drugs using a modified version of the standard WHO MarkIII micro-test (WHO 
2001b). The in vitro drug sensitivity of Rwanda isolates was assessed using the classical 
isotopic microtest technique (Desjardins et al. 1979).  
A set of 74 isolates from Rwanda were characterized for their in vitro susceptibility to 
dihydroartemisinin. The isolates from São Tomé were characterized for their in vitro 
susceptibility to artesunate (42 isolates) and artemether (51 isolates) and 56 isolates from 
Brazil were characterized for the in vitro susceptibility to artesunate and artemether.  
 
 Mbita - Kenya 
In Chapter 5 278 P. falciparum isolates, from one ACT clinical trial conducted in Kenya, 
were investigated. The participants were enrolled between April and June 2009 at the 
International Centre for Insect Physiology and Ecology - St. Judes Clinic, Mbita, Kenya. 300 
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children between 6 months and 15 years old, diagnosed with uncomplicated P. falciparum 
malaria mono-infection were enrolled and randomized to receive either 
artemether-lumefantrine (AL, n=156) or dihydroartemisinin-piperaquine (DHA-PIP, n=144). 
Treatment efficacy was assessed during a period of 42 day follow-up (Sawa et al. 2013). 
 
 Bobo-Dioulasso - -Burkina Faso 
P. falciparum isolates used in Chapter 6 were collected from patients during a treatment 
trial in Burkina Faso. The clinical trial was carried out in three different periods (from 
December 2008 to February 2009, from July 2009 to March 2010 and from July to 
December 2010) at the Dafra Medical Centre, Bobo-Dioulasso. Participants who were at 
least 6 months of age and under 15 years old with uncomplicated P. falciparum malaria 
were enroled in the study. 440 participants were randomly assigned to receive AL or 
amodiaquine-artesunate (ASAQ). Treatment efficacy was assessed during a period of 42 
day follow-up. The isolates from this trial were tested in vitro (classical isotopic microtest 
technique) for their response to dihydroartemisinin, quinine, chloroquine, lumefantrine, 
piperaquine  and monodesethylamodiaquine (Tinto et al. 2014). 
 
3.2. DNA EXTRACTION 
In Chapter 4, 5 and 6, molecular analysis was performed from blood samples collected 
on filter paper. DNA was extracted according to the method described by Plowe and co-
workers (Plowe et al. 1995). Briefly, circular punches of 6mm diameter were taken from 
individual dried filter paper blood spots, using a sterile hole punch. Each filter paper punch 
was incubated with 1 mL of 0.5 % saponin solution in 1X phosphate buffered saline (PBS) 
overnight at 37 ⁰C. Afterwards, the samples were centrifuged briefly, saponin and debris 
were removed and the pellets washed twice in PBS. The samples were then suspended in 
6 % Chelex®100 resin in nuclease-free water and heat-sealed in deep 96-well plates. The 
samples were incubated in boiling water for 25 - 30 minutes to elute the DNA and then 
centrifuged to remove resin. After the centrifugation approximately 100 μl of supernatant 
containing DNA was transferred into a new 96-well plate and stored at -20 °C. 
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3.3. MOLECULAR ANALYSIS OF DRUG-RESISTANCE ASSOCIATED GENES 
3.6.1. PRIMER DESIGN 
The P. chabaudi chabaudi genes previously proposed as putative modulators of drug 
resistance were the following: a gene encoding a deubiquitinating enzyme (ubp1), a gene 
encoding the mu (µ) chain of the AP2 adaptor protein complex (ap2-mu), and the 26S 
proteasome regulatory subunit gene (26S-protSU). The DNA sequences of these genes were 
available online at the PlasmoDB genome database (http://plasmodb.org/plasmo/) with 
the following accession numbers: PCHAS_020720, PCHAS_143590 and PCHAS_133430, 
respectivelly. In order to obtain the P. falciparum orthologues of the genes we used the 
genetic synteny maps provided by PlasmoDB. The table 3.1 shows summarised information 
extracted from the PlasmoDB database regarding the candidate genes. 
Table 3.1. Identification number (gene ID) in P. chabaudi (Pc) and in P. falciparum (Pf), gene 
length in Pf, full name, abbreviation and brief summary of the biological process of the 
investigated candidate genes. 
Gene ID in Pc Gene ID in Pf Gene length 
in Pf 
Annotation Abbreviation Biological process 
PCHAS_020720 
PF3D7_0104300 
(PFA0220w) 
10962 bp 
ubiquitin-specific 
protease 1 
ubp1 
ubiquitin-dependent protein 
catabolic process 
PCHAS_143590 
PF3D7_1218300 
(PFL0885w) 
1866 bp 
adaptor protein 
subunit 
ap2-mu Vesicle-mediated transport 
PCHAS_133430 
PF3D7_1466300 
(PF14_0632) 
3775 bp 
26S proteasome 
subunit 
26S-protSU 
Ubiquitin-dependent 
protein catabolic process 
 
Individual gene sequences of P. falciparum orthologues were retrieved from the synteny 
maps and used has templates for designing primers to amplify each open reading frame 
using an overlapping PCR fragment strategy.  
Primers were manually designed for each of the genes, according to the following 
parameters: avoidance of the formation of self and hetero-dimers, hairpins and self 
complementarity, appropriate primer length and melting temperature. These properties 
were verified using primer design software entitled Oligonucleotide Properties Calculator:  
(http://www.basic.northwestern.edu/biotools/oligocalc.html). 
Several primers were designed and used in order to amplify the complete pfap2-mu and 
pf26S-protSU genes and one partial sequences of the pfubp1 gene; a 304 bp region 
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encompassing amino acid codons 1463 – 1563 (fragment 1). Primers producing positive 
results are shown in Table 3.2. These primers were then used in PCR amplifications, as 
described below. 
Table 3.2. Primer sequences, PCR product sizes and annealing temperatures for 1st and 2nd 
amplification used for the PCR amplifications of the pfubp1, pfap2-mu and pf26S-protSU 
genes. 
 
p
fa
p
2
-m
u
 
1 
Fw - AAGACTGTCAAATGTAAAAGACCC 
Rev - CTCATGTAAAACAAAAAGTGAGG 
2247 bp 50 °C 
Fw - GTTAACACGATTAGCGTCATTTG 
578 bp 53 °C 
Rev - GTCCTATTATGTATATGTGGATC 
2 
Fw - GATATCCACAAACATTAGAAGTG 
841 bp 52 °C 
Rev - CCATCTGGTGGTGTGAAGG 
3 
Fw - GCATATTTCATCATTGTGTTACC 
753 bp 53 °C 
Rev - ACACCCGATTGAACTATTTATAC 
p
f2
6
S-
p
ro
tS
U
 
1 
Fw - CCGCCAGTGGTGTAATAGC 
597bp 55 °C 
 
Rev - GTCTAGCATCTAAAGCAACACC 
2 
Fw - GTTGATGAAATGATAGATGTGTGC 
690 bp 52 °C 
Rev - GCCATCATTTATTGCCTTATCATC 
3 
Fw - GATAATCTAACAAATGATGAACC 
744 bp 52 °C 
Rev - CGTATTTTCATCATTACTATCTCC 
4 
Fw - GCAAATTATAACACCAATGACAAG 
875 bp 55 °C 
Rev - CCTGCGCTTACTATAGCACC 
5 
Fw - CGAATGAACACTGTAATCCAAAC 
842 bp 55 °C 
Rev - ACAGGGATTTTTCATATCGACC 
6 
Fw - GCCAAAAGTAAAAGTGGAGCC 
494 bp 55 °C 
Rev - GTGGTGCCTCTTTTTTAGACG 
a
Size – PCR product size; 
b
AT - Annealing temperature. 
 
3.6.2. PCR 
Genotyping of P. falciparum infections was performed with nested PCR-based methods 
targeting the different candidate genes pfap2-mu (Chapter 4, 5 and 6), pfubp-1 (Chapter 5 
and Chapter 6) and pf26Sps (Chapter 6). Each PCR was performed in a total volume of 25 
µL with the following reaction mixture: 0.2 µM of each primer, 4.0 mM MgCl2, 0.4 µM 
deoxynucleotides (dNTPs) and 1 U Bioline Taq polymerase (Bioline, UK). Extracted DNA 
(5 µL) was added to each first round PCR mixture. One microliter of the first round product 
was then used as a template in a 25 µL nested amplification. The thermal cycle program for 
each 1st amplification was 94 °C for 3 min, and 30 cycles of 94 °C for 30 sec, annealing 
G
e
n
e
 
Fragment 
1
st
 amplification primers  
(5’ to 3’) 
Size
a
 AT
b
 
2
nd
 amplification primers  
(5’ to 3’) 
Size AT 
P
fu
b
p
1
 
1 
Fw – CGCCCGTACTATGAAGAAGATC 
484 bp 52 °C 
Fw - CGTAAACAGAATATTCAGGATTGC 
304 bp 57 °C 
Rev - GGCTTTTACCTGAACTGTTCAGG Rev - CTAGCCCTTTATTATCATTATCG 
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temperature for 30 sec and 68 °C for 1 min with a final extension of 68 °C for 15 min. The 
second round of PCR consisted of one initial denaturation hold at 94 °C for 3 min, followed 
by 40 cycles of 94 °C for 30 sec, annealing temperature for 30 sec and 68 °C for 45 sec with 
a final extension of 68 °C for 10 min. Annealing temperatures for the 1st and 2nd 
amplifications are described in Table 3.2. DNA sample extracted from parasite line 3D7 was 
used as positive control. PCR products were analysed by ethidium bromide-stained agarose 
2 % gel electrophoresis.  
 
3.6.3. SEQUENCING OF PCR PRODUCTS 
The PCR-amplified products were purified with Exonuclease I (ExoI) and 
Thermosensitive Alkaline Phosphatase (AP) enzymes (Fermentas, UK) in order to eliminate 
non-incorporated dNTPs and primers. The enzymatic purification was carried out in a final 
volume of 10 µL containing 5 µL of the PCR product, 3 units ExoI, 1 U AP and 1X AP reaction 
buffer, which were incubated for 60 min at 37 °C followed by 15 min at 72 °C for enzyme 
denaturation.  
The cycle sequencing reactions were carried out using 1 µL ExoI/AP purified PCR 
amplicons, 0.5 µL BigDye® Terminator v3.1 Cycle Sequencing Kit reaction mix (Applied 
Biosystems, UK), 0.2 µM of each PCR primer, 1.75 µL Big Dye Sequencing Buffer (Applied 
Biosystems, UK) in a total volume of 10 µL..Single-base extension was performed as follow: 
one denaturation hold at 96 °C for 1 min followed by 25 cycles of 96 °C for 30 s, 50 °C for 
15 sec, and 60 °C for 4 min. 
The sequenced reaction fragments were purified using ethanol/sodium acetate 
precipitation method, where 3 µL 3 NaOAc (pH 4.6), 62.5 µL 100 % ethanol and 24.5 µL of 
nuclease free water were added to each sample. The samples were mixed by inversion and 
incubated at -20 °C for 25 min. After incubation, samples were centrifuged at 4° C at 3000 g 
for 30 min. The supernatant was discarded by inversion and 150 µL ice cold 70 % ethanol 
was added to each sample. The samples were centrifuged at 4 °C at 3000 g for 10 min. The 
supernatant was discarded by inversion and each sample was allowed to dry at room 
temperature for 30 min. Finally, pellets were resuspended in 10 µL Hi-Di formamide. 
Samples were electrophoresed on an ABI prism 3730 Genetic Analyzer (Applied 
Biosystems). 
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3.6.4. EDITING AND ASSEMBLING OF SEQUENCE PRODUCTS 
Raw sequence data in the form of chromatograms from both sense and antisense 
primers were edited, aligned and assembled into contigs using Geneious Pro software 
(version 5.5.3; Biomatters) (Drummond et al., 2011), after resolving potential ambiguities 
by eye. Genetic polymorphisms were identified by comparing each sequence to that of the 
3D7 reference genome (PlasmoDB).  
 
3.4. CONTINUOUS CULTURE OF PLASMODIUM FALCIPARUM 
P. falciparum in vitro culturing was performed using previously described methods 
(Trager and Jensen 1976) (Chapters 7 and Chapter 8). All parasites studied were cultured in 
A+ blood (National Health Blood & Transplant, UK) and in complete media containing RPMI 
1640 growth medium (Invitrogen) supplemented, 147 μM hypoxanthine (Sigma-Aldrich), 
5 g/L Albumax II (Invitrogen), 10 mM D-glucose (Sigma-Aldrich) and 2 mM L-glutamine 
(Sigma-Aldrich), in the case of Dd2 (Chapter 8). The complete media used for Dd2attB 
culturing (Chapter 7) was further supplemented with 2.5 % (v/v) human AB serum (Sigma-
Aldrich) and 5 nM WR99210 (a kind gift from Jacobus Pharmaceuticals, New Jersey, USA). 
The parasites were kept at a 2 % haematocrit and inside of an 5 % CO2 at 37 °C. The culture 
medium was changed every 48 hours and the parasites were sub-cultured when 
parasitaemia was too high. Parasitaemia was determined by microscopy examination of 
Giemsa (Sigma-Aldrich) stained thin films prepared from the cultured material at regular 
intervals. Parasite cultures were synchronized at the ring stage using sequential D-sorbitol 
(Sigma-Aldrich) lysis treatment (Lambros and Vanderberg 1979) and were allowed to grow 
for one cycle after the last treatment and then used for transfection or in vitro 
susceptibility testing. 
 
3.5.CLONING METHODS 
3.6.1. PCR AMPLIFICATION OF DNA 
The PCR reactions were performed with Phusion® high-fidelity DNA polymerase (New 
Englands Biolabs). The reactions were carried out in a volume of 50 µl, containing 0.4 mM 
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dNTP mix (dATP, dTTP, dCTP, dGTP), 0.1 pmol/μl of each primer, 1 μl of DNA template, 
10 µl of 5X concentrated Phusion HF buffer, 1 mM MgCl2 and 2 units of DNA polymerase. 
DNA amplifications were performed using the following conditions: Initial denaturation 
(98 °C, 30 sec), 35 cycles of denaturation (98 °C, 10 sec), annealing (56 °C, 30 sec) and 
extension (68 °C, 1 min 30 sec), followed by a final extension (68 °C, 10 min). The yield of 
PCR products and correct sizes were checked by electrophoresis.  
 
3.6.2. RESTRICTION/LIGATION CLONING 
Digestion of the PCR products and plasmids were carried out using appropriated 
restriction enzymes (New England BioLabs, UK) by standard techniques. The PCR products 
were analysed by agarose electrophoresis, and were further purified using a Qiaquick Gel 
Extraction kit (Qiagen, UK). Ligations were carried out using T4 DNA Ligase (New England 
BioLabs, UK) and were incubated 2 h at room temperature and heat inactivated (at 65 °C 
for 10 min) prior to transformation.  
 
3.6.3. TRANSFORMATION INTO COMPETENT CELLS 
The plasmid DNA was transformed into 100 µl of XL10-Gold ultracompetent cells 
(Agilent Technologies, UK) that were previously incubated for 10 min on ice with 4 µl of 
β-mercaptoethanol (provided with the XL10-Gold ultracompetent cells kit). The mixture 
was incubated on ice for 30 min and after that time, the heat shock was performed as 
followed: 42 °C for 30 sec followed by 2 min on ice. Later, 0.9 ml of SOC medium 
(Invitrogen, UK) without antibiotics was added, to allow recovery of the cells Cells were 
then incubated for 1 hour at 37 °C. 100 µl of cell suspension was plated on the LB agar 
supplemented with 50 µg/ml of carbenicillin (Sigma-Aldrich) and incubated at 37 °C 
overnight. Only XL10-Gold cells containing the plasmids should be able to grow in the 
presence of carbenicillin. The following day, single colonies were picked from the plates 
and grown overnight up in polypropylene tubes containing 5 ml LB media and carbenicillin 
at 37 °C. 
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3.6.4. PURIFICATION AND IDENTIFICATION OF RECOMBINANT DNA 
The cells transformed with required DNA constructs were used to isolate plasmid-DNA 
using QIAprep Spin Miniprep kit (Qiagen, UK). The presence of the correct DNA insert in the 
plasmid was confirmed by restriction digestion analysis and by sequencing. Once the 
correct sequences of the inserts and the correct integration of the P. falciparum DNA into 
the plasmids was confirmed, the plasmid DNA copy number was amolified using the 
CompactPrep Plasmid Maxi kit (Qiagen). 500 ml LB with carbenicillin was inoculated with 
the XL10-Gold cell colony containing the correct plasmid and incubated overnight at 37 °C 
for each of the plasmids. The plasmid DNA was then isolated according to manufacturer’s 
instructions for parasite transfections. The concentration and purity of preparation was 
confirmed on the 0.8 % agarose gel supplemented with ethidium bromide.  
 
3.6.GENERATION OF P. FALCIPARUM TRANSFECTION CONSTRUCTS 
3.7.1. SITE-SPECIFIC INTEGRATION USING THE MYCOBACTERIOPHAGE BXB1 INTEGRASE 
SYSTEM 
Overexpression of the wild-type and mutant (160Asn) pfap2-mu gene in P. falciparum 
was performed using the bxb1 integrase system, developed by Nkrumah et al. (Nkrumah et 
al. 2006) (Chapter 7). This system allows the efficient and site-specific integration of 
genetic information into P. falciparum genome and consists of three components. The first 
component is a P. falciparum cell line containing an attB site in a defined locus. In this study 
we have used the Dd2attB clone of P. falciparum. This clone harbours an attB site for 
mycobacteriophage integration in the glutaredoxin-like gene cg6 locus of chromosome 7. 
This locus was chosen because the disruption of this gene does not affect the growth of the 
asexual blood stages (Nkrumah et al. 2006). The second component is a plasmid containing 
the attP site for recombination, the transgene and drug resistance cassette. The last 
component is the plasmid containing the Bxb1 integrase, which facilitates the 
recombinantion event. In a dually transfected parasite, the integrase expressed from pINT 
catalyzes the crossover of the plasmid containing the attP site with the genomic attB site, 
resulting in the integration the transgene into the genome. 
In this study we have used the following plasmids: the integrase-expressing plasmid 
pINT, which contains a Neomycin selectable marker that confers G418 resistance; the 
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attP-containing plasmids pDC2-cam-pfap2-mu-attP, which harbors a wild-type or a 
mutant (160Asn) pfap2-mu expression cassette as well as a bsd (blasticidin S-deaminase) 
selectable marker that confers resistance to blasticidin hydrochloride (Figure 3.1). 
 
Figure 3.1. Site specific integration of pfap2-mu gene (WT and 160Asn) into the P. falciparum 
Dd2
attB
 line. (A) Schematic diagram of the integrase-mediated attB x attP recombination approach 
((Nkrumah et al. 2006). The top panel shows the cotransfected plasmids: plasmid pINT, carrying the 
integrase expression unit that catalyses the recombination, and the neomycin resistance cassette 
(neo); and the pDC2-CAM-pfap2-mu-bsd-attP plasmid carrying the WT or a mutant 160Asn 
pfap2-mu gene sequence under the control of the calmodulin promoter, a blasticidin resistance 
cassette (bsd) and the attP site. The middle panel shows the recipient cg6-attB recombinant locus 
present in Dd2
attB
. The attB x attP recombination generates two sites, attL (left) and attR (right). The 
hDHFR represent the drug selection markers for WR99210. The lower panel represents the 
integration of the pDC2-CAM-pfap2-mu-bsd-attP plasmid into the cg6-attB locus of Dd2
attB
. 
 
To generate the pDC2-cam-pfap2-mu-attP (whose expression cassette is illustrated in 
Fig 3.1) and the pDC2-cam-pfap2-mu160Asn-attP plasmids, the open reading frames of both 
the wild-type and mutant (160Asn) allele of the pfap2-mu gene were amplified, from 
genomic DNA of P. falciparum parasite line 3D7 and from a P. falciparum field sample 
previously shown to harbour the 160Asn mutation, respectively (Henriques et al. 2014b). 
The full gene was amplified by PCR with the following primers (start and stop codons of the 
gene are in red font):  
forward primer 5’- CGTAACTAGTATGATCGATGCGCTGTACAT -3’ (SpeI site underlined) 
reverse primer 5’- ATGCCTCGAGCTATTTATACTGGTAGATGCC -3’ (XhoI site underlined) 
 
The pfap2-mu amplicons were cloned using AvrII/XhoI sites (New England BioLabs, UK) 
and integrated between the calmodulin (Pf14_0323) promoter and the hsp86 
(PF07_0030) 3′ UTR in a pDC2 vector (Lee et al. 2008) with the bsd selectable marker.  
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3.7.2. CONSTRUCTION OF PFAP2-MU-GFP FUSION CONSTRUCTS 
To localize pfAP2-mu in the parasite, we have engineered P. falciparum Dd2 parasites 
stably expressing GFP fused to pfap2-mu gene under the control of its endogenous 
promoter, using a single-cross-over homologous recombination strategy (Chapter 8). A 
region encoding the 3’ end (leaving out the stop codon) of pfap2-mu gene was PCR 
amplified from 3D7 genomic DNA using the following primers: 
 
forward primer 5’-CGTACTGCAGGATATCCACAAACATTAGAAG-3’ (PstI site underlined) 
reverse primer 5’-CGTAGCGGCCGCATTTATACTGGTAGATGCCCG -3’ (NotI site underlined) 
 
The 1508 bp pfap2-mu amplicon was digested with PstI and a NotI (New England 
Biolabs) and cloned into similarly digested pH-GFP transfection plasmid (Witmer et al. 
2012) before the GFP coding sequence, to generate pH-pfap2-mu-GFP vector (Figure 3.2).  
Figure 3.2. GFP tagging of pfap2-mu. Schematic representation of the single-cross-over homologous 
recombination strategy showing the the pH-pfap2-mu-GFP plasmid containing ~1500 bp of the 3’ 
end coding sequence of pfap2-mu fused in frame with the GFP sequence (top panel); the wild type 
pfap2-mu locus (middle panel); and the recombined pfap2-mu-GFP locus resulting from integration 
of the GFP-tag construct (lower panel). Transcription termination and polyadenylation of the 
pfap2-mu-GFP transgene are ensured by the presence of the Hrp2-3’ untranslated region (UTR) of 
P. falciparum histidine-rich protein 2. The human dihydrofolate reductase (hDHFR) represents the 
positive drug selection marker for WR99210.  
 
The resulted plasmids were verified by sequence analysis and DNA for transfection was 
purified using the Qiagen CompactPrep Plasmid Maxi Kit (Qiagen, UK).  
3.7.TRANSFECTION EXPERIMENTS 
Transfections of P. falciparum were carried out as described by Adjalley and colegues 
(Adjalley et al. 2010) with slightly modifications. Briefly, 250 µl of infected red blod cells, 
from a synchronized 6-9 % parasitaemia ring-stage cultures was added to 400 µl of the 
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plasmids preparation. To achieve the integrase mediated recombination (Chapter 7), 50 µg 
of the plasmid containing the attP site together with the pfap2-mu gene (WT or the 160Asn 
copy) and 50 µg of the pINT plasmid containing the integrase expression unit that catalyses 
the recombination, and the neomycin resistance cassette (each in 25 µl TE buffer) were 
resuspended in cytomix [120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA (pH 7.6), 5 mM MgCl2, 
10 mM K2HPO4/KH2PO4 (pH 7.6) and 25 mM HEPES (pH 7.6)]. In the GFP tagging esperiment 
(Chapter 8) 50 µg of the vector containing the pfap2-mu-GFP fusion construct was 
resuspended in cytomix.  
Parasites were transfected by electroporation (voltage of 0.31 kV, capacitance of 950 µF 
and infinite resistance; Bio-Rad Gene Pulser II, Bio-Rad, UK), using Bio-Rad Gene Pulser 
electroporation cuvettes (0.2 cm gap) and then immediately transferred to culture flasks 
containing 10 ml of complete media and 500 µl of fresh red blood cells. One to four hours 
after electroporation the culture medium was replaced with fresh complete media. 
Transfectants were allowed to recover in drug-free medium of 24 h and then were selected 
with the appropriated drug. For the site specific integration (Chapter 7) the parasites were 
selected with 2.5 µg/ml blasticidin (Sigma-Aldrich) and 125 μg/ml of G418 (Invitrogen, Life 
Technologies). Since the integrase-mediated recombination is thought to be a rapid event, 
the drug pressure with G418 (that selects the pINT plasmid) was only applied for 6 days. 
Alternatively, the parasites were selected with 5 nM WR99210 (a kind gift from Jacobus 
Pharmaceuticals, New Jersey, USA) (Chapter 8).  
The medium was changed daily for the first 6 days, and then every other day with fresh 
medium containing the blasticidin or WR99210 selection agents. Cultures were diluted 3:5 
weekly (by the addition of 30 % fresh blood cells) and monitored by Giemsa staining every 
4-5 days for appearance of the transfected parasites. Once the transfected parasites 
reached a parasitemia of approximately 5 % rings they were frozen, and genomic DNA was 
prepared for analysis to determine if the plasmid had been correctly integrated into the 
parasite genome. 
 
3.8.ISOLATION OF GENOMIC DNA FROM P. FALCIPARUM  
Genomic DNA was harvested from schizont stages parasites at ≥ 5 % parasitaemia 
(Chapter 7 and Chapter 8). The cells were lysed with saponin and after centrifugation; the 
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pellet was resuspended in lysis buffer (500 mM Na Acetate pH 5.2, 100 mM NaCl, 1 mM 
EDTA, 3 % SDS). DNA was isolated with phenol/chloroform extraction at room temperature 
and ethanol precipitation. Finally the DNA was resuspended in TE buffer. 
 
3.9.GENOTYPE ANALYSIS OF TRANSGENIC PARASITES BY PCR 
Genotype analysis of transformed parasites was performed by PCR in Chapter 7 and 
Chapter 8. For the transgenic paraites obtain in Chapter 7, correct integration was verified 
by PCR using the P1/P2 primer pair (Table 3.3) and the presence of the 160Asn mutation in 
the Dd2attB::160Asn-pfap2-mu line was confirmed by sequencing using primers P2/P3 (Table 
3.4). Integration of the GFP-tag construct in the pfap2-mu locus (Chapter 8) was confirmed 
by a diagnostic PCR using primer pair P5/P6 (Table 3.3). 
 
Table 3.3. Primer sequences used in vector integration confirmation by PCR  
Primer Sequence (5’ – 3’) Description 
P1 CCAGGATCCAAAAGAAGGAGGAGG 
Confirming integration of the bsd cassette into 
the attB recombinant locus (Forward) 
P2 ATGCATGCCAAGCCTTTGTCTCAAG 
Confirming integration of the bsd cassette into 
the attB recombinant locus (Reverse) 
P3 GATATCCACAAACATTAGAAGTG 
Confirming the presence of the 160Asn mutation 
(Forward) 
P4 CCATCTGGTGGTGTGAAGG 
Confirming the presence of the 160Asn mutation 
(Reverse) 
P5 CCGTATTAACAAGAAGCAATTC 
Confirming integration of the GFP-tag construct 
in the pfap2-mu locus (Forward) 
P6 CCCTCTCCACTGACAGAAAAT 
Confirming integration of the GFP-tag construct 
in the pfap2-mu locus (Reverse) 
 
3.10.CONFIRMATION OF INTEGRATION BY SOUTHERN BLOT ANALYSIS 
For Southern blot analysis the pfap2-mu-GFP transgenic parasites (Chapter 8), genomic 
DNA was digested with ClaI/NcoI (New England Biolabs, UK) and the digested DNA was 
separated on a 0.8 % agarose gel. The gel was depurinated in 0.25 M HCL and denaturated 
in 0.4 M NaOH before transferred overnight to a BrightStar®-Plus positively charged nylon 
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membrane (Ambicon, UK) by gravitational flow. The DNA was UV cross-linked to the 
membrane. 
The integrants were screened using probes against the 5’-end of the pfap2-mu gene. 
The pfap2-mu probe was PCR amplified using the following primers: 
 
Forward primer 5’- CGGGCAACTTCTGATACAAAG -3’  
Reverse primer 5’- GTCCTATTATGTATATGTGGATC -3’  
 
The PCR was performed with the following conditions: 15 sec denaturation at 98 °C, 30 
sec annealing at 55 °C, and elongation 45 min at 68 °C; the cycle was repeated 35 times. 
The PCR product was purified using a QIAquick PCR purification kit (Qiagen, UK). 
The probe was 32P-labelled by random priming using the Redoprime-II random prime 
labelling system (GE Healthcare). The target DNA was denatured for 5 min at 96 °C and 
cooled on ice for 5 min. Denatured DNA was added to the labelling reaction mix (Klenow 
fragments, dNTPs, random hexamers), then 32P dATP (3000 Ci/mM) was added and the 
mixture was incubated for 15 min at 37 °C and the reaction was stopped using TE buffer. 
Unincorporated nucleotides were removed using Ilustra Microspin G-25 columns (GE 
Healthcare, UK) and hybridization was performed overnight at 60 °C, in a solution 
containing 6X SCC buffer, 2X Denhardt’s, 0.1 % SDS, 100 μg/ml of sheared herring DNA. 
Membranes were washed two times at 60 °C, with 2X SSC buffer and exposed to an 
Amersham Hyperfilm MP (GE Healthcare, UK) at −80 °C. 
 
3.11.QUANTITATIVE RT-PCR ON MRNA SAMPLES OF P. FALCIPARUM 
In order to verify the constituitive blood-stage expression of the introduced transgenes 
we performed quantitative RT-PCR analysis of cultures of the parental (Dd2attB) and 
transfected Dd2attB::WT-pfap2-mu and Dd2attB::160Asn-pfap2-mu parasite lines (Chapter 7). 
For total RNA isolation, parasitized red cells (from ring stage and late stage samples) 
were rapidly lysed in TRI Reagent (Sigma-Aldrich, UK) and then stored at -80 °C prior to RNA 
extraction, which followed the manufacturer’s protocol as previously described (Schwank 
et al. 2010). Briefly, the TRI Reagent lysates were thawed at 37 °C, 0.4 ml of chloroform 
(Sigma-Aldrich, UK) was added, and the mixture was vigorously mixed and incubated for 15 
min at room temperature before centrifugation (12,000 xg, for 15 min at 4 °C). The 
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aqueous phase was precipitated with 0.5 ml of isopropanol (Sigma-Aldrich, UK), incubated 
for 10 min at room temperature and centrifuged (12,000 xg, for 10 min at 4 °C) to allow 
RNA precipitation, and the pellet washed with 75 % ethanol (Sigma-Aldrich, UK). The 
samples were stored at 4 °C overnight and then centrifuged at 12,000 xg, for 10 min at 4 °C. 
The ethanol was removed and the RNA pellet was air-dried, before being resuspended in 
20 µl of nuclease free water (Promega, UK).  
Extracted RNA was treated with RQ1 RNAse-free DNAse (Promega, UK) and reverse 
transcribed using gene specific primers (pfap2-mu: Q2 and pfpgmet: Q4; Table 3.4) and the 
GoScript reverse transcriptase Kit (Promega), as described by the manufacturer. Each 
DNAase treated preparation was then split in two. In the control tubes the reverse 
trascriptase was replaced with water (DNA contamination control). 
Table 3.4. Primer sequences used in quantitative RT-PCR on P. falciparum mRNA 
Primer Sequence (5’ – 3’) Description 
Q1 GGAAAGGTAACCTTAAAATGTC pfap2-mu amplification (Forward)  
Q2 GTTACTACCGGCGAGAATATT pfap2-mu amplification (Reverse) and cDNA synthesis 
Q3 TGAAAGCAGCGTAGCTCAGA tRNA amplification (Forward)  
Q4 CGCGTGGTTTCGATCCACG tRNA amplification (Reverse) and cDNA synthesis 
 
Quantitative RT-PCR (qRT-PCR) was performed using QuantiTect SYBR Green PCR Kit 
(Qiagen) in a Rotor-Gene RG3000 machine (Corbett Research). Transcripts of the pfap2-mu 
gene were amplified using the Q1/Q2 primer pair (Table 3.4, above) and the Plasmodium 
tRNA methionine (PgMET) gene was used as a reference source of RNA. Previously 
published primer sequences Q3/Q4 (Table 3.5) were used to amplify the pgmet gene as 
described (Beshir, Hallett, et al. 2010). Reactions were carried out in 25 µl volumes using 
QuantiTect SYBR Green PCR master mix according to the manufacturer's guidelines. The 
PCR cycles used were 95 °C for 6 minutes followed by 40 cycles of 95 °C for 15 sec and 60°C 
for 1 min, for all reactions. Each parasite RNA sample was tested in triplicate in each 
experiment. Relative expression of pfap2-mu was calculated from the average threshold 
cycle (CT) values from two experiments, normalized to pgmet, using the Ct method, 
where the parental line was used as the comparator. 
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3.12.DRUG SUSCEPTIBILITY ASSAYS 
We analysed the susceptibility of the transgenic P. falciparum parasites expressing an 
extra copy of either the wild-type (WT) pfap2-mu gene or the 160Asn form (Chapter 7) to 
several antimalarial drugs using the following drug susceptibility assays. 
 
Standard 48 hour drug susceptibility assays 
Standard 48 hour drug exposure assays were performed to determine the susceptibility 
of parasites to dihydroartemisinin (DHA), quinine, chloroquine, lumefantrine, mefloquine 
and atovaquone according to protocols using the intercalating dye PicoGreen to provide a 
fluorescent signal, as previously deployed in our laboratory (van Schalkwyk et al. 2013). The 
resulting IC50
48h estimates were used as primary indicators of anti-malarial susceptibility, 
determined from a log-dose response analysis using the Prism v6.04 (GraphPad Software, 
Inc., San Diego, CA). Each assay was performed with two replicates on at least two 
(range 2 – 6) independent occasions for each drug. For statistical analysis best-fit estimates 
of the IC50 and their 95 % confidence intervals were obtained by nonlinear regression fitting 
of the sigmoidal dose response curve for each drug across all experiments, after 
normalisation using control well fluorescent signals. For statistical comparison of each 
transgenic with the parental curve and comparison between the two transgenic curves, 
data were first fitted independently and then globally to find a shared best-fit value for the 
IC50
48h. Results were compared by a sum-of-squares F-test.  
 
Artemisinin 6 hour pulse assays 
To generate IC50
6h estimates for artemisinin, we devised an alternative in vitro drug 
susceptibility protocol. DHA was serially diluted in complete medium (250 µl) in 
microcentrifuge tubes, using the same ten concentrations generated for the standard 48 
hour drug assays. 250 µl of ring stage culture was added to each drug dilution (2 % final 
hematocrit and 0.5 % final parasitemia) and incubated at 37 °C for 6 hours. After the 
incubation time half of the culture was placed in a 96-well tissue culture plate (modified 48 
hour assay) and the other half was washed three times with 1000 μL of RPMI, to remove 
dihydroartemisinin, before being replenished with drug free medium and placed in the 
96-well culture plate. The plate was then incubated at 37 °C for 42 hours until growth 
assessment using the PicoGreen detection method. As described for the standard 48 hour 
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assays, PicoGreen detection method generates a measure of DHA sensitivity in the form of 
an IC50
6h estimate.  
 
Ring stage survival assays (RSA) 
The RSA was performed as described by Witkowski and collegues (Witkowski et al. 
2013) with minor modifications. The parasite cultures were tightly synchronized across two 
consecutive ring stage cycles with sorbitol treatment. Late schizont stage parasites cultures 
were enriched using MACS separation columns (Miltenyi Biotech GmbH) and were cultured 
for 3 hours at 37 °C with fresh erythrocytes, and again sorbitol-treated. This early ring stage 
(0-3 hours) parasite preparation, at 1 % parasitaemia, 2 % haematocrit in 2 ml final volume, 
was then exposed for 6 hours to 700 nM of dihydroartemisinin in 0.1 % DMSO. After the 6 
hour exposure the cultures were washed and resuspended in drug-free culture medium 
and cultured at 37 °C for a further 66 hours. Dihydroartemisinin susceptibility was then 
assessed microscopically on thin films by estimating the percentage of viable parasites that 
had developed into a new generation of trophozoites, 66 hours after dihydroartemisinin 
exposure, compared to parasites exposed to 0.1 % DMSO alone.  
 
3.13.FLUORESCENCE MICROSCOPY 
Localization of fluorescent protein-tagged pfAP2-mu in transfected parasites (Chapter 8) 
was analyzed through direct detection of the green fluorescence in paraformaldehyde fixed 
parasite samples and through imunofluorescence assays (IFA). For IFA, thin smears of 
parasite cultures were air dried and fixed using 100 % methanol at -20 °C for 2 minutes. The 
fixed cells were washed with PBS. After washing, the slides were incubated for 1 h at RT 
with mouse anti-GFP (1:20, Roche, UK) antibody diluted in 3% bovine serum albumin (w/v) 
in PBS. Cells were washed three times with PBS and incubated with IgG-specific secondary 
antibody coupled with Alexa Fluor® 488 (1:400, Sigma, UK) for 1 h at RT and then washed 3 
times with PBS. 
The smears were mounted for microscopic examination with vectashield mounting 
medium with 4’,6-diamidini-2-phenylindole (DAPI) (Vector). Images were acquired using a 
Zeiss LSM510 laser scanning confocal microscope (Carl Zeiss Jena GmbH, Germany) and 
images were processed using Zeiss LSM Image Browser software version 4.0.0.157. 
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Abstract 
Malaria, caused by Plasmodium falciparum, is a devastating infectious disease, whose 
control is hampered by the relentless evolution of drug resistance. Because artemisinin 
derivatives are now used in the most effective antimalarial therapies, resistance to 
artemisinin would be catastrophic. Indeed, studies suggest that parasites resistant to 
artemisinin have already appeared in natural infections. Understanding the mechanisms of 
resistance would help to prolong the effective lifetime of these drugs. Genetic markers of 
resistance are therefore required urgently. Previously, a mutation in a de-ubiquitinating 
enzyme was show to confer artemisinin resistance in the rodent malaria parasite 
Plasmodium chabaudi. 
Here, increased resistance to artemisinin in a related parasite is characterised and 
genetic variation investigated using Illumina whole-genome re-sequencing. We identify just 
one point mutation in a gene encoding an AP2 adaptor protein, a component of the 
endocytic machinery. Homology models indicate that the mutated residue interacts with a 
cargo recognition sequence. We investigated polymorphisms in the orthologous gene in 
natural infections of the human malaria parasite Plasmodium falciparum. One specific 
polymorphism was weakly correlated with in vitro responses to an artemisinin derivative in 
isolates from Rwanda.  
In conclusion, whole-genome re-sequencing identified a mutation in a gene encoding an 
adaptor protein, suggesting that the endocytosis and trafficking of membrane proteins is 
modified in artemisinin-resistant rodent malaria parasites. This provides new insights into 
possible mechanisms of resistance to artemisinin and its derivatives. Analysis of P. 
falciparum field isolates showed a weak association between a polymorphism in this gene 
and in vitro artemisinin responses.The genotypes of this adaptor protein should be 
evaluated for its role in ART resistance in human infections of P. falciparum 
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Introduction 
Without an effective vaccine, prevention and treatment of human malaria has 
traditionally relied on chemoprophylaxis and/or chemotherapy [1]. However, Plasmodium 
falciparum has developed resistance to nearly every anti-malarial drug introduced to date, 
compromising its control. Resistance arises via the selection of parasites bearing specific 
mutations, and is decisive in determining the effective lifetime of anti-malarial agents. 
Artemisinin combination therapy (ACT) is now a widely used anti-malarial treatment. 
The artemisinin component is a highly effective and rapidly acting drug [2]. The 
understanding of its mode of action is incomplete [3,4], but independent lines of evidence 
from a number of laboratories suggest that its action depends upon its endoperoxide group 
and activation by haem or other iron sources [3]. Downstream, it may localize close to the 
digestive vacuole (DV) [5] and effect changes in DV morphology [6] or the distribution, 
endocytosis and digestion of haemoglobin [7]. Alternatively, it has been suggested that 
artemisinin may inhibit the Ca2+-ATPase (PfATP6) [8]. 
Alarmingly, recent data indicate that resistance to artesunate, one of several artemisinin 
derivatives (ARTDs), is emerging in Cambodia and Thailand [9-14]. Molecular (DNA) 
markers of resistance are therefore required urgently. These tools will help to monitor the 
evolution of resistance, to establish rational treatment policies and to design drug 
combinations that delay the evolution of resistance. At present however, in P. falciparum, 
there are no universally accepted and validated molecular markers of artemisinin 
resistance in the field. Polymorphisms in PfATPase6 [15,16] or amplification of the 
multidrug resistance gene, Pfmdr1 [17-19] have been investigated. However, no correlation 
was found between variants of these genes and in vivo responses to ARTDs in the first 
suggested cases of resistance along the Thai/Cambodian border [20,21]. 
Candidate gene approaches may not focus on the critical genes nor grasp the full 
complexity of the drug response mechanisms. Instead, analysis of genetic haplotype 
variation and conservation and geographic differentiation using genome-wide SNP typing 
of P. falciparum parasites from Southeast Asia (Thailand, Cambodia and Laos), where 
resistance to ARTDs is emerging, has identified candidate regions associated with slow 
parasite clearance rates after drug treatment [21], particularly in a region on chromosome 
13. No specific genes in this region were identified as candidates for influencing artemisinin 
response. 
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Other experimental studies that do not prejudge the critical genes are especially 
informative; for example, the in vitro generation of mutant P. falciparum parasites resistant 
to drugs. Parasites resistant to ARTs have been generated and mdr1 duplications identified 
[22], but often the phenotypes and genetic changes have tended to be unstable in the 
absence of drugs [23,24]. Genetic linkage analysis of the experimental P. falciparum Hb3 x 
Dd2 cross has shown that three loci, including pfmdr1 and two additional loci (on 
chromosomes 12 and 13) [24] that were associated with artemisinin (ART) responses or the 
potential to evolve ART resistance, but neither of these parental parasites offered a distinct 
ART-R phenotype. 
 
 
 
Figure 1 The AS lineage of drug resistant parasites, featuring artemisinin (ART) phenotypes and 
ubp-1 genotypes. Parasites were selected by passage in presence of drugs shown [29-33]. 
Artemisinin resistance (phenotype 1) appears during selection by chloroquine [25,26] and is 
mediated by either of two mutations in the ubp-1 gene (PCHAS_020720) [25,27]. AS-ART was 
generated during selection by artemisinin [29]. Its increased resistance to artemisinin (phenotype 2) 
and its genotype is the subject of the present study. *, parasites used in the present study; wt, wild-
type. 
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In vivo experimental studies using the rodent malaria Plasmodium chabaudi can 
circumvent some limitations faced by in vitro experimentation. A lineage (strain AS) of 
genetically stable mutant parasite clones that are resistant to various drugs has been 
generated by experimental evolution under drug selection (Figure 1). The genetic 
mutations conferring resistance to pyrimethamine, sulphadoxine, chloroquine, mefloquine, 
lumefantrine and artemisinin have been mapped using efficient genetic linkage mapping 
(population based genome-wide scans of selection) and Illumina whole-genome 
sequencing [30-33]. The identification of the critical mutations exploits four important 
features relevant to the present study. Firstly, the resistance phenotype appears at the 
same time/position in the lineage as the critical mutation. Secondly, the mutation will lie at 
the bottom of a ‘selection valley’ (genomic region selected by drug). Thirdly, these studies 
exploited a previously completed reference genome sequence isogenic to the progenitor 
parasite, AS-sens. Fourthly, the numbers of point mutations (genome-wide) fixed at each 
step by selection or during cloning are very small, typically 1–3 [31]. 
For artemisinin, a mutation in a de-ubiquitinating enzyme (V2728F ubp1) was proposed 
previously as the critical determinant of an artemisinin-resistance (ART-R) phenotype [30] 
in parasite AS-30CQ (Figure 1). This ubp1 mutation has also been shown to contribute to 
resistance to mefloquine and lumefantrine [32] and higher doses of chloroquine [31], as 
well as ARTs, suggesting that ubp1 may mediate parasite responses to multiple drugs, as 
does mdr1 duplication [32]. 
Here, another parasite, AS-ART (Figure 1), derived from AS-30CQ after prolonged and 
progressive ART selection [25], is investigated. An increased ART-R phenotype is 
characterized and a single point mutation in its genome is defined. The 3D structures of 
homologues of the mutated protein are investigated for possible functional consequences. 
Allelic variations of the P. falciparum orthologue of the mutated gene are defined in a set of 
P. falciparum field samples. 
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Methods 
Ethics 
All animal work was conducted according to relevant national and international 
guidelines: in Portugal, after approval by the Ethics Committee of the Instituto de Higiene e 
Medicina Tropical of Lisbon, Portugal, under PARECER 2/2006 from 1 August, 2006 and in 
the UK, in compliance with the UK Animals (Scientific Procedures) Act 1986. 
 
Parasite lines, maintenance, parasite preparation and DNA extraction 
All the parasite clones used in this study are members of the AS lineage (Figure 1). Three 
parasite clones were used: i) AS-3CQ, a parasite that is resistant to low levels of 
chloroquine [34]; ii) AS-30CQ, that is resistant to high levels of chloroquine [34]; and, iii) AS-
ART, which was derived from AS-30CQ through multiple sub-inoculations in mice under 
increasing doses of artemisinin (ART) [25]. All parasites were routinely inoculated, passaged 
in CBA mice (four to six weeks) and cryopreserved as previously described [26]. Parasites 
were prepared and DNA extracted as previously described [35], ensuring that host white 
cells were removed by CF11 cellulose (Whatman) and Plasmodipur filters (Eurodiagnostica). 
DNA samples from other clones within the lineage were used to determine the earliest 
appearance of specific mutations within the lineage. All animal work was conducted 
according to relevant national and international guidelines: in Portugal, after approval by 
the Ethics Committee of the Instituto de Higiene e Medicina Tropical of Lisbon, Portugal, 
under PARECER 2/2006 from August 1st 2006 and in the UK, in compliance with the UK 
Animals (Scientific Procedures) Act 1986. 
 
 
In vivo ART drug tests 
In vivo ART response phenotypes were assessed as follows. Four to six-week-old inbred 
CBA mice were divided into nine groups of three mice each. Mice in groups 1–3 were 
inoculated with 10exp6 parasitized red blood cells (pRBC) of AS-3CQ, AS-30CQ or AS-ART, 
respectively and given the diluting solvent DMSO orally (untreated controls). Treatment 
groups 4–6 were inoculated with 10exp6 pRBC of either AS-3CQ, AS-30CQ or AS-ART and 
treated with an oral daily dose of 200 mg ART kg-1 mouse bodyweight, administered for a 
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total of three consecutive days, starting day 1 post-inoculum (pi). Treatment groups 7–9 
were inoculated with 10exp7 pRBC of either AS-3CQ, AS-30CQ or AS-ART and treated with 
200 mg ART kg-1 mouse bodyweight, administered for a total of five consecutive days. 
Individual percentage (%) parasitaemia was followed from day 4 pi onwards and up to day 
15 in the case of untreated control mice. For treated mice, % parasitaemia was first 
assessed one day after the last day of treatment and up to day 18 pi. Results were 
expressed as daily average % parasitaemia ± standard error from the three mice within 
each experimental group. 
 
 
Genome-wide resequencing 
Clone AS-sens was previously resequenced with the Illumina® platform using 36 bp 
single reads [30]. Clone AS-ART was also re-sequenced using 36 bp single-end reads. 
Individual sequence strings (reads) from AS-sens and AS-ART were aligned against the 
isogenic AS reference genome assembly (AS-WTSI [36], provided by the Wellcome Trust 
Sanger Institute, using two different software packages: MAQ (Mapping and Assembly with 
Quality) [37] and SSAHA2 (Sequence Search and Alignment by Hashing Algorithm) [38]. The 
AS-WTSI sequence data consisted of a recently completed assembly and annotation made 
available during this investigation. Detection of SNPs was performed with Samtools [39] 
and MAQ, using default parameters, as described in Hunt et al. [30]. Small (≤3 bp) indels 
were detected using Samtools internal algorithm only. The list of single nucleotide 
polymorphisms (SNPs) and small indels were further filtered by removing mutations 
proposed for both AS-sens and AS-ART and that therefore did not arise within the AS 
lineage. Heterozygous and “multiple variant” SNPs, as well as small indels called by less 
than three reads and less than 50% of the total reads were also removed. Larger indels 
(>3 bp) and CNVs were detected with both MAQ and SSAHA2 using “comparative coverage” 
analysis, which measures the ratio of the relative coverage (local coverage divided by 
overall mean coverage) in AS-ART relative to AS-sens. A comparative coverage ratio >1.5 
over 200 bp for defining CNVs and <0.25 over 10 bp for defining indels (both adjusted for 
different genome coverage in AS-sens and AS-ART) were used, as previously described [30]. 
Unlike previous work, “comparative coverage” analysis was also performed using MAQ. 
This required running the “pileup” command on both the AS-ART and AS-sens reads using 
the variable “-q 1” (which excludes reads with a mapping quality <1). The pileup files thus 
produced were then used for “comparative coverage” analysis with custom made scripts, 
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similarly to the SSAHA2 approach. Confidence levels were assigned to mutations based on 
the following criteria: a) Samtools quality scores (for SNPs) and b) identification by both 
MAQ and Samtools (for SNPs and large indels/CNVs). All high confidence putative point 
mutations proposed by MAQ and/or Samtools were verified by di-deoxy sequencing. Only 
limited verification was done for potential indels and CNVs. Small indels were defined as 
“low confidence” mutations by default, due to a majority of calls being confirmed as false 
positives by di-deoxy sequencing in this and other studies [30,33]. 
 
 
Protein structure-function analysis 
The P. chabaudi AP2-mu sequence was used to search the protein structure database 
(PDB) for homologues. The closest match found was the μ chain of AP2 from Rattus 
norvegicus, with a bit score of 167 and an E-value of 2e-41. 11 different structure entries of 
this and related proteins and complexes were present in the PDB. Structure 2PR9 was 
selected because of the level of R-factors (R: 0.204, R-free: 0.240) and its resolution (2.51Å). 
The I-TASSER server [40] was used to construct a homology model of the P. chabaudi 
homologue, with the R. norvegicus 2PR9 structure as a template onto which the P. 
chabaudi sequence was modelled. The same method was used to construct a P. falciparum 
μ model. 
 
 
Plasmodium falciparum isolates- in vitro responses to ART derivatives 
In the present study, we intended to characterize the genetic variation in the P. 
falciparum ap2-mu gene in natural infections and to check whether any polymorphism 
correlated with the parasite’s previously determined responses to ART derivatives. We re-
analysed artemisinin responses obtained previously from a collection of isolates of P. 
falciparum from Rwanda, the Democratic Republic of São Tomé & Principe (São Tomé) and 
Brazil [41, 42, 43]. These previous studies had shown that samples displayed a broad range 
of in vitro responses in all countries and for all the ART derivatives tested. Additionally, 
such differences in IC50 values, were shown previously not correlate with previously 
suggested markers of ART resistance, namely, pfmdr1, pfatpase6, pfcrt or pftctp (Table 1). 
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Table 1. P. falciparum isolates used in the present study, with previously characterized 
genotypes and in vitro responses to artemisinin derivatives 
Country and drug 
tested 
N 
Mean IC50 
(nM) 
Range IC50s  
(nM) 
Molecular markers 
investigated 
Rwanda 
   Dihydroartemisinin 
 
74 
 
2.6 
 
0.3 – 14.3 
 
 
mdr1, PfATPase6, pfcrt, pftctp 
(unpublished) 
São Tomé 
   Artesunate 
 
42 
 
0.58 
 
0.05 - 9.0 mdr1, PfATPase6, pfcrt, pftctp 
[42] 
   Artemether 51 1.12 0.2 – 12.5 
Brazil  
   Artesunate 
 
56 
 
0.85 
 
0.1 – 4.9 
 
mdr1, PfATPase6, pfcrt [43]  
   Artemether 56 3.0 0.2 – 23.0  
 
 
Plasmodium falciparum ap2-mu genotyping 
DNA was first extracted from all samples above and the reference strain 3D7 according 
to the method described by Plowe and co-workers [44]. The P. falciparum ap2-mu gene 
was then sequenced in a subset of twenty-four P. falciparum isolates which were initially 
selected according to their geographical origin and response to each drug. Thus, we picked 
8 samples from Rwanda, 8 from São Tomé and 8 from Brazil, according to their response to 
artemisinin derivatives (4 samples with the lowest IC50 and the 4 with the highest values, 
from each country) (Table 2). 
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Table 2. P. falciparum isolates in which pfap2-mu was sequenced with corresponding ART 
derivative IC50s 
Site of Sample Collection Sample ID Drug 
IC50 
(nM) 
Rwanda 
[41] 
RW10 
D
ih
yd
ro
ar
te
m
is
in
in
 
0.3 
RW32 0.3 
RW58 0.4 
RW30 0.5 
RW57 8.8 
RW106 9.6 
RW77 10.1 
RW40 14.3 
São Tomé 
[42] 
STP27 
A
rt
es
u
n
at
e
 
0.02 
STP29 0.03 
STP41 0.04 
STP46 0.05 
STP35 1.7 
STP34 2.0 
STP44 3.4 
STP58 9.0 
Brazil 
[43] 
BR58 
A
rt
es
u
n
at
e
 
0.1 
BR05 0.2 
BR15 0.2 
BR45 0.2 
BR38 3.4 
BR07 4.8 
BR67 4.8 
BR68 4.9 
 
 
The sequence of the P. falciparum orthologue of the ap2-mu gene (accession n. 
PF3D7_1218300) was retrieved from PlasmoDB and used as template for designing primers 
to amplify its open reading frame using an overlapping PCR fragment strategy (Table 3). 
PCR assays were performed with 1lof DNA into a 50lmixture containing 0.2 M of each 
primer, 1.5 mM MgCl2, 0.2 mM deoxynucleoside triphosphates and 1.25 units of GoTaq®  
Flexi DNA Polymerase (Promega). 
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Table 3. Primer sequences and PCR reactions for the pfap2-mu gene 
 
Primers Sequence (5’ to 3’) 
Coordinates 
(length) 
PCR Program 
  
-54 to 524 
(578 bp) 
  
PfClR-1F GTTAACACGATTAGCGTCATTTG 94 ºC, 3 min  
PfClR-2R GTCCTATTATGTATATGTGGATC [94°C, 30’; 53°C, 45’; 72°C, 60’] 35 cycles 
  72 °C, 10 min  
  
358 to 1199 
(841 bp) 
  
PfClR-3F GATATCCACAAACATTAGAAGTG 94 ºC, 3 min  
PfClR-4R CCATCTGGTGGTGTGAAGG [94°C, 30’; 52°C, 45’; 72°C, 60’] 35 cycles 
  72 °C, 10 min  
  
1126 to +58 
(753 bp) 
  
PfClR-5F GCATATTTCATCATTGTGTTACC 94 ºC, 3 min  
PfClR-6R ACACCCGATTGAACTATTTATAC [94°C, 30’; 53°C, 45’; 72°C, 60’] 35 cycles 
  72 °C, 10 min  
 
PCR products were analysed by ethidium bromide-stained agarose 2% gel 
electrophoresis and sequenced directly in both sense and antisense directions with the 
appropriate PCR amplification primer. 
 
PIRA-PCR and RFLP 
One particular mutation in the pfap2-mu gene (G479A) encoding an S160N 
replacement, was determined in all samples characterized for their in vitro response to 
artemisinin derivatives using a PCR-restriction fragment length polymorphism (RFLP) assay. 
Since this point mutation does not create a natural endonuclease restriction site, a primer 
introduced restriction enzyme analysis PCR (PIRA-PCR) method was used. 
A PIRA primer PfCLR-G479A-F (forward) with sequence 5'-ATC AAA TGA ATT ATT AAA 
TGT AAc TA -3' was thus designed, where an A-to-C mismatch was incorporated at the 3rd  
base position from 3'-end terminus (shown in small letter in primer sequence). This creates 
a recognition site (ACTAGT) for the restriction enzyme BcuI in presence of the wild type 
allele G479. 
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A PCR product was amplified using primers PfCLR-G479A-F and PfCLR-G479A-R (sequence: 
5'- AAA ATG ATT TGC TGT CTT ATT A -3’) with final concentration of 0.2 μM, of each primer, 
1.5 mM MgCl2, 0.2 mM dNTPs and 1.25 units of GoTaq® Flexi DNA Polymerase (Promega). 
Conditions of PCR were: initial denaturation at 94 °C for 3 min, followed by 40 cycles of 94 
°C for 30 s, 51 °C for 45 s and 72 °C for 60 s, and a final extension step of 72 °C for 10 min. 
10 μl the PCR reaction mixture was digested with 20 units of BcuI restriction enzyme 
(Fermentas) with 1 ×Buffer Tango in a final volume of 20 μl and incubated at 37 ºC for 3 h. 
The predicted size of the PIRA-PCR product resulting from amplification with primers PfCLR-
G479A-F and PfCLR-G479A-R is 268 bp, which can then be cleaved into 245 and 23 bp 
fragments when digested with BcuI, in the presence of the wild-type (wt) allele (AGT). No 
cleavage is expected in the presence of mutant (mut) allele (AAT). The 268 and 245 bp 
fragments can be easily resolved on 3 % agarose gel, whereas the 23 bp fragment is 
normally difficult to visualize or discriminate from primer-dimers. Therefore, the 245 bp 
band was scored as wt and 268 bp as mut. Figure 2 shows typical results of these PIRA-PCR 
assays. 
 
Figure 2. Typical results of the Pfap2-mu gene PIRA-PCR results. M: molecular weight marker. Lanes 
1 and 6: Pfap2-mu 160N variants; lanes 2 and 4 Pfap2-mu 160S variants; lanes 3 and 5: mixture of 
genotypes. Samples were run in 3% agarose gels stained with ethidium bromide 
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Data analysis 
In the absence of recent contact with drugs, P. falciparum populations generally display 
a log-concentration normal distribution regarding enzyme-inhibiting compounds. The 
D'Agostino and Pearson omnibus normality test [45] was used infer whether or not the IC50 
values obtained for our samples follow a log-normal distribution. Grubbs outlier test was 
used to test for and exclude statistical outliers. The parametric two tailed t-test (with 
significance level set at 0.05) was applied to test whether or not there are significant 
differences between in vitro artemisinin derivatives response and the S160N mutation in 
the PfAP2-muadaptor protein. The normality tests, t-tests and plots were done using 
GraphPad Prism 4.0 (GraftPad Software, San Diego, California). Grubbs outlier test was 
done using R software version 2.11.1 (The R Foundation for Statistical Computing). 
In order to evaluate whether the distribution of the S160N genotype correlated 
significantly with ART IC50s, the following statistical analyses were carried out. We first 
performed normality tests to infer whether or not the IC50 values obtained for our samples 
followed a log-concentration normal distribution. The untransformed wild-type data 
deviated from a normal distribution, as confirmed by D'Agostino and Pearson omnibus 
normality test, with all values of p<0.0001. After log-transformation, IC50s were log-
normally distributed, with p-values equal to 0.29, 0.18 and 0.054 for Rwanda 
(Dihydroartemisinin), São Tomé (Artesunate) and São Tomé (Artemether), respectively. The 
mutant datasets also followed a log-normal distribution with the exception of Rwanda (p-
value =0.013). This deviation arose from an outlier identified by the Grubbs outlier test (p-
value = 0.00026). After removal of this outlier the Rwandan distribution conforms to a log-
normal distribution (p-value=0.83). The ensuing analyses were therefore performed 
excluding this outlier.  
F tests were performed to assure that the variances were not significantly different 
between wild-type and mutant data. Table 12 summarizes the results of the statistical tests 
performed. 
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Results 
The Plasmodium chabaudi AS-ART phenotype 
Here, the ART responses of isogenic parasites of the P. chabaudi AS lineage are 
investigated further; namely, AS-3CQ (ART-S clone), AS-30CQ (ART-R clone) and the AS-ART 
(ART-R clone) generated during selection by ART (Figure 1) [25]. In previous work, 
artemisinin resistance at 100 mg ART kg-1 (body weight) d-1 was demonstrated in both 
AS-30CQ and AS-ART relative to other clones, which preceded them in the AS lineage, 
including AS-3CQ [30]. Here, the hypothesis that AS-ART would resist higher doses of ART 
than AS-30CQ is tested. Parasites were treated for three (1 × 10 exp6 inoculum) or five (1 × 
10 exp7 inoculum) days (treatments A and B, respectively) with a daily dose of 200 mg ART 
kg-1 d-1 and their response to the drug was assessed by comparing both peak parasitaemia 
and the time taken for each parasite to recrudesce after treatment. 
In the absence of treatment, all three parasite clones produced their peak parasitaemia 
of between 23% (AS-ART) and 40% (AS-30CQ), appearing between days 8 and 9 pi (Figure 
3A). Under either ART treatment A and B however, no parasites were detected in mice 
infected with AS-3CQ over the follow-up period (Figure 3B and 3C). After treatment A, AS-
30CQ produced detectable parasites between days 13–14, with parasitaemia reaching their 
peak (~12%) on day 17. However, mice infected with AS-ART presented more rapid 
recrudescence (days 8–9), with parasitaemia reaching ~12% on day 15 after treatment 
(Figure 3B). A similar trend was observed after treatment B: mice infected with AS-30CQ 
first presented a detectable parasitaemia between days 13–14 and peak parasitaemia (~10% 
on day 18), whilst the AS-ART group recrudesced three days earlier (Figure 3C) achieving a 
similar peak parasitaemia on day 15. 
As previously reported [30] it is concluded that AS-3CQ is sensitive to ART treatment 
whereas both AS-30CQ and AS-ART are resistant. Here, however, at high ART doses, AS-ART 
shows both earlier recrudescence and reduced time to reach peak parasitaemia relative to 
AS-30CQ. It is concluded that AS-ART has a higher degree of resistance to ART. Here, this 
enhanced resistance phenotype is called ART-R phenotype 2. The response of AS-30CQ and 
AS-ART to 100 mg ART kg-1 d-1 (3 day) is called ART-R phenotype 1. 
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Figure 3 Artemisinin responses of Plasmodium chabaudi AS-3CQ, AS-30CQ and AS-ART. Mean% 
parasitaemia ± standard error of groups of three mice. A, untreated controls; B, 1 × 10exp6 parasites 
on day 0 and treated with 200mg ART/kg
-1
 day
-1
 days 1–3; C, 1 × 10exp7 parasites on day 0 and 
treated with 200mg ART/ kg
-1
 day
-1
 days 1–5. AS-sens, blue; AS-30CQ, red; AS-ART, green [The 
experimental work contributing to this figure was done by Gisela Henriques and Louise Rodrigues]. 
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Genome re-sequencing of AS-ART 
AS-ART was sequenced using the Illumina platform using 36 base single-end reads. In 
total, 45,879,892 short single-end reads were produced for clone AS-ART, of which 89 % 
were mapped onto the 2009 version of the reference genome (Welcome Trust Sanger 
Institute P. chabaudi AS parasite, AS-WTSI, genome size 18,832,196 bp [36]: by the 
mapping software, SSAHA2. The mean genome-wide read coverage was 84 reads per 
nucleotide (Table 4). Approximately 87% of the total reads (39,979,351) were mapped in 
unique positions. Some 98% of the nucleotides in the genome were covered by at least 10 
reads and 93% by at least 40 reads; 1.67% was covered by less than three reads (the 
minimum required for SNP and small indel detection). Similar data were obtained using an 
alternative mapping software, MAQ. Clones AS-sens and AS-30CQ had been re-sequenced 
previously and reads aligned similarly [30,31,33]. 
 
Table 4. Summary of the Solexa whole genome re-sequencing performed on clone AS-ART 
of Plasmodium chabaudi 
Clone analysed AS-ART 
Reference sequence Sanger (09/2009) 
Read length 36 
Total Number of Reads 45.879.892 
Mapped Reads (SSAHA2) 41.198.901 
Uniquely Mapped Reads (SSAHA2) 39.979.351 
% Genome covered by >= 10reads 98,00% 
% Genome covered by <3 Reads 1,67% 
x coverage (SSAHA2) 84.16X 
x coverage (MAQ) 86.18X 
 
SNP detection 
Preliminary SNP calling and filtering (see Methods) identified eight point mutations in 
AS-ART (see Table 5), relative to the resequenced clone AS-sens [30-33]. There were 11 
additional low quality SNP calls considered to be false positives (see Table 6). 
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Table 5. Confirmed and high confidence mutations in the ART-resistant Plasmodium chabaudi clone AS-ART (relative to progenitor clone, AS-sens) 
 
Chromosome Type Analysis 
Nucleotide 
start 
Nucleotide 
end 
reference 
base 
variant 
base 
SSAHA 
quality 
Confirmation 
of mutation by 
dideoxy 
sequencing 
P. chabaudi  
gene ID 
Amino 
acid 
change 
Nearest gene ID  
(P. chabaudi) 
P. falciparum 
orthologue 
SNPs             
2 SNP SSAHA/MAQ 216,954  C A 99 confirmed PCHAS_020720 V2728F  PF3D7_0104300 
3 SNP SSAHA/MAQ 70,553  G T 99 confirmed PCHAS_030200 T707N  None 
3 SNP SSAHA/MAQ 474,123  C A 99 confirmed PCHAS_031370 T719N  PF3D7_0214800 
7 SNP SSAHA/MAQ 994,546  G A 99 confirmed PCHAS_072830 S106N  PF3D7_0417200 
10 SNP SSAHA/MAQ 634,932  T C 99 confirmed PCHAS_101550 Y162H  PF3D7_1430000 
11 SNP SSAHA/MAQ 996,332  G T 99 confirmed PCHAS_112780 A173E  PF3D7_0629500 
14 SNP SSAHA/MAQ 936,945  T G 92 confirmed   5'-PCHAS_142600 PF3D7_0813400 
14 SNP SSAHA/MAQ 1,270,184  T C 99 confirmed PCHAS_143590 I568T  PF3D7_1218300 
 
 
  
 
approximate 
size  
comparative 
coverage  
    
Indels 
 
           
4 indel SSAHA/MAQ 793,940 793,988 49  0.16 tbc   PCHAS_042080-5 None 
5 deletion SSAHA/MAQ 683,724 684,989 1,266  0.21 tbc PCHAS_051920   None 
7 deletion SSAHA/MAQ 876,907 876,921 15  0.18 34bp deletion   PCHAS_072420-3' PF3D7_0815700 
bin indel SSAHA/MAQ 261,129 284,496 23,368  0.02 tbc PCHAS_000700-760  None  
 
All point mutations and 34 bp deletion (light grey) were confirmed by di-deoxy sequencing. A small deletion on chromosome 4 and large deletions on 
chromosome 5 and ‘bin’ (dark grey), have strong supporting evidence (extended area of low and zero coverage, SNP-proxies for deletions). Base quality scores 
(which only apply to SNPs) are derived from the SSAHA2 algorithm (with 99 being the best score). For indels, the approximate size of the affected area (as 
measured by SSAHA2) and a comparative coverage are given. Amino acid substitutions (non-synonymous mutations) are in bold characters. One point mutation 
in AP2-mu chain specific to AS-ART (relative to preceding clone, AS-30CQ) is in bold and underline characters. Tbc: to be confirmed. 
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Table 6. AS-ART Genome re-sequencing – validated and low-confidence point mutations  
 
Chromosome Position Analysis 
Reference 
base 
AS-ART 
base 
SSAHA2 
Quality 
score 
Confirmation of 
mutation by di-deoxy 
sequencing 
P. chabaudi Gene ID Mutation 
P. falciparum 
orthologue 
Nearest gene ID 
(P. chabaudi) 
1 551,969 SSAHA G A 3   intergenic  None PCHAS_011470-5’ 
2 216,954 SSAHA/MAQ C A 99 YES PCHAS_020720 V2728F PF3D7_0104300  
3 25,017 SSAHA G A 5   intergenic  None PCHAS_030080-5’ 
3 70,553 SSAHA/MAQ G T 99 YES PCHAS_030200 T707N None  
3 474,123 SSAHA/MAQ C A 99 YES PCHAS_031370 T719N PF3D7_0214800  
5 684,091 SSAHA T A 33   PCHAS_051910-20 non-syno None  
7 31,783 SSAHA T C 5   intergenic  PF3D7_1033400 PCHAS_070080-5’ 
7 72,468 SSAHA T A 8   PCHAS_070170 K-N None  
7 994,546 SSAHA/MAQ G A 99 YES PCHAS_072830 S106N PF3D7_0417200  
10 634,932 SSAHA/MAQ T C 99 YES PCHAS_101550 Y162H PF3D7_1430000  
10 1,625,436 SSAHA C T 7   intergenic  None 5’-PCHAS_104250 
11 996,332 SSAHA/MAQ G T 99 YES PCHAS_112780 A173E PF3D7_0629500  
12 875 SSAHA A G 12   PCHAS_120010 nonsyn None  
14 936,945 SSAHA/MAQ T G 92 YES intergenic  PF3D7_0813400 5’-PCHAS_142600 
14 1,270,184 SSAHA/MAQ T C 99 YES PCHAS_143590 I568T PF3D7_1218300  
bin 5,256 SSAHA G C 13   PCHAS_000020 A-G None  
bin 106,638 SSAHA A C 3   PCHAS_000260 N-T None  
bin 177,899 SSAHA A G 2   PCHAS_000480 Y-C None  
bin 270,747 SSAHA T A 31   intergenic  None PCHAS_000730-5’ 
 
Summary of all point mutations proposed prior to stringent analysis and filtering (see text) in AS-ART.  Those confirmed by di-deoxy sequencing (light grey) are 
indicated.  Low probability mutations (dark grey, see Results) are indicated. For intergenic SNPs, the nearest P. chabaudi gene is indicated, with indication as to 
whether it lies to the left or right of 5’ or 3’ end of gene.  For example, 5’ - PCHAS_011470 indicates that the mutation is found to the left (upstream) of the 5’ 
end of PCHAS_011470.  For 11 low-confidence (black) point mutations, 6 lie within predicted genes (chr05, chr07, chr12 and bin (3)).  Two of these (chr05 and 
chr12) are non-synonymous.  Candidate on chr05 is considered as ‘proxy for deletion’ (see main text). 
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Eight point mutations identified by both Samtools and MAQ had higher quality scores 
(≥92, maximum 99) (Methods) than the other 11 (quality scores <34, see Table 6) calls, and 
were subsequently verified by di-deoxy sequencing in AS-ART (Table 5). Seven of these 
eight were previously reported from the AS-ART progenitor, AS-30CQ [30,31]. They include 
five point mutations, previously linked to drug resistance phenotypes. These are: a) S106N 
dhfr (encoding dihydrofolate reductase) (PCHAS_072830), (quality score: 99), which confers 
pyrimethamine resistance [33]; b) A173E (quality score: 99) in an amino acid transporter 
(aat1, PCHAS_112780), conferring chloroquine resistance [31]; c) T719N (quality score: 99) 
in a hypothetical protein (PCHAS_031370) conferring intermediate chloroquine resistance 
[31]; and, d) a V2728F (quality score: 99) substitution in the ubp1 gene (PCHAS_020720), 
conferring artemisinin resistance phenotype 1 [30], high-level chloroquine resistance [31] 
and mefloquine resistance [32]. A fifth point mutation namely T707N (quality score 99) in a 
member of the P. chabaudi-specific interspersed repeat (cir) gene family (PCHAS_030200) 
may also contribute to the intermediate CQ-R phenotype of AS-30CQ [31]. In all cases, the 
position of their appearance in the P. chabaudi AS lineage coincides with the appearance of 
the corresponding drug-resistance phenotype. Two point mutations have not been linked 
to any particular phenotype. These are: Y162H (quality score 99) in a gene annotated as a 
hypothetical protein (PCHAS_101550) appearing first in AS-30CQ, and an intergenic 
mutation (quality score: 92) at base position 936,945 on chromosome 14, located between 
genes PCHAS_142590 and PCHAS_142600 (both hypothetical proteins with no significant 
Pfam matches), first appearing in AS-PYR1, the first drug-resistance clone of the lineage. 
One point mutation only in clone AS-ART relative to AS-30CQ was confirmed. This 
mutation was I568T (quality score 99) in a gene (PCHAS_143590) predicted to encode the 
mu (μ) chain of the AP2 adaptor protein complex, which, in other organisms, is involved 
with clathrin-mediated endocytosis [46]. This gene was denoted ap2-mu. 
In contrast to the eight confirmed mutations above, the other 11 low-quality calls (see 
Table 6, highlighted in dark grey) were predicted only by Samtools; nine of these have 
extremely low Samtools quality scores (2 to 13) and were variously mapped to the extreme 
ends of chrs 01, 03, 07 (two), 10 and 12, where P. chabaudi-specific genes are located 
(often in multigene families), or to contigs yet to be mapped to the final genome assembly 
(three in ‘bin’). Here, read alignment may be less reliable, as reflected in their low mapping 
quality. A similar low quality SNP call in AS-30CQ was previously identified as a false 
positive by di-deoxy-sequencing [33]. Accordingly, these nine low confidence SNPs are 
strongly predicted to be false positives. In any case, their genomic locations suggest that 
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they would be unlikely to play a role in a conserved artemisinin resistance phenotype 
because four of these candidates were intergenic (chr01, 03, 07, 10) and the other five 
(chr07, 12 and bin (three)) were in genes without orthologues in P. falciparum, in contrast 
to the eight confirmed point mutations. 
The two remaining low confidence point mutations mapped to chr05 or contig11844 
and had higher quality scores (33 and 31, respectively). However, they were located close 
to, or within extended regions of low coverage proposed to be deletions (one of which, on 
chr05, was previously noted) [31], see below. False positive SNPs such as these were 
previously termed ‘proxies for deletions’ and their artefactual appearance explained [30]. 
It is concluded that the I568T mutation in the gene PCHAS_143590 encoding the mu (μ) 
chain of the AP2 adaptor protein complex is likely to be the only point mutation in AS-ART 
relative to its immediate precursor AS-30CQ. 
 
Small indels, larger deletions and CNV detection 
Forty-one potential insertions or deletions (indels) (14 larger (>3bp) indels, 27 small (≤3 
bp) indels) and seven potential copy number variants (CNVs) were called (see Tables 7, 8 
and 9) in AS-ART relative to AS-sens. The specific detection and identification of large 
insertions was not feasible because the single-end sequencing data used in these studies 
were not able to support the use of more sophisticated detection algorithms that depend 
upon the availability of paired-end data. 
The 27 small indels were considered to be low confidence predictions, ie, false positives. 
Dideoxy-sequencing confirmed that the five tested were all false positives (see Table 7), as 
in previous studies of AS-15MF and AS-30CQ [30,33]. It is suggested that the majority of 
these predicted low confidence mutations are therefore false positives. In any case, only six 
of the other 22 small indels were intragenic. 
For larger indels, analysis based on read depth reveals large deletions (say >20 bp) with 
greater reliability than for intermediate deletions (say 3<bp<20) and all larger insertions. 
Four (see Table 8, highlighted in grey) of the 14 intermediate and large indels candidates 
were classified as high confidence mutations (Table 9, Methods), principally because they 
were predicted using both MAQ and SSAHA2 but also because they generate consistently 
low read coverage over an extended region. Also, three (chr04, 05, 07) were previously 
identified in the progenitor clone AS-30CQ or in a related clone AS-15MF [30,31]. One of 
these was previously confirmed by dideoxy-sequencing as an intergenic 34 bp deletion on 
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chr07. Another was a potential large deletion (>1 kb) on chromosome 5 located within a 
gene coding for a non-syntenic (i.e. its chromosomal location is not conserved across 
malaria species relative to surrounding genes) S-antigen (PCHAS_051910-20). The third was 
a deletion in non-coding sequence at the right hand end of chromosome 4, in a region 
previously defined to be the site of deletion and translocated copy of a large duplicated 
chr12 fragment containing mdr1 in the related clone AS-15MF [32]. The remaining high 
confidence large deletion corresponds to a potential ~23 kb deletion on an unassigned 
contig (‘bin’ contig11844), not predicted in the progenitor clone AS-30CQ, spanning several 
non-syntenic genes (PCHAS_000700 to PCHAS_000760). The regions corresponding to 
deletions on chr05 and in contig 11844 also contain an example of a SNP ‘proxy for deletion’ 
(see section above). Verification of the three deletions (in chr04, chr05 and contig 11844) 
by di-deoxy sequencing was not possible due either to their size or position or both. For the 
other 10 larger deletion candidates, six are intergenic and four are predicted to interrupt P. 
chabaudi-specific genes, three mapping to the extreme ends of chr13 (two) and chr14, and 
one to an unassigned contig (see Table 8). 
It is worth noting that the frequency of indels in the chicken and human genomes (e.g. 
[47,48]) is less than the SNP frequency; confirmed in next generation short-sequencing 
analysis [49]. If applicable to Plasmodium spp, the number of indels will be less than the 
number of point mutations. Since the number of point mutations in AS-ART (relative to AS-
sens) is likely to be eight, the four high-confidence deletions detailed above may represent 
the full complement of indels. Only one (in contig 11844) appears in AS-ART, relative to AS-
30CQ. 
For the seven potential CNVs, identified by higher read comparative coverage (range 1.5 
– 3.1), they extend over very small regions (205–282 bp) and lie outwith coding regions of 
genes (see Table 9). In other clones of the P. chabaudi AS lineage, previously validated 
large-fragment CNVs (involving mdr1) were identified using a similar comparative read-
coverage analysis ([32] and data not shown). In the present case, the seven potential CNVs 
are unlikely to represent gene duplication/amplification events, simply reflecting natural 
variation of read coverage. 
It is likely that there is only one high-confidence deletion (contig 11844) arising in AS-
ART relative to AS-30CQ. The likelihood of other indels or CNVs arising in AS-ART is 
considered to be low and, in any case, unlikely to confer artemisinin resistance phenotype 
2. 
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Table 7. AS-ART Genome re-sequencing – low probability small Indels 
 
Chromosome 
Insertion 
or 
Deletion 
Nucleotide 
start 
Nucleotide 
finish 
Size of 
region 
Small indel 
quality 
index 
Dideoxy-
sequencing 
validation 
P. chabaudi 
gene ID 
Nearest  
P. chabaudi  
gene ID 
1 Insertion 203,105 203,105 1 22/38   intergenic 5-PCHAS_010530 
2 Insertion 32 32 1 5/10   intergenic 3-PCHAS_020010 
4 Deletion 104,874 104,874 1 33/49   intergenic PCHAS_040280-5 
5 Deletion 281,711 281,711 1 3/5   intergenic 3-PCHAS_050670 
5 Deletion 716,257 716,257 1 23/38   intergenic PCHAS_052010-5 
6 Insertion 430,538 430,538 1 110/118 NO PCHAS_061120  
6 Deletion 678,850 678,851 2 3/6   intergenic 3-PCHAS_061760 
7 Deletion 779,270 779,270 1 314/200   PCHAS_072120  
7 Deletion 910,035 910,035 1 7/9   intergenic PCHAS_072520-5 
7 Insertion 910,341 910,341 1 9/12   intergenic 3-PCHAS_072530 
8 Insertion 854,448 854,448 1 22/35 NO PCHAS_082240  
9 Deletion 1,113,660 1,113,660 1 62/82   PCHAS_093250  
10 Deletion 290,661 290,661 1 81/84 NO intergenic 3-PCHAS_100680 
10 Deletion 719,577 719,577 1 6/8   intergenic PCHAS_101800-3 
10 Deletion 908,717 908,718 2 118/155 NO PCHAS_102390  
10 Insertion 1,625,438 1,625,438 1 3 / 4   intergenic 5-PCHAS_104250 
11 Insertion 694,180 694,180 1 314/452   intergenic 3-PCHAS_111970 
11 Deletion 760,507 760,507 1 47/62 NO PCHAS_112150  
11 Deletion 836,567 836,567 1 54/80   PCHAS_112370  
13 Deletion 1,792,799 1,792,799 1 7/13   intergenic 3-PCHAS_134780 
14 Insertion 9,124 9,124 1 3/3   intergenic 3-PCHAS_140040 
14 Deletion 54,440 54,440 1 3/6   intergenic PCHAS_140140-3 
14 Insertion 82,779 82,779 1 3/3   intergenic 5-PCHAS_140200 
14 Deletion 347,257 347,257 1 39/58   PCHAS_140880  
14 Deletion 926,444 926,444 1 20/32   PCHAS_142560  
14 Insertion 1,415,664 1,415,664 1 4/7   intergenic PCHAS_143940-5 
bin Deletion 352,973 352,973 1 161/166   PCHAS_000930  
 
Summary of all small indels predicted (see text) in AS-ART. Analysis was done using the SSAHA 
package. Those rejected by di-deoxy sequencing are indicated (light grey).  Other small indels (dark 
grey) are expected to represent false positives (see text).  Quality scores indicate no of reads calling 
indel/total reads.  For intergenic small indels, the nearest P. chabaudi gene is indicated, with 
indication as to whether it lies to the left or right of 5’ or 3’ end of gene.  For example, 5’ - 
PCHAS_010530 indicates that the mutation is found to the left (upstream) of the 5’ end of that gene. 
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Table 8. AS-ART Genome re-sequencing – larger indels  
 
 
Regions of low comparative coverage (see Methods) were identified. 4 higher probability larger indels (see text) are indicated (light grey, not validated or dark grey, 
validated).  Indels of low probability are indicated (not coloured).  For intergenic indels, the nearest P. chabaudi gene is indicated, with indication as to whether it 
lies to the left or right of 5’ or 3’ end of gene.  For example, 5’ - PCHAS_030010 indicates that the mutation is found upstream of the 5’ end of that gene. 
 
Table 9. AS-ART Genome re-sequencing – possible CNVs 
 
 
 
 
 
 
 
 
 
Regions of high comparative coverage (see Methods) was used to identify potential CNVs. Analysis was done using the SSAHA package. These regions are all 
considered low probability (see Results).  All CNVs were intergenic, the nearest P. chabaudi gene is indicated, with indication as to whether it lies to the left or right 
of 5’ or 3’ end of gene.  For example, 5’ - PCHAS_031010 indicates that the mutation is found to the left (upstream) of the 5’ end of that gene. 
chromosome Analysis 
Nucleotide 
start 
Nucleotide 
finish 
Size of 
region 
comparative 
coverage 
Dideoxy-sequencing 
validation 
P. chabaudi gene ID 
Nearest P. chabaudi 
gene ID 
1 SSAHA 127 149 23 0.17  intergenic  
3 SSAHA 62 207 146 0.12  intergenic 5-PCHAS_030010 
4 SSAHA/MAQ 793,940 793,988 49 0.16 tbc intergenic PCHAS_042080-5 
5 SSAHA 544,355 544,403 49 0.24  intergenic PCHAS_051440-5 
5 SSAHA/MAQ 683,722 684,999 1,278 0.21 tbc PCHAS_051910-20 
7 SSAHA 56,889 56,899 11 0.11  intergenic PCHAS_070140-5 
7 SSAHA/MAQ 876,902 876,929 28 0.18 34bp deletion intergenic PCHAS_072420-3 
13 SSAHA 36,490 36,500 11 0.17  PCHAS_130090  
13 SSAHA 1,598,774 1,598,789 16 0.22  PCHAS_134220  
14 SSAHA 943,900 943,923 24 0.21  intergenic 5-PCHAS_142620 
14 SSAHA 2,277,029 2,277,055 27 0.24  PCHAS_146230  
bin SSAHA 116,319 117,071 753 0.19  intergenic 3-PCHAS_000290 
bin SSAHA/MAQ 261,129 284,496 23,368 0.02 tbc PCHAS_000700-760 
bin SSAHA 300,040 300,050 11 0.19  PCHAS_000790  
chromosome Nucleotide start Nucleotide finish Size of region comparative coverage Nearest P. chabaudi gene ID 
3 349,895 350,122 228 2.90 5-PCHAS_031010 
6 678,733 678,961 229 1.50 3-PCHAS_061760 
7 677,772 678,012 241 2.40 PCHAS_071850-5 
8 814,443 814,647 205 2.50 PCHAS_082110-5 
12 926,886 927,167 282 2.80 5-PCHAS_122590 
14 1,595,074 1,595,327 254 1.60 3-PCHAS_144430 
14 1,758,897 1,759,122 226 3.10 3-PCHAS_144820 
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Conservation and structure of AP2 mu-chain 
An alignment of the predicted amino acid sequences of AP2-mu of P. chabaudi 
(PCHAS_143590, 597 aa) and its P. falciparum orthologue, PF3D7_1218300 (Figure 4A) and 
other Plasmodium spp (data not shown) confirm that this gene is highly conserved in 
Plasmodium spp. Specifically, the I568T mutation appears close to the C-terminus in a 
particularly highly conserved region. BLAST searches identify AP2 adaptor mu-chains from 
other species such as R. norvegicus (435 aa) (Figure 4B) showing high sequence 
conservation in both the N-terminal domain (aa 1–154, numbering P. chabaudi unless 
otherwise stated) and the C-terminal domain (aa 244–597) which forms two subdomains 
each composed of a β-sheet. These large regions of β-sheets bind to, and hence select 
cargo protein during coated pit formation and vesicle formation during endocytosis [46,50]. 
In addition to the conservation of its amino acid sequence, other sequence and 
structural features of PCHAS_143590 support its designation as the μ-chain of the AP2 
adaptor complex and a role in recognition of cargo protein and endocytosis. Residues 155 
to 243 comprise Plasmodium specific sequence and extend the linker (rat136 – 158) 
between the AP2-mu N-terminal and C-terminal domains. At its C-terminal end, this linker 
contains T245, homologous to rat T156 that requires phosphorylation for endocytosis in 
vitro and in vivo [51]. Also, the P. chabaudi protein contains 17 lysine residues (aa 410 – 
537) in a region where positively charged patches in rat µ-chain interact with 
phosphatidylinositol bisphosphate (PIP2) [52]. Both phosphorylation and PIP2 or PIP3 
binding stabilize a large conformational change that allows cargo signal motifs to access the 
µ-chain signal recognition site at the membrane surface [53]. 
BLAST alignments (Figure 4A, 4B) support the designation of P. falciparum I592 and 
R. norvegicus V401 as the corresponding residues to P. chabaudi I568, suggesting that 
these residues will have similar positions within the protein structure, and therefore, a 
corresponding functional significance. 
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Figure 4 Conservation of AP2 mu-chain amino acid sequence. Conservation between P. chabaudi 
(PCHAS_143590) sequence and (A) P. falciparum (PF3D7_1218300) or (B) rat (P84092 
(UniProtKB/Swiss-Prot) sequences. The P. chabaudi mutated residue I568 and the corresponding P. 
falciparum residue I592 (A) and Rat V401 (B) are highlighted (purple). Note Plasmodium spp.-specific 
sequence (~90 residues, relative to rat) lying between positions154–244 (P. chabaudi). [The 
experimental work contributing to this figure was done by Pedro Cravo and Paul Hunt]. 
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Figure 5. I568T mutation in AP2 mu-chain interacts with YXXΦ motif on cargo protein. A. Rat 
(P84092) V401 is homologous to P. chabaudi AP2 mu-chain I568, and contributes to the hydrophobic 
pocket that binds L9 residue of bound peptide (DEEYGYECL) in structure 2PR9. B. Homology model 
for P. chabaudi wild-type homologue shows similar structure with I568 corresponding to rat V401. C. 
Homology model for P. falciparum orthologue shows similar structure, with I592 corresponding to 
rat V401 and P. chabaudi I568. D. Homology model for P. chabaudi mutant - 568T is predicted to 
reduce the hydrophobic character of the binding pocket in which peptide L9 binds. Note increased 
polar character associated with threonine hydroxyl group in D relative to B. [The experimental work 
contributing to this figure was done by Douglas Houston]. 
 
X-ray structures for both the μ-chain alone or the adaptor complex cocrystallised with 
peptides containing YXXΦ (where Φ represents a hydrophobic residue such as F, I, V, L or M) 
recognition motifs on the target (cargo) ligands [54] include a rat μ-chain structure (pdb 
2PR9), showing that the V401 residue of the rat μ-chain is adjacent to the L9 Φ residue (L, 
lysine) of the bound DEEYGYECL peptide and, along with rat L173, L175, L404 and V422, 
forms a hydrophobic pocket into which the Φ residue binds (Figure 5A). The high sequence 
conservation between PCHAS_143590 and the rat AP2 mu-chain (Figure 5B, Figure 4B) 
suggests that I568 will play a similar role in the P. chabaudi AP2 adaptor to that of V401 in 
the rat homologue. Homology models of the P. chabaudi structure were predicted by 
threading the P. chabaudi amino acid sequence into the rat crystal structure, using I-
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TASSER. The resulting structures indeed show that I568 (P. chabaudi, Figure 5B) and I592 (P. 
falciparum, Figure 5C) are predicted to lie in a corresponding position, relative to the Φ 
residue in the bound peptide. The likely effect of the I568T mutation was investigated in 
the P. chabaudi homology model. The most likely conformation of 568T was predicted by 
minimising the contact of the side chain oxygen atom in 568T to nearby hydrophobic 
residues. This results in the oxygen pointing towards the solvent, hence forming part of the 
Φ-binding pocket (Figure 5D). The effect of the 568T hydroxyl group is therefore to add 
some hydrophilic character to the hydrophobic pocket into which the Φ residue fits. Similar 
results were obtained for the P. falciparum μ2 homology model (data not shown). The 
I568T mutation is predicted to moderate but not abrogate the binding of the μ subunit to 
the YXXΦ recognition motif present in the cargo protein. In any case, at least in yeast, an 
AP-2 μ-chain knock-out is not lethal [55] and clathrin may function independently of the 
adaptor [56]. Similar results were obtained for the P. falciparum μ2 homology model (data 
not shown).  
 
 
Analysis of MDR1 as a putative target 
 
MDR1 is a 12 transmembrane (TM)-domain ATP-binding cassette (ABC) transporter 
known to be involved in modifying responses of malaria parasites to various drugs [57]. In 
view of the many reports regarding the effect of mdr1 amplification on ART responses in P. 
falciparum [57] and in P. chabaudi [33], we investigated whether the I568T mutation could 
interact with mdr1 and thus affect its localisation and trafficking. 
The P. chabaudi mdr1 amino acid sequence contains many instances of FXXsignals 
(Figure 6). This suggests that mdr1 may contain (multiple) signals which regulate the 
trafficking of mdr1 from the parasite membrane to other organelles or positions in the 
endosomal system. Signal sequences tend be located within 10-40 amino acids of a 
transmembrane helix [46], or between 6-9 amino acids for proteins destined for the 
lysosome. We were however unable to identify strong candidate YXXsignals which 
fulfilled these requirements and which were not structurally constrained to bind to 
AP2-mu. 
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Figure 6. P. chabaudi and P. falciparum mdr1 amino acid sequences with YXXGɸ motifs. Protein 
sequences A P. chabaudi, B, P. falciparum.  YXXF motifs (yellow), YXXGF non-canonical motifs (blue). 
DXXLL motifs binding to different adaptor chain (purple). Blue text, approximate extent of 
transmembrane domains; red text, approximate extent of predicted ABC (ATP binding cassettes) 
regions; C, similar conserved duplicated motifs in P. chabaudi (top) and P. falciparum (bottom). [The 
experimental work contributing to this figure was done by Pedro Cravo and Paul Hunt]. 
Pfmdr1 (PFE1150w) 
 
       1 MGKEQKEKKD GNLSIKEEVE KELNKKSTAE LFRKIKNEKI SFFLPFKCLP  
      51 AQHRKLLFIS FVCAVLSGGT LPFFISVFGV ILKNMNLGDD INPIILSLVS  
     101 IGLVQFILSM ISSYCMDVIT SKILKTLKLE YLRSVFYQDG QFHDNNPGSK  
     151 LRSDLDFYLE QVSSGIGTKF ITIFTYASSF LGLYIWSLIK NARLTLCITC  
     201 VFPLIYVCGV ICNKKVKLNK KTSLLYNNNT MSIIEEALMG IRTVASYCGE  
     251 KTILNKFNLS ETFYSKYILK ANFVEALHIG LINGLILVSY AFGFWYGTRI  
     301 IINSATNQYP NNDFNGASVI SILLGVLISM FMLTIILPNI TEYMKALEAT  
     351 NSLYEIINRK PLVENNDDGE TLPNIKKIEF KNVRFHYDTR KDVEIYKDLS  
     401 FTLKEGKTYA FVGESGCGKS TILKLIERLY DPTEGDIIVN DSHNLKDINL  
     451 KWWRSKIGVV SQDPLLFSNS IKNNIKYSLY SLKDLEAMEN YYEENTNDTY  
     501 ENKNFSLISN SMTSNELLEM KKEYQTIKDS DVVDVSKKVL IHDFVSSLPD  
     551 KYDTLVGSNA SKLSGGQKQR ISIARAIMRN PKILILDEAT SSLDNKSEYL  
     601 VQKTINNLKG NENRITIIIA HRLSTIRYAN TIFVLSNRER SDNNNNNNND  
     651 DNNNNNNNNN NKINNEGSYI IEQGTHDSLM KNKNGIYHLM INNQKISSNK  
     701 SSNNGNDNGS DNKSSAYKDS DTGNDADNMN SLSIHENENI SNNRNCKNTA  
     751 ENEKEEKVPF FKRMFRRKKK APNNLRIIYK EIFSYKKDVT IIFFSILVAG  
     801 GLYPVFALLY ARYVSTLFDF ANLEYNSNKY SIYILLIAIA MFISETLKNY  
     851 YNNKIGEKVE KTMKRRLFEN ILYQEMSFFD QDKNTPGVLS AHINRDVHLL  
     901 KTGLVNNIVI FSHFIMLFLV SMVMSFYFCP IVAAVLTFIY FINMRVFAVR  
     951 ARLTKSKEIE KKENMSSGVF AFSSDDEMFK DPSFLIQEAF YNMHTVINYG  
    1001 LEDYFCNLIE KAIDYKNKGQ KRRIIVNAAL WGFSQSAQLF INSFAYWFGS  
    1051 FLIKRGTILV DDFMKSLFTF IFTGSYAGKL MSLKGDSENA KLSFEKYYPL  
    1101 MIRKSNIDVR DDGGIRINKN LIKGKVDIKD VNFRYISRPN VPIYKNLSFT  
    1151 CDSKKTTAIV GETGSGKSTF MNLLLRFYDL KNDHIILKND MTNFQDYQNN  
    1201 NNNSLVLKNV NEFSNQSGSA EDYTVFNNNG EILLDDINIC DYNLRDLRNL  
    1251 FSIVSQEPML FNMSIYENIK FGREDATLED VKRVSKFAAI DEFIESLPNK  
    1301 YDTNVGPYGK SLSGGQKQRI AIARALLREP KILLLDEATS SLDSNSEKLI  
    1351 EKTIVDIKDK ADKTIITIAH RIASIKRSDK IVVFNNPDRN GTFVQSHGTH  
    1401 DELLSAQDGI YKKYVKLAK*  
P chabaudi mdr1 (PCHAS_123820) 
 
       1  MADKRSNNNS IKDEVEKELN KQSTVDLFKK IKKQNIPLFL PFHSLPSKHK  
      51  RLLAISFICA TISGAALPIF ISVFGLTMAN MNMGESVNDI VLKLVIVGIC  
     101  QFVISSISCL CMGTVTTEII RMLKLKYLKS VFHQDGEFHD NNPGSKLTSD  
     151  LDFYLEQVNS GIGTKFTTIF TYSSSFLGLY FWSLYKNVRL TLCVTCVFPV  
     201  IYIISTICNK RVRLNKKTSL LYNNNSMSII EEALVGIKTV VSYCGESTIL  
     251  KKFKLSEQFY SKYMLKANFM ESLHVGFING FILASYAMGF WYGTRIMIHD  
     301  IKNLSSPSDF NGGSVISILL GVLISMFMLT IILPNVTEYM KALEATNNIH  
     351  EVINRKPAVD RNQNKGRKLD DIKKIEFKNV KFHYGTRKDV EIYKDLNFTL  
     401  KEGNTYAFVG ESGCGKSTIL KLLERFYDPT EGDIVINGAH NLKDVDLKWW  
     451  RSKIGVVSQD PLLFSNSIKN NIKYSLISPN TLEAMENGFT MNGSSDSSLN  
     501  NNKNGKSTSI LDEISKRNTT NDLLEVISSI NSVEDSKVVD VSKKVLIHDF  
     551  VAALPDKYDT LVGSSASKLS GGQKQRISIG RAVIRNPKIL ILDEATSYLD  
     601  NKSEYLVQKT INNLKGNENR ITIIIAHRLS TIRYANQIFV LSNRDQESTG  
     651  IDEKKQGAIN SNNGSVIVEQ GTHDSLMKNK NGIYYSMIQN QKVSSSGNGE  
     701  NGDDNNSSVY KDSNPGDAKS VTDTNMDIGT NKNLNTKKEK EIADADKQTK  
     751  PSIFKRMFGK KKKKPNNLNM VYKEIFSHRK EVAIMLLSTI VAGGLYPLFA  
     801  VLYAEYVVTL FDIPNLEYNS NKYSIFILFI ALAMFISETL KNYYNNKIGE  
     851  KVESKIKYLL FENIIHQEIA FFDKDAHAPG FLSSYINRDV HLLKTGLVNN  
     901  IVIFTHFIIL FIVSMILSFY FCPIIAAALT LTYTFIMRAV TARVRMEKSN  
     951  KIEKIGDKKD GCLSYTTDDE IFKDPNFLIQ EAFYNMQTII TYGLEDYYCK  
    1001  LIENAIDHYN KEQRKSIIVN SILWGFSQCT QLFINAFAYW LGSILIKHKI  
    1051  IVVDDFMKSL FTFIFTGSYG GKLMSFKGDS DNAKLTYEKY YPIMVRKSNI  
    1101  DVRDEGGIRI KNPHQIDGKV EVKDVNFRYL SRPNVPIYKD LSFSCDSKKT  
    1151  TAIVGETGCG KSTIMHLLMR FYDLKDDHVL LDNQHVEKDN KDKSNDIEMT  
    1201  NATSMNELNE LHKKNATEEY TLYKNSGKIL LDGVDICDYN LKDLRKLFAI  
    1251  VNQEPMLFNM SIYENIKFGK EDATLEDVKR ACRLAAIDEF IESLPNKYDT  
    1301  NVGPYGKSLS GGQKQRVAIA RALLREPKIL LLDEATSALD SHSEKLIEKT  
    1351  IVDIKDRADK TIITIAHRIA SIKRSNKIVV FNNNDKNGSF VQAQKTHDEL  
    1401  IRDKDSVYTK YVKLTK* 
Note the following motifs duplicated within P. chabaudi
374 399
KIEFKNVKFHYGTRKDVEIYKDLNFT
KVEVKDVNFRYLSRPNVPIYKDLSFS
1119 1144
They are also conserved in P. falciparum
377 402
KIEFKNVRFHYDTRKDVETYKDLSFT
KVDIKDVNFRYISRPNVPIYKNLSFT
1125 1150
A
B
C
P. alciparum mdr1 (PF3D7_0523000)
P. Chabaudi mdr1 (PCHAS_123820)
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 Polymorphisms in Plasmodium falciparum ap2-mu gene 
Because the only confirmed point mutation arising in P. chabaudi AS-ART along with 
ART resistance phenotype 2 lies in the AP2-mu gene, the polymorphisms in the P. 
falciparum orthologue (PF3D7_1218300) were investigated. The DNA sequence analysis of 
PF3D7_1218300 in 24 samples (see Table 2) from Brazil, São Tomé and Rwanda revealed a 
total of 12 independent polymorphic sites, consisting of nine SNPs and three indels. Seven 
SNPs and all the insertions were novel genetic variants (relative to existing information in 
PlasmoDB, Table 10) and unrelated to each other. A polymorphism similar to P. chabaudi 
I568T was not detected in any of the isolates inspected. 
 
Table 10. Genetic polymorphisms identified in the pfap2-mu gene (PF3D7_1218300). 
Nucleotide 
Reference 
sequence (3D7) 
variant 
Codon, variant 
Amino acid 
substitution 
Location 
300 ATA ATC I100syn Rwanda 
381 GTG GTT*/GTC V127syn Brazil 
437 AGA AAA R146K Rwanda 
479 AGT AAT S160N Rwanda, ST 
486 ATT ATC I162syn Rwanda 
489 GAA GAG* E163syn Rwanda, ST 
596 AAA ACA K199T Rwanda 
699 AAT AAG N233K Rwanda 
1311 TTC TTA F437L Rwanda 
     
Insertions      
 Codon insertion Amino acid insertion  
699 AAT AATAAT 233 + N ST 
972 AAT AATAAT 324 + N Rwanda, ST 
987 AAT AATAAT 329 + N ST 
Polymorphic bases are underlined. *- SNP previously identified and recorded in PlasmoDB. 
Non-synonymous SNPs are shown with amino acid substitutions (bold). ST, São Tomé. 
Five of the nine SNPs were non-synonymous (aa 146, 160, 199, 233 and 437) while four 
were synonymous (Table 10). The non-synonymous mutations R146K, S160N and F437L 
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occur within regions which appear to be well conserved in Plasmodium spp of the N-
terminal domain of AP2-mu , although residues in these regions are not well-conserved 
relative to the rat homologue (data not shown). The non-synonymous SNPs, K199T and 
N233K are situated in unconserved regions (data not shown). 
The three indels were three-nucleotide insertions of an asparagine amino acid were 
found adjacent to codon 233, 324 or 329 in an asparagine-rich sequence (Table 10) not 
conserved in the P. chabaudi orthologue. Amino acids 324 and 329 are located on a P. 
falciparum-specific region relative to both P. chabaudi and the rat homologue (data not 
shown). 
 
Correlation of in vitro susceptibility to artemisinin derivatives and S160N 
polymorphism in Plasmodium falciparum isolates 
We investigated possible associations between the AP2-muS160N polymorphism and 
the previously reported [41, 42] in vitro ART-derivative response in Rwanda and São Tomé 
(Table 11, Figure 7). 
Table 11. Frequency distribution of pfap2-mu alleles among P. falciparum samples from 
Brazil, São Tomé and Rwanda. 
pfap2-mu allele Brazil (N=56) São Tomé (N=51) Rwanda (N=73) 
Wild-type (S) N = 56 (100%) N = 44 (86.2%) N = 61 (83.6%) 
Mutant (N) N = 0 (0%) N = 6 (11.8%) N = 9 (12.3%) 
Mixed (S + N) N = 0 (0%) N = 1 (2.0%) N = 3 (4.1%) 
 
The prevalence of the 160N allele was investigated in 180 isolates; 56 from Brazil [43], 
51 from São Tomé [42] and 73 from Rwanda [41]. The frequency of the 160N genetic 
variant was ~12% in both African sites and absent in the Brazilian samples (Table 11). 
  
Chapter 4 – Artemisinin resistance in rodent malaria 
 
 
110 
 
Figure 7: Density function curves for the WT (N160 pfap2-mu) (in green) and MUT (160S pfap2-mu) 
samples (in red). The ticks below the curves illustrate the measured IC50 values for each sample. 
DHA: dihydroartemisinin; ATN: artesunate; ATH: artemether. 
 
ART response data were log-transformed and an ‘outlier’ identified and removed from 
the dataset as described in Methods. Comparison of mutant vs. wild-type log-transformed 
datasets revealed a significant difference between the mean IC50 values registered for 
genotypes 160S (4.86 +/- 0.07 nM) and 160N (2.49 +/- 0.04 nM) in parasites from Rwanda 
(p-value = 0.026, Table 4). This difference could also be observed in the function curves 
(shift to higher IC50 values) in the parasites from Rwanda (Figure 7). No significant 
differences were identified for parasites from São Tomé (Table 12).  
 
Table 12. Average log (IC50) values (nM) ± correspondent standard error and the associated 
t-test p-value for mutant and wild-type samples. The values in bold represent the average 
IC50 without log transformation 
 Rwanda- DHA São Tomé- ATN São Tomé- ATH 
Mutant 
(160S pfap2-mu) 
 
0.687 (4.86) ± 0.0701 
(N=8) 
-0.670 (0.512) ± 0.383 
(N=5) 
-0.122 (0.885) ± 0.235 
(N=6) 
Wild-type 
(N160 pfap2-mu) 
 
0.396 (2.49) ± 0.0450 
(N=61) 
-0.909 (0.403) ± 0.120 
(N=36) 
-0.232 (0.793) ± 0.0649 
(N=44) 
p-value 0.0256 0.500 0.580 
DHA: dihydroartemisinin; ATN: artesunate; ATH: artemether 
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Discussion 
Increased artemisinin resistance phenotype 
An ART resistance phenotype (phenotype 1) in P. chabaudi was previously described 
and the underlying genetic mechanism (mutations in ubp1) identified [30]. That phenotype 
had been experimentally evolved in AS-30CQ under chloroquine selection and without any 
exposure to ART. Subsequently AS-ART was evolved from AS-30CQ by ART selection [25]. 
Here, an increased artemisinin resistance (phenotype 2) in AS-ART relative to AS-30CQ is 
characterized. The increased resistance is apparent at 200 mg ART kg-1 d-1 (inoculation of 
106 parasites, three-day drug treatment). Interestingly a five-day treatment using a higher 
inoculum (107 parasites) also differentiated AS-ART from AS-30CQ. These data are 
consistent with the hypothesis that quiescence or dormancy responses may underlie 
survival of artemisinin treatment [58,59]. 
 
Genetic basis of increased artemisinin resistance 
Illumina whole-genome sequencing reveals a single point mutation arising between 
AS-30CQ and AS-ART. This mutation encodes an I568T substitution in the µ subunit of the 
AP2 adaptor complex (PCHAS_143590). The number of false negatives due to insufficient 
coverage is estimated to be less than one/genome, as previously discussed [30,31] and 
given the minimum threshold for point mutation detection (three reads), the proportion of 
the genome covered by less than three reads (1.67%, see Table 7) and the accurate 
identification of simulated mutations (random alterations in reference sequence) [30]. The 
frequency of a false negative arising from incorrect read alignment is minimized because 
the re-sequenced and reference genomes are largely identical, and because optimal 
hashing-table algorithms were used. Importantly the likely appearance of only one point 
mutation is consistent with previous genome re-sequencing studies [31] that reveal a 
consistent set of a small number of point mutations, most of which confer drug-resistance 
phenotypes in other drug-resistant clones of the P. chabaudi AS lineage (Table 1) [30-33]. 
For example, four or five out of seven single nucleotide substitutions between AS-sens and 
AS-30CQ confer resistance to pyrimethamine, chloroquine and artemisinin phenotype 1 
[30,31]. This is consistent with similar studies using other parasites; for example, only four 
non-synonymous mutations arose in each of two miltefosine-selected Leishmania major 
genomes [60]. 
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Although the possibility that increased ART-R is conferred by unidentified point 
mutations in the small fraction of the unassembled genome cannot be excluded, regions of 
low read coverage, the indel identified in AS-ART, or further unidentified indels, suggest 
that the mutation I568T in AP2-mu on chr14 is the principal determinant of higher-level 
artemisinin resistance (ART-R phenotype 2) in AS-ART which also bears the ubp1 mutation 
[30] but no mdr1 amplification [32]. This hypothesis should be validated by transfection 
experiments. 
Other results are consistent with this hypothesis. A previous study suggested that a 
locus on chr14 contributes to artemisinin responses in genetic selection experiments using 
AS-ART [23]. Also, two recent independent reports show evidence of the involvement of 
adaptor proteins in drug resistance phenotypes in other human parasites. A genome-wide 
RNAi target sequencing approach revealed Trypanosoma brucei parasites with a 
knockdown of one of each of the four AP1 adaptor subunit genes (as well as lysosomal 
proteases, vacuolar protein sorting factors, etc.) of the endosomal system in suramin-
treated populations [61]. In a similar experimental paradigm to that described here, an in 
vitro miltefosine-resistant L. major line bore a D762 mutation in the α-subunit of an 
adaptor protein and a different mutation in the Leishmania infantum orthologue [60]. The 
probability that mutations in adaptor subunits confer resistance to three structurally and 
functionally unrelated drugs (suramin, miltefosine and artemisinin) in three different 
parasites (Trypanosoma, Leishmania and Plasmodium) suggests that a conserved aspect of 
drug treatment and response is targeted by these mutations. 
 
Clathrin-mediated endocytosis - insights regarding ART action and resistance 
The AP2 adaptor complex is a heterotetramer (α, β, μ, σ) that selects and recruits other 
factors, including membrane protein (cargo) and intracellular clathrin, mediating clathrin-
mediated endocytosis (CME) [46]. CME is involved in the internalization of extracellular 
molecules and ligands (e g, low density lipoprotein, transferrin, growth factors, antibodies 
and bacterial toxins), the remodelling of the plasma membrane (removal of variable 
antigen), and membrane protein trafficking and vesicular sorting through the endosomal 
system and lysosomes [50]. In P. falciparum, these cellular processes are being studied 
particularly regarding digestive vacuole genesis, haemoglobin uptake and digestion [62], 
the role of (poly)phosphorylated phosphatidyl inositol [63], the action of aminoquinolines 
and artemisinins [6,7,64-66] and the trafficking of a critical determinant of chloroquine 
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resistance (the membrane protein, crt) [67]. The participation of clathrin (as coated vesicles) 
in endocytosis and its relationship to the formation of cystosomes has not been fully 
clarified and, in any case, the mechanism would require the production of vesicles with 
double membranes (parasitophorous vacuole and parasite membranes). Nevertheless, it is 
possible that some elements of CME have been recruited to the haemoglobin uptake 
mechanism. The existence of Plasmodium-specific additional sequence between the N- and 
C-terminal domains of the AP2-mu chain may reflect non-canonical functional attributes of 
the AP2 adaptor complex. 
The I568T mutation in the AP2 mu-chain locates to a residue forming a hydrophobic 
pocket into which the Φ residue of the YXXΦ recognition motif on the cargo proteins binds. 
This suggests that modulation of cargo trafficking may be the key event in this resistance 
pathway. The I568T mutation in AP2-mu may reduce its binding to membrane cargo and 
mediates artemisinin resistance phenotype 2 by reducing endocytosis or the recycling or 
trafficking of one or more membrane proteins. Previous work has shown that fluorescent 
artemisinin derivatives concentrate in neutral lipid bodies close to the digestive vacuole [5], 
suggesting that drug may be taken up by endocytosis. Artemisinin interacts with the 
endocytic and endosomal pathway. For example, it inhibits endocytosis [64] and 
haemoglobin uptake [7], resulting in the disruption of the DV membrane [6] and some 
derivatives may increase the accumulation of endocytic vesicles [6]. Also, artemisinin 
activity is dependent on haemoglobin digestion [7]. A reduction in haemoglobin uptake or 
digestion may therefore constitute a strategy for surviving exposures to short-lived 
artemisinins. The I568T mutation might therefore reduce the rate of haemoglobin uptake 
and hence the activation or action of artemisinin. Indeed, the reduced growth of AS-ART in 
relation to its sensitive progenitor AS-30CQ in absence of treatment (Figure 3A), indirectly 
supports this notion. The involvement of adaptor proteins in resistance to suramin, 
miltefosine and artemisinin in Trypanosoma, Leishmania [68,69] and Plasmodium however, 
may suggest a rather general resistance mechanism involving, for example, the reduction 
of drug uptake through endocytosis. 
A V2728F mutation in ubp1 was previously identified as the critical determinant of 
artemisinin resistance phenotype 1 in AS-30CQ [30], predicting that this mutation would 
decrease de-ubiquitination. The ubiquitination of membrane receptors and proteins may 
induce clathrin-independent (caveolae) endocytosis [70]. Therefore, the ubp1 and AP2-mu 
mutations may both modulate endocytosis, possibly changing the balance of endocytosis 
toward a clathrin-independent pathway. Interestingly, chloroquine is also known to 
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interact with endocytosis, vesicular transport, haemoglobin digestion and actin and DV 
dynamics [64-66,71] and the V2728F ubp1 mutation has been shown to confer high-level 
CQ-resistance [31]. This artemisinin- and chloroquine-cross resistance is therefore 
consistent with the suggestion that endocytic pathways are involved in the mode of action 
of both of these drugs and the resistance mechanisms in P. chabaudi. 
In addition, a number of observations are consistent with the view that mdr1 could be a 
critical cargo protein. Firstly, mdr1 duplication has been identified as another determinant 
of ART-R [32]. Secondly, mdr1 sequences (both P. chabaudi and P. falciparum) contain 
many YXXΦ recognition motifs (Figure 6), suggesting that it’s trafficking and localization 
may be subject to control by the µ-adaptor. Thirdly, changes in the clathrin-dependent 
endocytosis and trafficking of mdr1-encoded P-glycoprotein (in human cancer cell lines) 
alter both its partition between cell membrane and intracellular pools, as well as the level 
of drug resistance [72]. Finally, distributions of P-glycoprotein within cancer cells and their 
drug-resistance phenotypes are also mediated by ubiquitination [73]. 
The present study therefore suggests that experimental studies on the molecular 
interactions between ubiquitination pathways, endocytosis and artemisinin uptake and 
sensitivity may provide important insights regarding artemisinin action and resistance 
mechanisms. 
 
Field studies of P. falciparum 
12 genetic polymorphisms (nine SNPs and three insertions) were identified in the P. 
falciparum orthologue (PF3D7_1218300) in field samples from Rwanda, São Tomé and 
Brazil, one of which (S160N) was associated with previously published in vitro DHA 
responses in parasites from Rwanda (p = 0.026). We cannot exclude the possibility that a 
different genetically linked gene may regulate the parasite’s in vitro response to DHA, 
particularly since linkage disequilibrium in this region of the genome was not estimated in 
these samples. It has been suggested that modified in vitro assays may be required for 
improved estimation and sensitivity of responses to ART [74]. 
Association studies in locations in Southeast Asia where ART-R has been reported would 
be of particular interest. A recent linkage analysis of a P. falciparum genetic cross (HB3 x 
Dd2) revealed 3 loci linked to in vitro artemisinin responses; on chr05, chr12 and chr13 
[24]. Marker C12M63 was the most highly linked marker on chr12. However, this marker 
maps over 1 Mbase downstream from PF3D7_1218300 suggesting that a different gene 
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was involved in that study. A genome-wide analysis of genetic diversity in P. falciparum 
parasites from Asia, with different artemisinin responses mapped a possible genetic 
determinant to a region of chr13 [21]. However, no SNPs were identified in these genes 
that could be associated with the in vivo parasite’s responses to ART. Recently however, 
the genotyping of P. falciparum isolates from Asia established associations between four 
SNPs (on chromosomes 10, 13 and 14) and both recent positive selection and parasite 
clearance phenotypes after artemisinin treatment [75]. However, the genes and regions 
where these SNPs lie are not linked to the P. falciparum orthologue of the AP2 mu-chain on 
chromosome 12, suggesting a different gene to that identified here is involved. 
We note that all of the field samples analyzed here were collected before the official 
implementation of ACTs. Therefore, although baseline levels of ART responses vary 
considerably between isolates this variability may be more likely to arise from pre-existing 
genetic variation than from that selected by drug use. However, naturally occurring 
polymorphisms (such as S160N), with small drug response effects, may represent the first 
step on the pathway to full resistance. For example, those recombinant clones of the HB3 x 
Dd2 cross with the lowest ART responses were, indeed, those in which resistance was most 
easily selected [24]. 
Due to the relatively small number of samples analyzed and the fact that all the samples 
were collected before the official implementation of ACTs, further studies will therefore be 
required to fully evaluate the association between PF3D7_1218300 polymorphisms and in 
vitro artemisinin responses in P. falciparum parasites. 
 
Conclusions 
An increased artemisinin resistance phenotype in a lineage of P. chabaudi drug-resistant 
parasites was identified. Genome-wide re-sequencing identifies a single point mutation in a 
critical part of the AP2 adaptor mu-chain. This mutation is predicted to increase artemisinin 
resistance by modulating clathrin-mediated endocytosis. Analysis of the orthologous gene 
in P. falciparum field isolates demonstrates existing genetic variation in the human malaria 
parasite and a weak association between a polymorphism in pfap2-mu gene and in vitro 
artemisinin responses.  
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Lastly, the possibility was considered that mutations in a different gene(s) may play a 
role in responses to artemisinin derivatives in P. falciparum. However, further than 
assigning particular mutations to ART resistance phenotypes, it is suggested that a 
potentially novel biological pathway through which artemisinin resistance may occur may 
be involved. 
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ABSTRACT  
Background 
The efficacy of ACT for Plasmodium falciparum malaria may be threatened by parasites 
with reduced responsiveness to artemisinins. Among 298 ACT-treated children from Mbita, 
Kenya, sub-microscopic persistence of P. falciparum on day 3 post-treatment was 
associated with subsequent microscopically detected parasitaemia at days 28 or 42.  
Methods 
DNA sequences of resistance-associated parasite loci pfcrt, pfmdr1, pfubp1 and 
pfap2mu were determined in the Mbita cohort before treatment, on days 2 and 3 after 
initiation of treatment and on the day of treatment failure. 
Results 
Parasites surviving ACT on day 2 or day 3 post-treatment were significantly more likely 
than the baseline population to carry the wild type haplotypes of pfcrt (CVMNK at codons 
72-76; P < 0.001) and pfmdr1 (NFD at codons 86, 184, 1246; P < 0.001). In contrast, variant 
alleles of the novel candidate resistance genes pfap2-mu (S160N/T; P = 0.006) and pfubp-1 
(E1528D; P < 0.001) were significantly more prevalent post-treatment. No genetic 
similarities were found to artemisinin-tolerant parasites recently described in Cambodia.  
Conclusions 
Among treated children in western Kenya, certain P. falciparum genotypes defined at 
pfcrt, pfmdr1, pfap2-mu and pfubp1 more often survive ACT at sub-microscopic level, and 
contribute to onward transmission and subsequent patent recrudescence.  
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INTRODUCTION  
Over the last decade, the widespread deployment of artemisinin-based combination 
therapy (ACT), with improved vector control and other measures, has contributed to a 
reduction of malaria-related morbidity and mortality across sub-Saharan Africa [1, 2]. These 
public health gains may be lost if the efficacy of ACT against Plasmodium falciparum is not 
sustained. Recent evidence suggests that parasite genotypes have arisen in Cambodia and 
surrounding countries that are less rapidly cleared by artesunate monotherapy [3-6]. This 
has been interpreted by some as bona fide emerging artemisinin resistance [4, 6], and by 
others as “treatment failure”, with full-blown resistance to ACT not yet present [7]. The 
efficacy of ACT remains high in Africa, with no reports to date of slow clearance as in 
Cambodia. However, evidence based on classical microscopic parasite detection suggests 
that a proportion of ACT-treated children in Kenya do not completely clear P. falciparum 
parasitaemia [8]. More recently, qPCR-detectable sub-microscopic residual parasitaemia on 
day 2 or 3 post-ACT in Kenyan children was shown to be a significant risk factor for parasite 
transmission to mosquitoes, and for microscopically-detected parasitaemia recurring on 
day 28 or 42 [9]. Thus residual asexual parasitaemia, if genetically determined, may provide 
an enhanced likelihood of infecting the vector population, and thus further human hosts. 
Such evolutionary success, where parasites harbouring genetic markers of drug resistance 
exhibit a transmission advantage, has previously been implicated in the development of 
resistance to chloroquine and anti-folate malaria drugs [10-12]. 
The possibility that P. falciparum populations in Kenya may be less responsive to ACT 
therapy than previously reported provides a strong rationale for further investigation, for 
two reasons. Firstly, identification of any heritable genetic signature for this phenotype 
would enable monitoring of its spread by tracking relevant molecular markers. Secondly, it 
is important to determine whether the sub-microscopic persisting parasite phenotype 
described in Kenya is related to the more pronounced microscopically detectable slow 
clearance described from western Cambodia [3,4], given important differences in 
transmission intensity, population prevalence of acquired immunity and treatment policy. 
Genetic characterisation of the persisting Kenyan parasites at candidate loci known or 
suspected to be under selection by ACT would address both objectives. Candidate loci 
include, firstly, markers for resistance to the quinoline drugs chloroquine and amodiaquine, 
known to be selected by ACT towards quinoline-sensitive alleles [13-16]. Secondly, new 
candidates pcubp1 (encoding ubiquitin carboxyl-terminal hydrolase 1) and pcap2mu 
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(encoding clathrin vesicle-associated adaptor 2,  subunit), both implicated in artemisinin 
resistance in the rodent parasite P. chabaudi, have been shown to have polymorphic 
homologues in P. falciparum [17-18]. These polymorphisms have yet to be fully validated as 
markers in parasites with reduced sensitivity to artemisinin derivatives in vivo. However, 
genome-wide association studies of P. falciparum isolates from coastal Kenya in which the 
pfubp1 variant E1528D was associated with reduced susceptibility to artemisinin in vitro 
were recently reported [19]. 
To characterise any genetic signature of slow clearing sub-microscopic infections in ACT-
treated children from Mbita, Kenya [9], pfcrt, pfmdr1, pfubp1, and pfap2-mu genotypes 
were determined on days 2 and 3, and on day of recrudescence in the case of later 
treatment failures. These were compared with pre-treatment parasite genotypes isolated 
from children at baseline, and evaluated for evidence of post-treatment selection in vivo.   
 
METHODS  
Trial design and participants  
As previously described in detail [20], 298 children aged 6 months to 10 years were 
randomly allocated to receive a 6-dose regimen of artemether-lumefantrine (AL) or a 3-
dose regimen of dihydroartemisinin-piperaquine (DP), fully observed, and followed for 42 
days, according to a protocol approved by the KEMRI Scientific Steering Committee (#1556, 
2009) and the LSHTM Ethics Committee (#5455, 2009). Detailed parasite clearance 
dynamics were assessed by qPCR as described elsewhere [9]. 
 
Detection of genetic polymorphisms in loci of interest 
Parasite DNA was extracted from ~10L blood spots collected on Whatman filter paper 
prior to treatment (day 0) and on days 2, 3, 7, 14, 28 and 42 after treatment as previously 
described [9]. Polymorphisms in the pfcrt gene (PF3D7_0709000), encoding the 
P. falciparum chloroquine resistance transporter, were determined in parasite DNA by 
multiplex qPCR as described [21]. Polymorphisms at codons 86, 184 and 1246 in the pfmdr1 
gene (PF3D7_0523000), encoding P-glycoprotein H1, were identified using direct 
sequencing of PCR products as previously described with minor modifications [16].  
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Polymorphisms in the pfap2-mu gene (PF3D7_1218300), encoding the -subunit of 
clathrin-associated AP2 adaptor protein [18], were determined by PCR amplification and 
direct sequencing of three fragments encompassing codons 1-174, 121-399 and 377-621, 
as described [22].  
Polymorphisms in pfubp-1 (PF3D7_0104300) in the 300bp region encompassing codons 
1463 – 1563 were determined using a PCR strategy designed and optimised for this study. 
Nested PCR products were generated using the primer sets: 
 
Nest 1 Forward Primer (pfubp1_1452_1F) CGCCCGTACTATGAAGAAGATC 
Nest 1 Reverse Primer (pfubp1_1612_1R) GGCTTTTACCTGAACTGTTCAGG 
Nest 2 Forward Primer (pfubp1_1463_2F) CGTAAACAGAATATTCAGGATTGC 
Nest 2 Reverse Primer (pfubp1_1563_2R) CTAGCCCTTTATTATCATTATCG  
 
Amplification was performed with two nested reactions of 40 cycles of 3-step PCR, with 
30s annealing at 53°C (nest 1) or 57°C (nest 2) and elongation at 72°C for 45s. Products 
were characterised by direct sequencing as described [22]. Ambiguous mixed haplotypes of 
pfmdr1 were excluded from the analysis as previously described (14). Mixed genotypes 
were included in the analysis at the pfcrt locus, where only two haplotypes were found at 
codons 72-76, and at both the pfap2-mu and pfubp1 loci, for which only a single variable 
codon was evaluated. 
 
Analysis of locus polymorphism in global P. falciparum genome data  
Single nucleotide polymorphic residues in the pfap2-mu and pfubp1 loci were examined 
in Plasmoview (http://pathogenseq.lshtm.ac.uk/plasmoview) [23], in an ordered set of 631 
P. falciparum genomes stratified by geographical region.  
 
Statistical analysis  
Binary variables were compared across pairs of categories, and odds ratios (OR) with 
95% confidence intervals (CI) estimated. Significance was determined using the chi-squared 
distribution. Directional selection in paired samples from the same patient at different 
time-points was tested for statistical significance using McNemar’s symmetry test. All 
analyses were performed in STATA 11 (Timberlake Associates, College Station, Texas).   
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RESULTS  
Codons 72-76 of pfcrt  
The wild-type pfcrt allele, encoding CVMNK at codons 72 – 76 of the CRT protein, was 
confirmed as present in 143 of the 278 (51.4%) evaluable parasite isolates prior to 
treatment (day 0), of which 89 also harboured the CVIET allele. The remaining 135 isolates 
(48.6%) were CVIET alone. The CVMNK allele was significantly more common among sub-
microscopic infections at day 3, being detected in 66 of the 73 successfully evaluated 
(90.4%; OR 8.90; 95% CI 3.88 - 23.7; P < 0.001). A significant proportion on day 3 (68%) 
were mixed infections comprising both the CVMNK and CVIET genotypes. Thirty-five of the 
65 children with detectable CVMNK parasites at day 3 did not carry this genotype at day 0, 
compared to only 3 children presenting with CVMNK but having only CVIET detected at day 
3, demonstrating significant asymmetry, interpretable as strong directional within-host 
selection for the CVMNK allele (2 = 26.95, 1 d.f.; P < 0·001). This effect remained 
significant after stratification for treatment group (Table 1). These findings suggest that in 
those children with both pfcrt genotypes present prior to treatment, CVMNK significantly 
increased in relative abundance from day 0 to day 3. There was evidence that carriage of 
CVMNK prior to treatment was associated with risk of parasite recurrence at day 28 or day 
42 for AL (OR 2.461, 95% CI 1.004 – 6.23; P = 0.030) but not for DP (OR 1.405, 95% CI 0.154 
– 17.3; P = 0.714).    
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Table 1.  Prevalence of pfcrt and pfmdr1 haplotypes before and after treatment with artemether-lumefantrine or dihydroartemisinin-
piperaquine.  
 
Gene Treatment 
Odds Ratio: occurrence on day 3 
Vs 
baseline (95% CI) 
Directional selection within-host* 
LOSS 
(frequency) 
GAIN 
(frequency) 
P value 
 
 
 
 
AL 
(N = 43, 143) 
 
10.32 (3.42 - 41.4) 
P < 0.001 
1 15 P < 0.001 (N = 43) 
pfcrt  
codons 72-76 
CVMNK 
 
DP 
(N = 30, 135) 
 
7.64 (2.17 - 40.8)  
P < 0.001 
1 
 
9 
 
P = 0.0114 (N = 30) 
 
 
Combined ACT  
(N=73, 278) 
  
8.90 (3.88 - 23.69)  
P < 0.001 
 
2 
 
24 
 
P < 0.001 (N = 73)  
      
 
 
 
 
AL 
(N = 26, 101) 
 
3.15 (1.19 - 8.60)  
P = 0.001 
 
1 
 
9 
 
P = 0.0114 (N = 22) 
 
pfmdr1  
codons 86, 184, 1246 
NFD 
 
DP 
(N = 15, 104) 
 
8.52 (1.76 - 80.3)  
P = 0.002 
 
1 
 
6 
 
P = 0.0588 (N = 15) 
 
 
 
 
Combined ACT 
(N=42, 206) 
 
 
3.59 (1.68 - 7.95) 
P < 0.001 
2 
 
15 
 
 
P = 0.0016 (N = 38) 
 
* change in genotype in the same patient between day 0 and day 3 is scored as loss or gain; significance tested using McNemar’s test of asymmetry  
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Codons 86, 184 and 1246 of pfmdr1  
Previous studies have proposed that the haplotype NFD at codons 86, 184 and 1246 is 
associated with parasite recurrence after AL. We collated information at these three 
positions into haplotypes, using strict criteria to eliminate ambiguity due to mixed 
infections by excluding all isolates with mixed alleles called at two or more of the codons of 
interest [14]. The proportion of children carrying the haplotype NFD prior to treatment was 
38.4%, but this rose to 69.1% on day 3 (N = 42; OR 3.59; 95% CI 1.68 - 7.95; P < 0.001). 
However, this strict haplotype definition may have led to biased loss of data from pre-
treatment isolates because of higher parasite density, and thus greater clonal multiplicity. 
The analysis was repeated using less stringent criteria for assigning pfmdr1 haplotypes (i.e. 
assigning the NFD haplotype to all ambiguous isolates where this may have been present). 
This also showed significantly higher prevalence of the NFD haplotype (sensu lato) on day 3 
than in the baseline population (N = 48 at day 3; OR 4.31, 95% CI 2.09 - 9.30; P < 0.001). 
Paired analysis on both days 0 and 3 at all three codon positions was available for 38 
children, and evidence of significant within-host directional selection was found for the 
NFD haplotype sensu strictu (P = 0.0016). Despite loss of statistical power, stratification by 
treatment group suggested that this effect occurred in both the AL (N=22) and DP arms 
(N=15) (P = 0.011, 0.059 respectively; Table 1). Presence of the NFD haplotype at day 0 was 
not associated with risk of recrudescence in either arm (data not shown). 
 
Polymorphisms in pfap2-mu  
As this is the first study to examine the role of pfap2-mu polymorphisms in a 
prospective study of ACT sensitivity, sequence data was obtained at all 621 codons for 166 
pre-treatment isolates, and for codons 121-399 for a further 78 isolates. A variety of 
mutations including synonymous and non-synonymous single nucleotide polymorphisms, 
deletions and insertions were identified within this gene in the study population, and these 
are summarised in Tables 2 and 3. We were able to assemble 57 distinct haplotypes from 
the 166 full-length pfap2-mu sequences, 38 of which only occurred once. The most 
common haplotype, found in 32 pre-treatment isolates, was identical to the reference 
sequence from 3D7.  
Pilot analysis of the first 20 isolates found to have persisting parasites on day 2 or day 3 
identified the non-synonymous polymorphism at codon 160, Ser to either Asn or Thr (Table 
2), as differing in prevalence between pre- and post-treatment infections. We therefore 
focussed on this mutation for detailed analysis. Among 244 evaluable pre-treatment 
Chapter 5 – Directional selection of candidate genes  in Kenyan children 
 
 
134 
samples, 18.3% and 1.2% carried the Asn or Thr alleles, respectively, at codon 160 of pfap2-
mu. In contrast, combining 32 evaluable paired samples, each consisting of one sample 
collected before treatment (day 0) and one sample collected after the treatment (day 2 or 
day) from the same patient, the prevalence of parasites with either the S160N or S160T 
variant rose immediately following ACT treatment from 28.1% to 40.6% (OR 2.87, 95% CI 
1.20 – 6.61; P = 0.006). Among these 32 individuals, evidence of directional selection for 
either variant was found between day 0, with nine of the individuals carring either mutant 
or mixed alleles (mutant and Wt) and day 2/3 (P = 0.046), with an extra four individuals 
carrying the mutant variants (S160N/T). This selection was not seen at the day of failure, 
when the overall prevalence of codon 160 mutations was 25% (Table 2). There was no 
evidence that carriage of the S160N or S160T variant prior to treatment was associated 
with risk of recurrent infection (data not shown).  
 
Table 2. Synonymous and non-synonymous single nucleotide polymorphisms in the 
pfap2-mu gene, and prevalence at day 0, day 2/3 and day of failure after ACT treatment.  
 
Codon 
Reference 
sequence 
AA 
Nucleotide 
substitution 
AA 
changes 
Prevalence 
 day 0 
(N=244)* 
Prevalence  
day 2/3 
(N=32) 
Prevalence  
day failure  
(N=28) 
5 G Leu 15A - 8.4% 4.2% no data 
146 G Arg 437A Lys 1.2% 0% 3.6% 
160 G Ser 
479A 
479C 
Asn 
Thr 
18.0% 
1.2% 
37.5% 
3.1% 
25.0% 
0% 
161 G Val 483A - 0.4% 0% 0% 
162 T Ile 486C - 9.8% 3.1% 0% 
163 A Glu 489G - 16.8% 18.8% 17.9% 
188 A Arg 564G - 0.8% 3.1% 0% 
199 A Lys 596C Thr 3.3% 3.1% 7.1% 
200 A Asn 598T Tyr 0.4% 0% 0% 
233 T Asn 699G Lys 0.4% 0% 0% 
337 C Ala 1010G Gly 1.2% 0% no data 
324 T Cys 1026C - 0.6% 0% no data 
437 C Phe 1311A Leu 4.2% 9.4% no data 
476 T Ser 1428G - 4.2% 3.1% no data 
478 A Val 1434T - 2.4% 0% no data 
The middle sequencing fragment (codons 121-399) was successfully analysed in all isolates. Codon 5 was not 
determined in 2 isolates without fragment 1 data; codons 5, 337, 324, 437, 476 and 478 were not determined in 74 
isolates without fragment 1 or 3 data, and codons 337, 324, 437, 476 and 478 were not determined in 1 isolate without 
fragment 3 data. 
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Table 3. Indels identified in the pfap2-mu gene, consequent amino acid replacements and 
prevalence at day 0, day 2/3 and day fail after treatment. 
 
Codon 
Reference 
sequence 
Deletions/ 
Insertions 
Prevalence day 0 
(N=244) 
Prevalence day 2/3 
(N=32) 
Prevalence day failure 
(N=28) 
226 7xAsn 
5xAsn / 6xAsn 0.4% / 0.4% 0% / 0% 0% / 0% 
8xAsn / 9xAsn 17.6% / 1.2% 9.4% / 3.1% 25.0% / 0% 
233 1xLys 2xLys 2.0% 3.1% 7.1% 
319 5xAsn 6xAsn 12.7% 6.3% 42.9% 
326 4xAsn 5xAsn 13.1% 9.4% 3.6% 
 
Polymorphisms in pfubp1  
An amplification strategy was designed for a region of pfubp1 from codons 1463 to 
1563, encompassing the polymorphic codon 1528 identified by Borrmann et al. [19] as 
being associated with in vitro parasite responses to artemisinin in Kenya. Direct sequencing 
of this region was successful in 123 pre-treatment isolates, and identified 16 distinct 
haplotypes defined by synonymous and non-synonymous point mutations, indels of one to 
15 amino acids and repeat number variations in low complexity nucleotide tracts (Figure 1). 
We focussed on the codon E1528D substitution, which occurred in 12 of 123 evaluable 
individuals (9.8%) prior to treatment. Day 3 finger-prick samples had been largely 
exhausted by investigations of the other three loci, and by previous qPCR analysis [9], but 
sequencing of pfubp1 was possible for 35 samples from day 3, of which 6 (17.1%) encoded 
Asp at codon 1528. To increase the sample, we amplified this region from 33 parasitological 
failures identified by microscopy on day 28 or day 42 [20], of which 14 (42.4%) carried 
1528D. Thus evidence was found that the E1528D mutation was significantly more 
common among parasite isolates after treatment (days 3, 28 or 42) than among the pre-
treatment population (OR 3.85, 95% CI 1.63 - 9.32; P < 0.001). Paired analysis in the 36 
evaluable individuals (i.e. those with pfubp1 sequence data on day 0 and at least one of day 
3, day 28 or day 42) showed strong evidence of directional selection (P = 0.002).  Carriage 
of the 1528D variant at day 0 was not associated with risk of recurrent infections (data not 
shown).  
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1. n=51 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE---------------KYDKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
2. n=25 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE------------KYDKYDKYEKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
3. n=11 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE------------KYDKYDKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
4. n=11 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE---------------KYDKYDKYDKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
5. n= 7 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE---------------KYDKYEKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
6. n= 6 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE------KYDKYDKYDKYDKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
7. n= 2 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE---------------KYDKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL* 
8. n= 2 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNEKYDKYDKYDKYDKYDKYDKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL* 
9. n= 1 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE---------KYDKYDKYEKYDKYDKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
10. n= 1 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE------KYDKYDKYEKYEKYEKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
11. n= 1 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE---------------KYDKYEKYDKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
12. n= 1 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE---KYDKYDKYDKYDKYDKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
13. n= 1 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEEEDKYGKNEKNE---------------KYDKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
14. n= 1 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEEEDKYGKNEKNE------------KYDKYEKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
15. n= 1 RKQNIQDWSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEEEDKYGKNEKNE------KYDKYEKYEKYEKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
16. n= 1 RKQNIQDWSSYTKDKENKINMDDDINMNKGNDQDVNRTYKNEKNKEE-DKYGKNEKNE---------------KYDKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDNKGL 
 
Figure 1. Haplotype frequencies at codons 1463 – 1563 of pfubp1 in 123 pre-treatment isolates. A 303nt fragment was amplified from genomic DNA using primers 
described in the text, and sequenced directly. Sequences were ordered from the most frequent to the least, and aligned in Clustal W and formatted in Boxshade, 
with additional hand-editing for clarity. Codon 1258, as identified by Borrman et al. [19] is arrowed. Haplotype 1 is identical to the sequence found in the 3D7 
reference genome.  *Haplotypes 7 and 8 carry a synonymous mutation at codon 1518, encoding Asn. [The experimental work contributing to this figure was done 
by Gisela Henriques and Rachel Johnson]. 
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Polymorphism of pfap2-mu and pfubp1 in the global genome sequence database  
Having identified two novel candidate loci contributing to the genetic signature of 
persisting sub-microscopic P. falciparum in our treated Kenyan children, we sought to 
examine diversity in these two loci across 631 genomes using PlasmoView software [23]. 
For pfap2-mu, the S160N/T polymorphism occurred across both West African (Burkina 
Faso, Gambia, Ghana, Mali, Senegal) and East African (Kenya, Malawi) parasite populations. 
This polymorphism did not occur in SE Asian populations (Thailand, Cambodia, and 
Vietnam) nor in PNG (Fig. 2, left). For pfubp1, diversity across the locus was less 
geographically distinct, and mutations around codons 1520 – 1540 occurred in all 
populations (Fig. 2, right). By contrast, the recently described polymorphisms at codons 
493, 539, 543 and 580 of the kelch gene (PF3D7_1343700), associated with artemisinin 
sensitivity in Cambodia [6], were restricted to SE Asia, and do not occur in available African 
P. falciparum genomes. In contrast, the kelch polymorphism K189T was very common 
among African isolates but absent from Asian parasites included in the publicly available 
sample (data not shown). 
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Figure 2. Global sequence diversity in pfap2-mu (A) and pfubp1 (B) across genome sequences from 631 P. falciparum isolates mapped to the 3D7 reference 
genome [23]. Coloured bars at any chromosome position (horizontal axis) denote a non-reference substitution at that residue in the relevant isolate (vertical 
axis). At left is the regional origin of isolates in the analysis, comprising 8 laboratory isolates (Lab), 367 isolates from West Africa, 88 from East Africa, 151 from SE 
Asia and 17 from Oceania. Codon S160N/T of pfap2-mu and codon 1528 of pfupb1 are highlighted by red arrows at the bottom of the figure. For pfubp1, the 
position of two carboxy-terminal introns is also marked. Previous annotation of this region of chromosome 1 as two distinct genes (PFA0215w and PFA0220w) is 
shown above the right-hand figure. [The experimental work contributing to this figure was done by Colin Sutherland]. 
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DISCUSSION  
We have genetically characterised sub-microscopic P. falciparum infections in 
ACT-treated children from Mbita, Kenya and described a novel genetic signature at the 
pfcrt, pfmdr1, pfap2-mu and pfubp1 candidate drug-resistance marker loci. For three of 
these loci, the signature was already present three days after treatment with either AL or 
DP. For pfubp1, selection was seen on day of recrudescence in the case of later treatment 
failures. By microscopy, all children were parasite-free at day 3 and afebrile, and thus these 
were persisting, sub-microscopic and asymptomatic infections which, in some cases, 
contributed to mosquito transmission potential on day 7 and patent recrudescent 
parasitaemia on day 28 or day 42 [9, 20]. The evidence that these variant genotypes were 
over-represented on day 3, immediately following completion of the full (observed) course 
of either AL or DP, suggests that selection is exerted partly or primarily by the artemisinin 
component of combination therapy, and that P. falciparum response to artemisinin in vivo 
is modulated by variation at these loci. Although not directly shown by our data, this 
interpretation is supported by a recent study in Uganda [24], which found that 
lumefantrine and piperaquine did not select for the same haplotypes of pfmdr1 in 
recurrent infections, implying that early selection for the NFD haplotype is exerted by the 
artemisinin component in both treatment arms. 
 
Previous studies have documented selection at the pfcrt and pfmdr1 loci in late 
recurrent infections in ACT-treated African children [13-16], but this is the first 
demonstration of selection on day 3. The favoured CQ-sensitive haplotypes pfcrt CVMNK 
and pfmdr1 NFD were supplanted in the late 20th century by the spread of CQ-resistance. 
Thus it is difficult to distinguish between a general disadvantage in vivo caused by the 
relative lack of fitness of CQ-resistant P. falciparum in the absence of CQ [25, 26], and a 
specific interaction between these loci and artemisinin. Our study was not powered, nor 
designed, to explore inter-locus interactions, but we observed both pfmdr1-NFD and pfcrt-
CVMNK in 43 of 204 evaluable patients on day 0, and in 21 of 34 evaluable sub-microscopic 
infections on day 3 (OR 6.05, 95% CI 2.62 – 14.2; P < 0.001). This may suggest the benefit of 
the two wild-type genes was enhanced by the presence of artemisinin. Another weakness 
of our study was that some isolates of interest were not sequenced at all loci, mainly due to 
exhaustion of small, finite blood samples. Although the limited number of observations in 
each of the treatment arms precluded comparisons of effect estimates due to lack of 
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power, an exploratory stratification was carried out, generating odds ratios with very wide 
confidence intervals (data not shown). 
The S160N or S160T variants showed directional selection with a higher prevalence in 
samples collected 2 or 3 days after the drug treatment. However, comparisons between 
the prevalence of the different alleles before and after the treatment were only possible in 
a relatively small number of samples. The directional selection for pfap2-mu 160 
(AL: p=0.015; DP: p=0.063) and pfubp1 (AL: p=0.0002; DP: p=0.029) remained evident in 
both arms. Future studies with adequate power can now be designed using these estimates 
of prevalence and effect size, to more accurately determine the role of these genes in 
modulations of artemisinin in vivo responses. Moreover, age and multiplicity of infection 
were associated with parasite persistence in the Mbita trial [9], and thus are also potential 
confounders. These parameters should be investigated by multi-variate regression in 
studies with sufficient power to further dissect the interplay among parasite genotypes, 
host factors and different treatment regimens.  
 
This study provides the first preliminary evidence that P. falciparum response to 
artemisinin in vivo may be modulated by polymorphisms in the loci pfap2-mu and pfubp1, 
both homologues of genes identified in studies of experimentally-induced artemisinin 
resistance in the rodent parasite P. chabaudi [17, 18]. Clathrin-mediated endocytosis is a 
mechanism common to eukaryotic cells by which membrane-associated proteins and other 
cargo are transported from the plasma membrane, trans-Golgi network or endosomes to 
acceptor compartments; the adaptor complex 2 is associated with cell surface endocytosis, 
recruiting to the vesicle both cargo and structural components including clathrin, and may 
have a role in haemoglobin trafficking in malaria parasites. The ubiquitination of proteins 
modulates endocytosis and proteosomal recycling, with known substrates including 
P-glycoproteins such as Pgh1 (encoded in malaria parasites by pfmdr1) [27]. Thus these two 
loci may both contribute to endosomal digestion of haemoglobin in malaria parasites [18].  
 
The persistence of microscopically undetectable parasites following treatment of clinical 
malaria does not constitute in vivo antimalarial resistance as normally defined, and may 
have been equally common in the pre-ACT era. The application of a novel endpoint, qPCR 
positivity within 72 hours of treatment, has merely permitted this to be observed for the 
first time. In settings where a significant proportion of malaria patients are semi-immune, 
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newly acquired super-infecting parasites may flourish and cause symptomatic malaria, 
despite the presence of pre-existing “symbiotic” genotypes hitherto stably suppressed by 
the immune response, but adapted to continuing survival. As we have previously 
hypothesised [28], it may be these pre-existing parasites that remain in some individuals 
after drug clearance of the symptomatic infection. This hypothesis is only plausible if 
current ACT regimens are ineffective against low density parasitaemia, but recent data do 
suggest this is the case [28, 29]. Evaluation of current and alternative regimens against 
asymptomatic parasitaemia, using appropriate study protocols specifically designed for this 
purpose, is required to test this possibility.  
 
Our interpretation is that the phenomenon studied here is not antimalarial resistance 
per se. Consistent with this, the genetic signature described does not resemble that of the 
“artemisinin-resistant” parasites associated with the slow-clearance phenotype in 
Cambodia. Firstly, the latter do not carry the CVMNK haplotype of pfcrt and, secondly, 
pfmdr1 polymorphisms are not associated with the phenotype [30]. Finally, we found no 
evidence of codon 160 polymorphism in pfap2-mu occurring in SE Asian isolates in the 
available genomic sequence database, nor evidence of kelch propeller domain 
polymorphism in any African isolates [6]. We thus conclude that the persisting 
sub-microscopic parasites observed in our cohort of ACT-treated Kenyan children are not 
related to slow-clearing parasites as seen in Cambodia and nearby countries. Only 
polymorphisms in pfubp1 may be shared determinants in Cambodia and Kenya. 
PF3D7_0104300 encompasses two loci, PFA0215w and PFA0220w, from earlier genome 
annotations (Fig. 2B), and variant alleles of the former were identified in sub-populations of 
P. falciparum in Cambodia associated with slow clearance after artesunate monotherapy 
[31]. 
 
We have described a novel genetic signature at four loci in P. falciparum, and implicate 
these genes in modulating in vivo parasite response to artemisinin. Further evaluation in 
purpose-designed, adequately powered studies of asymptomatic malaria in vivo, and in 
genetically modified P. falciparum in vitro, are needed to determine the potential public 
health implications of these observations, and the utility of these loci as markers of 
artemisinin sensitivity in natural populations of P. falciparum worldwide.  
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Abstract 
 
In 2006, Burkina Faso adopted artemisinin-based combination therapy (ACT) as the 
first-line treatment for uncomplicated malaria. To determine whether parasite 
susceptibility has been affected by the introduction of the ACTs in Burkina Faso, an ex vivo 
susceptibility study was conducted on P. falciparum isolates obtained during a clinical trial 
of Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (AS + AQ). Here we 
investigate the association between in vitro antimalarial drug susceptibility with genetic 
polymorphisms in pfubp1, pfap2-mu and pf26S-protSU, three new molecular marker 
candidates that have been implicated in artemisinin resistance in Plasmodium chabaudi. 
Data revealed that polymorphisms in pfubp1 and pf26S-protSU can modulate in vitro and in 
vivo responses to Lumefantrine. Additionally, this study is in agreement with the recent 
suggestion that polymorphisms in pfap2-mu may contribute to P. falciparum susceptibility 
to multiple drugs. Further studies are necessary to further confirm the importance of these 
new molecular markers in modulating P. falciparum antimalarial drug susceptibility. 
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Introduction 
Resistance to antimalarial drugs represents a major obstacle for control and elimination 
of malaria in endemic countries. In response to increasing resistance to antimalarials and to 
delay the development of resistance, artemisinin based combination therapies (ACTs) are 
now the mainstay of recommended treatment for P. falciparum malaria. ACT, which 
combines highly potent artemisinin (ART) derivatives with long acting partner compounds 
are the most effective antimalarial drugs available at the moment (WHO, 2013). 
Burkina Faso is located in the middle of the West African Sahel region and is one of the 
poorest countries in the world, ranking 183 out of 186 countries as surveyed by the United 
Nations Development Program’s 2012 Human Development Index (Programme, 2014). 
Malaria is a major public health problem in Burkina Faso, with the entire population at risk 
for Infection. Despite suggestion of a general decline in malaria burden in sub-Saharan 
Africa, health facilities reported an increase in the number of malaria cases in Burkina Faso 
from an estimated 2 million in 2007 to 6 million in 2012 (WHO, 2013). In 2005, Burkina Faso 
adopted ACT as first-line treatment against malaria and chloroquine was replaced by 
artemether-lumefantrine (AL) and artesunate amodiaquine (AQ +AS). However, since the 
introduction of ACT there are very little data available on the efficacy of ACT against 
Plasmodium falciparum in Burkina Faso. Due to the essential role of ACTs in malaria 
control, monitoring of the efficacy of both ART and its partner drug is a crucial step in 
preventing any potential catastrophic failure of ACTs. 
To determine whether parasite susceptibility has been affected by the introduction of 
the ACTs in Burkina Faso, an ex vivo susceptibility study was conducted on P. falciparum 
isolates obtained during a clinical trial of AL and AS + AQ (Tinto et al. 2014). The P. 
falciparum isolates were assessed for their susceptibility to several antimalarial drugs. In 
the present study, we investigate the relationship between the in vitro susceptibilities to 
the different drugs and the prevalence of polymorphisms in recently identified genes 
associated with antimalarial resistance. The loci of interest included genes encoding a de-
ubiquitinating enzyme (ubp-1) (Hunt et al. 2007; Hunt et al. 2010), the mu (µ) chain of the 
AP2 adaptor protein complex (ap2-mu) [(Henriques et al. 2013); Chapter 4], and the 26S 
proteasome regulatory subunit (26S-protSU) (Rodrigues, Cravo et al., in preparation). The 
potential associations between the polymorphisms found and treatment outcome were 
also investigated by comparing parasite genotypes of pre- and post-treatment isolates. 
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These new candidates have been implicated in artemisinin resistance in the rodent malaria 
parasite Plasmodium chabaudi. A recent study conducted in Kenya also showed that 
mutations in the pfap2-mu and pfubp1 genes may modulate the responses to artemisinin 
combination treatments in vivo (Henriques et al. 2014) (Chapter 5). 
 
Material and Methods 
Study site and clinical isolates 
Plasmodium falciparum  DNA was available from one clinical trial conducted at the 
Dafra Health Centre in Bobo-Dioulasso, Burkina Faso (Dr Halidou Tinto, unpublished results; 
ClinicalTrials.gov identifier: NCT00808951). In brief, the study was conducted to determine 
the in vivo and in vitro efficacy of AL and AS + AQ, in children with uncomplicated malaria. 
Children aged 6 months to 15 years, with P. falciparum monoinfection (parasitaemia of 
4,000-200,000 asexual parasites per µl), fever (axillary temperature ≥37.5 °C or fever in the 
last 24 hours) and whose parents or guardians agreed on participation were eligible to 
participate. Overall 440 participants were enrolled and randomized to receive AL or AS + 
AQ during three periods (December 2008 to February 2009, from July 2009 to March 2010 
and from July to December 2010). Treatment efficacy was assessed during a period of 42 
day follow-up and the isolates were tested by the laboratory team of Dr. Halidou Tinto, 
Centre Muraz, Bobo Dioulasso, using the classical in vitro isotopic microtest technique. For 
each patient isolate IC50 estimates were generated for dihydroartemisinin (DHA), quinine 
(QN), chloroquine diphosphate (CQ), lumefantrine (LUM), piperaquine (PIP) and 
monodesethylamodiaquine (MDA) (Tinto et al., 2014). At the end of the follow-up, the 
patients were classified according to their clinical and parasitological responses into 
treatment failure or adequate clinical and parasitological response (ACPR). Nested PCR 
reaction was used to genotype the MSP-1, MSP-2 and GLURP markers to distinguish true 
treatment failures from new infections (Halidou Tinto, unpublished results). The study was 
reviewed and approved by the Institutional Ethics Committee of Centre Muraz. The clinical 
and ex vivo susceptibility data, and dried filter-paper blood samples from each patient, 
were kindly provided for this study by the team of Dr Halidou and the MALACTRES 
consortium, coordinated by Dr Henk Schallig, Royal Tropical Institute, Amsterdam. 
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Assessed for eligibility
(n = 950)
Enrolled and randomised
(n = 440)
Randomized to AL
(n = 220)
Randomized to AS + AQ 
(n = 220)
Reach study endpoint d28
(n = 214)
Reach study endpoint d28
(n = 209)
Reach study endpoint d42
(n = 211)
Reach study endpoint d42
(n = 208)
Excluded (n = 510)
307 no malaria
153 parasitaemia outside range
25 no consent
6 non-falciparum mono-infection
2 low haemoglobin
17 other reasons
4 consent withdrawn
1 death
1 protocol violation
8 consent withdrawn
1 lost to follow-up
1 danger signs
1 severe malaria
2 lost to follow-up
1 consent withdrawn
1 lost to follow-up
In vivo treatment outcomes 
Of the 950 patients screened, 643 (67.7%) were positive for P. falciparum of which 440 
were qualified for enrolment (Figure 1).  
Figure 1: Trial profile. 
 
Of the 419 cases that completed the follow-up, 104 (49.3%) in the AL arm and 148 
(71.2%) in the AS + AQ treatment arm were defined as adequate clinical and parasitological 
response (ACPR). In the AL treatment arm 107 (50.7%) of the 211 children had recurrent 
parasitaemia during follow-up. MSP-1, MSP-2 and GLURP diversity analysis of day 0 
samples versus samples from the day of recurrence identified 19 (9.0%) recrudescent 
infections and 88 (41.7%) re-infections outcomes. In the AS + AQ treatment arm 60 (28.8%) 
of the 208 children had recurrent infections. They were classified as recrudescences 4 
(1.9%) and re-infections 56 (26.9%) after PCR correction (Table 1). 
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Table 1. Treatment outcomes for AL or AS + AQ against P. falciparum malaria in Burkina 
Faso 
 Treatment received 
 
AL 
N = 211 
AS+AQ 
N = 208 
Outcome Number (%) 
Adequate clinical and parasitological 
response (ACPR) 
104 (49.3%) 148 (71.2%) 
Recurrent infections 107 (50.7 %) 60 (28.8%) 
        Due to re-infection*          88 (41.7%)          56 (26.9%) 
        Due to recrudescence        19 (9.0%)         4 (1.9%) 
* PCR corrected values up to day 42 
 
Analysis of parasite genetic polymorphisms in candidate genes 
For this study, polymorphisms of the candidate genes were determined using a PCR and 
sequencing method. Parasite genomic DNA was isolated from filter paper samples by 
extraction with Chelex method, as previously described (Plowe et al. 1995). 
The pfap2-mu gene and a 300 bp fragment of the pfubp-1gene (containing the codon 
1528) were amplified using primers previously described (van Schalkwyk et al. 2013; 
Henriques et al. 2014). The complete pf26S-protSU gene was amplified using the primers 
and the PCR conditions described below. Each PCR was performed in a total volume of 
25 µL with the following reaction mixture: 0.2 µM of each primer, 4.0 mM MgCl2, 0.4 µM 
deoxynucleotides (dNTPs), 1 U Bioline Taq polymerase (Bioline, UK) and 5 µL of target DNA 
template. The thermal cycle program was 94°C for 3 min, and 40 cycles of 94°C for 30 sec, 
annealing temperature for 30 sec and 68°C for 45 sec with a final extension of 68°C for 15 
min. The primer sequence and annealing temperatures for the amplifications are described 
in Table 2. 
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Table2. Primer sequences, PCR product sizes and annealing temperatures for 1st and 2nd 
amplification used for the PCR amplifications of pf26S-protSU genes. 
p
f2
6
S-
p
ro
tS
U
 
1 
Fw - CCGCCAGTGGTGTAATAGC 
597bp 55°C 
Rev - GTCTAGCATCTAAAGCAACACC 
2 
Fw - GTTGATGAAATGATAGATGTGTGC 
690 bp 52°C 
Rev - GCCATCATTTATTGCCTTATCATC 
3 
Fw - GATAATCTAACAAATGATGAACC 
744 bp 52°C 
Rev - CGTATTTTCATCATTACTATCTCC 
4 
Fw - GCAAATTATAACACCAATGACAAG 
875 bp 55°C 
Rev - CCTGCGCTTACTATAGCACC 
5 
Fw - CGAATGAACACTGTAATCCAAAC 
842 bp 55°C 
Rev - ACAGGGATTTTTCATATCGACC 
6 
Fw - GCCAAAAGTAAAAGTGGAGCC 
494 bp 55°C 
Rev - GTGGTGCCTCTTTTTTAGACG 
 
Amplified DNA was purified using Exonuclease I and Thermosensitive Alkaline 
Phosphatase enzymes (Fermentas, UK) and sequenced using BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, UK) (van Schalkwyk et al. 2013). Sequences were 
aligned with the Geneious Pro software (version 5.5.3; Biomatters, New Zeland) with 
manual editing.  
 
Statistical analysis 
Data were analyzed using GraphPad Prism 6.0 (GraftPad Software, San Diego, 
California). Infections with mixed mutant/wild-type genotypes at the pfubp-1, pfap2-mu 
and pf26S-protSU loci were analyzed as mutant. The chi-squared distribution was used to 
evaluate the difference in genotype frequencies between pre-treatment samples and post-
treatment samples (day fail). The Mann–Whitney test (with significance level set at 0.05) 
was applied to investigate whether or not there are significant differences between in vitro 
IC50 estimates for each antimalarial drug and each observed polymorphism in the genes of 
interest. . As the study was the first of its kind with these loci, and thus exploratory in 
nature, we did not deploy any correction for multiple tests, but retained the 5% cut-off for 
statistical significance. 
G
e
n
e
 
Fragment 
1
st
 amplification primers  
(5’ to 3’) 
PCR 
product 
size 
Annealing 
temperature 
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Results 
P. falciparum isolates were tested for their ex vivo susceptibility to QN, CQ, MDA, 
LUM, DHA at day 0 (before treatment) and day fail after treatment. The mean IC50 for each 
anti-malarial drug is presented in Table 3. No significant difference was found between 
mean day 0 and day fail IC50 estimates (data not shown). 
 
Table 3. In vitro susceptibility of P. falciparum isolates from Burkina Faso to quinine (QN), 
chloroquine (CQ), monodesethylamodiaquine (MDA), lumefantrine (LUM), 
dihydroartemisinin (DHA) and piperaquine (PIP) at day 0 and at day fail. 
 Day 0 Day fail 
Drug N 
IC50 Mean 
(nM) 
Range (nM) N IC50 Mean (nM) Range (nM) 
QN 382 221.4 10.2 – 950.3 89 223.3 11.9 - 1421.4 
CQ 382 152.6 8.3 – 921.8 88 150.5 9.9 - 548.7 
MDA 377 25.0 0.8 – 595.9 87 21.8 5.4 - 62.2 
LUM 382 40.5 0.8 – 166.1 87 44.6 1.0 - 171.1 
PIP 349 10.8 0.8  - 375.2 81 9.9 1.0 - 194.8 
DHA 381 1.3 0.2 – 38.8 88 1.1 0.1 - 16.4 
 
Polymorphisms in pfubp1 
A partial sequence of the pfubp1 gene was sequenced (from codons 1463-1563) in 92 
isolates from day 0 and in 125 isolates from day fail after the treatment, as previously 
described (Henriques et al., 2014; Chapter 5). Overall, seven polymorphic sites were 
observed, consisting of three single nucleotide polymorphisms (SNPs) and four indels. Two 
of these SNPs were non-synonymous mutations, causing amino acid changes at 
Asp1525Glu and Glu1528Asp while only one was a synonymous mutation (at codon 1518). 
One indel lead to a deletion of a Glutamic acid (E) at position 1507 and the remaining three 
indels lead to both insertions and deletions of three amino acids at positions 1513, 1519 
and 1525 (KNE, KYD and KYE, respectively). Details of the genetic polymorphisms identified, 
consequent encoded amino acids and corresponding prevalences are shown in Table 4. We 
were able to assemble 33 distinct haplotypes.  
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Table 4. SNPs and indels identified in the pfubp1 gene, consequent amino acid 
replacements and prevalence at day 0, in reinfections and recrudescence isolates 
 
 
Polymorphisms in pfap2-mu 
Full length coding sequence of pfap2-mu was determined in 52 pre- and post-treatment 
isolates, and a partial sequence (codons 122-399) was obtained for a further 461 pre- and 
post-treatment isolates. DNA sequencing from the 513 isolates revealed nucleotide 
substitutions at 6 different positions, with 4 of these causing amino acid shifts at positions 
Gly99Ala, Arg146Lys, Ser160Asn and Asn233Lys. Table 5 shows detailed information on the 
genetic polymorphisms identified, corresponding encoded amino acids and prevalence. A 
second source of genetic diversity detected in the pfap2-mu gene was sequence length 
variation due to the presence of indels. The majority of the indels observed lead to 
insertions of the AAT codon that corresponds to an insertion of an Asn residue in the 
polypeptide chain at positions 226, 319 and 326 (Table 5). The remaining indel corresponds 
to an insertion of a Lysine residue at position 233. A total of 21 different haplotypes were 
identified. 
The amino acid substitution at position 99 (leading to a Glycine to Alanine substitution) 
is a previously undescribed mutation; all the other nine polymorphisms were described in 
previous studies (Henriques et al. 2013; Henriques et al, 2014). 
 
Codon 
Reference 
sequence 
(3D7) 
Amino 
acid 
Nucleotide 
substitution 
Amino 
acid 
changes 
Prevalence at 
Day 0 
(N=92) 
Prevalence in 
reinfections 
(N=113) 
Prevalence in 
recrudescences 
(N=12) 
1518 C Asn 4554T none 0 % 2.7 % 0 % 
1525 C Asp 4575A Glu 3.3 % 2.7 % 16.7 % 
1528 A Glu 4584C Asp 6.5 % 9.7 % 0 % 
Deletions / Insertions 
 
Reference sequence 
(3D7) 
Amino acid  
deletion / insertion 
  
 
1507 2xE 1xE 2.2 % 3.5 % 0 % 
1513 2xKNE 1xKNE / 3xKNE 4.3 % / 1.1 % 0.9 % / 0.9 % 0 % 
1519 2xKYD 1xKYD / 3xKYD 4.3 % / 5.4 % 4.4 % / 1.8 % 8.3 % / 0 % 
1525 2xKYE 1xKYE / 3xKYE 15.2 % / 12.0 % 21.2% / 18.6 % 0 % / 0 % 
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Table 5. SNPs and indels identified in the pfap2-mu gene, consequent amino acid 
replacements and prevalence at day 0, in reinfections and recrudescence isolates 
 
*Codon 99 was only determined in 39 Day 0 and 13 Day fail isolates. 
 
Polymorphisms in pf26S-protSU 
Analysis of the full pf26S-protSU open reading frame (ORF) within 96 isolates from day 0 
revealed eight polymorphic sites consisting of four non-synonymous mutations resulting in 
amino acid changes at positions Tyr107Phe, Asn250Lys, Glu535Ala and Lys711Arg, three 
synonymous mutations (at codons 123, 140 and 947) and one indel (Table 6). The 535 SNP 
was the most prevalent polymorphism found (96.9%), being present in 93 of the 96 
samples analyzed. The detected indel lead to an insertion of one or more Asn residues 
(numbers of Asn repeats ranged between 7 and 19). The 9xAsn and 10xAsn were the most 
frequent numbers of Asn repeats observed, at a frequency of 41.7 % and 26.1 %, 
respectively. We detected 36 distinct haplotypes. 
 
 
 
Codon 
Reference 
sequence 
(3D7) 
Amino 
acid 
Nucleotide 
substitution 
Amino 
acid 
changes 
Prevalence at 
Day 0 
(N=381) 
Prevalence in 
reinfections 
(N=115) 
Prevalence in 
recrudescences 
(N=17) 
99
*
 G Gly 296C Ala 5.1 % 0 % - 
146 G Arg 437A Lys 2.6 % 0 % 0 % 
160 G Ser 479A Asn 11.3 % 4.3 % 11.8 % 
163 A Glu 489G none 0 % 7.0 % 5.9 % 
188 A Arg 564G none 0 % 7.8 % 17.6 % 
233 T Asn 699G Lys 2.9 % 3.5 % 0 % 
Deletions / Insertions 
 
Reference sequence 
(3D7) 
Amino acid  
deletion / insertion 
  
 
226 7xAsn 8xAsn 20.9% 22.6% 41.2 % 
233 1xLys 2 xLys 2.1% 3.5% 0 % 
319 5xAsn 6xAsn 9.4% 15.6% 11.8 % 
326 4xAsn 5xAsn 16.3% 13.0% 5.9 % 
Chapter 6 – Molecular markers of drug resistance in Burkina Faso 
 
 156 
 
Table 6. SNPs and indels identified in the pf26S-protSU gene, consequent amino acid 
replacements and prevalence at day 0 
 
Correlation between polymorphisms and the in vivo outcomes 
To determine if any of the studied pfubp1 and pfap2-mu polymorphisms was under 
selection, the prevalence of the different alleles was compared between baseline infections 
and reinfections and recrudescences. The prevalence of the 1525Glu pfubp1 mutation is 
higher in recrudescence (16.7%) than in pre-treatment (3.3%) or reinfections (2.7%) 
isolates (Table 4). However, this difference is not statistically significant (p=0.10 and 
p=0.12, respectively). There was no evidence that carriage of the 1525Glu mutation prior to 
treatment was associated with risk of recurrent infection (data not shown). 
From the eight non synonymous mutations and indels described in pfap2-mu, an 
insertion of an Asn residue at position 226, was the only polymorphism statistically 
significantly selected in recrudescent infections (20.9 % versus 41.2%; p=0.0011).  
 
Codon 
Reference 
sequence (3D7) 
Amino acid 
Nucleotide 
substitution 
Amino acid 
changes 
Prevalence at Day 0 
(N=96) 
107 A Tyr 320T Phe 4.2 % 
123 A Arg 369G none 5.2 % 
140 G Gly 420A none 2.1 % 
250 T Asn 750A Lys 12.5 % 
535 A Glu 1601C Ala 96.9 % 
711 A Lys 2132G Arg 13.5 % 
947 G Thr 2841A none 3.1 % 
 
Reference sequence 
(3D7) 
Amino acid  
deletion / insertion 
4.2 % 
429 6xAsn 
7xAsn / 8xAsn 5.2 % / 8.3 % 
9xAsn / 10xAsn 41.7 % / 26.1 % 
11xAsn / 12xAsn 5.2 % / 5.4 % 
13xAsn / 14xAsn 1.0 % / 5.2 % 
15xAsn / 17xAsn / 19xAsn 1.0 % / 1.0 % / 1.0 % 
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Figure 2: Association of non-synonymous SNPs in pfubp1 with responses to QN, CQ, MDA, LUM, PIP and DHA. For each drug, IC50 values for each individual 
isolate are shown as black dots; geometric means are shown as colored bars. Statistical significance between groups was determined by Mann – Whitney tests (p<0.05 are 
in red). 
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Figure 3: Association of Indels in pfubp1 with responses to QN, CQ, MDA, LUM, PIP and DHA. (See legend to Figure 2) 
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Correlation between polymorphisms and in vitro drug responses 
Association between the IC50 to QN, CQ, MDA, LUM, PIP and DHA and P. falciparum 
polymorphisms in pfubp1 and pfap2-mu was assessed in pre-treatment and recurrent 
infections. This association was also assessed for pf26S-protSU gene but only in pre-
treatment samples. Only indels and non-synonymous polymorphisms were included in the 
analysis. The Gly99Ala pfap2-mu locus was excluded from the analysis due to the small 
sample size. 
 
Analysis of the potential associations between pfubp1 polymorphisms and drug 
responses revealed a significant but borderline increase in susceptibility to LUM in isolates 
carrying the 1525Glu mutation (73 nM; 95 % CI: 12-135) compared with those carrying the 
WT allele (36 nM; 95 % CI: 30-42) (p=0.032; Mann-Whitney test) (Figure 2). Parasites 
carrying this mutation also had diminished sensitivity to QN (231.7 nM; 95 % CI: 127.2-
336.3) and DHA (2.3 nM; 95 % CI: 0.5-4.1) compared to isolates carrying the wild type allele 
[(QN 211.1 nM; 95 % CI:180.2-242.0); (DHA 1.7 nM 95 % CI:1.2-2.1)]. However, this 
difference is not statistically significant (p=0.29 and p=0.07, respectively; Mann-Whitney 
test) (Figure 2). 
No significant association was observed between pfubp1 insertions or deletions and IC50 
estimates for any antimalarial drug (Figure 3). 
 
Evaluation of pfap2-mu polymorphisms revealed that isolates carrying the mutant 
146Lys allele appeared to be significantly more sensitive to QN (109.9 nM; 95 % CI:51.2-
168.6), CQ (47.6 nM; 95 % CI:6.7-88.5) and MDA (13.8 nM; 95 % CI:10.8-16.9) than those 
carrying the wild type allele [(QN 227.1 nM; 95 % CI:209-245.3); CQ; 159.0 nM; 95 % 
CI:142.2-175.9); (MDA 23.4 nM; 95 % CI:21.9-24.90] (p = 0.009, 0.020 and 0.029, 
respectively; Mann-Whitney test) (Figure 4). The trend was similar in samples carrying the 
233Lys allele. The mean QN IC50 in isolates carrying the 233Lys mutation was 126 nM (95 
% CI: 75.0-177.1), significantly lower than in isolates carrying the wild type allele (mean = 
227.5; 95 % CI: 209.3-245.7) (p=0.023; Mann-Whitney test) (Figure 4).  
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Figure 4: Association of non-synonymous SNPs in pfap2-mu with responses to QN, CQ, MDA, LUM, PIP and DHA. (See legend to Figure 2)  
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Figure 5: Association of Indels in pfap2-mu with responses to QN, CQ, MDA, LUM, PIP and DHA. (See legend to Figure 2) 
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Figure 6: Association of non-synonymous SNPs in pf26S-protSU with responses to QN, CQ, MDA, LUM, PIP and DHA. (See legend to Figure 2). 
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We found a weak association between insertion of an Asn residue at position 319 of 
pfap2-mu and reduced susceptibility to PIP. Isolates carrying six Asn residues had a mean 
IC50 of 8 nM (95 % CI: 6.1-9.9) compared to 22.8 nM (95 % CI: 3.1-42.6) in those isolates 
carrying only five Asn repeats (p=0.09; Mann-Whitney test) (Figure 5). In contrast, parasites 
carrying an extra Asn amino acid at position 326 have increased susceptibility to LUM (30 
nM 95 % CI: 23-38) when compared with wild type isolates (42 nM; 95 % CI:23-38) 
(p=0.012; Mann-Whitney test) (Figure 5).  
 
None of the mutations in pf26S-protSU were associated with reduced sensitivity to any 
of the drugs analyzed (Figure 6 and Figure 7). However we found significant association of 
the wild type allele at amino acid positions 107 (41 nM; 95 % CI:36-45), 250 (37 nM; 95 % 
CI:29-46) and 711 (39 nM; 95 % CI:30-47) with reduced sensitivity to lumefantrine 
(p=0.036, 0.022 and 0.032, respectively; Mann-Whitney test) (Figure 6). For isolates 
carrying the 107Phe, 250Lys and 711Arg alleles the LUM IC50 mean was 31 nM (95 % CI:22-
40), 19 nM (95 % CI:0-43) and 25 nM (95 % CI:0-53), respectively. 
 
Figure 7: Association of insertions in codon 429 in pf26S-protSU with responses to QN, 
CQ, MDA, LUM, PIP and DHA. (See legend to Figure 2). 
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Discussion 
Chemotherapy with ACTs has proved very effective and is one of the factors 
contributing to recent reductions in the malaria burden (WHO, 2012). Therefore, 
monitoring of drug efficacy and identification of potential molecular markers as well as 
understanding the mechanisms modulating parasite susceptibility to both artemisinin and 
its partner drug is a critical step towards sustaining the efficacy of ACTs. 
In this study we evaluated associations between polymorphisms in pfubp1, pfap2-mu 
and pf26S-protSU genes with in vitro susceptibilities of P. falciparum isolates from Burkina 
Faso to QN, CQ, MDA, LUM, PIP and DHA. We also investigated potential associations 
between the polymorphisms found and treatment outcomes.  
Molecular analysis of antimalarial drug resistance markers showed a high degree of 
polymorphisms in the three loci investigated. Analysis of pfubp1, pfap2-mu and 
pf26S-protSU sequences revealed seven, ten and eight polymorphic regions, respectively, 
and thus a large number of distinct haplotypes circulating. This is compatible with our 
observations for pfubl1 and pfap2mu in Kenya (Henriques et al 2014; Chapter 5). The 
diversity in these genes, none of which are either membrane transporters or known drug 
targets, is surprising. 
In the parasite population under study the 1525Glu pfubp1 mutation was significantly 
associated with increased LUM in vitro susceptibility. Interestingly, this mutation also 
appears to be more prevalent in recrudescent isolates than in pre-treatment isolates. Of 
note, the majority of the recrudescences occurred in the AL treatment arm (83%) (Table 1). 
Taken together these results suggest that the 1525Glu pfubp1 polymorphism has a role in 
modulating parasite susceptibility to LUM in vitro and in vivo sensitivity responses. 
Regarding pfap2-mu polymorphisms, the insertion of an Asn at position 319 was 
significantly associated with reduced susceptibility to PIP. Furthermore, isolates carrying an 
extra Asn residue at position 226 were significantly more likely to recrudesce. In contrast, 
parasites carrying the Arg146 wild type allele were more susceptible to QN, CQ and MDA. 
Similarly, parasites with the Asn233 wild type allele were also more susceptible to QN. 
These data is in agreement with the recent suggestion that polymorphisms in pfap2-mu 
may modulate P. falciparum responses to multiple drugs (Henriques et al., unpublished; 
Chapter 7). 
Chapter 6 – Molecular markers of drug resistance in Burkina Faso 
 
 165 
Although previous reports have shown association of pfap2-mu 160Asn/Tyr and pfubp1 
1528Asp mutations and the ACT responses [Chapter 4; (Henriques et al. 2014; Chapter 5)], 
in this study we did not find any significant association between these polymorphisms and 
treatment outcome or in vitro drug susceptibilities. The most likely explanation for this 
finding is that the direct correlation between point mutations and drug susceptibility may 
be dependent of the geographic origin of the parasites (implying different genetic 
backgrounds). As East and West Africa parasites may differ in terms of antimalarial drug 
pressures and parasite genetics (Dippmann et al. 2008) it is possible that the association of 
pfap2-mu and pfubp1 mutations and modulation of drug responses observed in other 
studies may be dependent on the genetic background of the parasites. Furthermore, 
selection of the 160Asn/Tyr pfap2-mu was noted on day 2 or 3 after the ACT treatment but 
was not present in recurrent infections. This finding stresses the importance of studying the 
parasite population dynamics during the first few days of ACT treatment, which was not 
done in the Burkina Faso study.  
The present study provides the first data on pf26S-protSU alleles. Reduced sensitivity to 
LUM was significantly associated with wild type alleles in three loci (107, 250 and 711), 
suggesting that mutations in pf26S-protSU can modulate in vitro responses to this drug. 
However, further studies are needed to confirm this relationship. 
In conclusion, the data obtained in the present study might be used as a baseline for 
surveillance of resistance markers to ACT in future studies. Nevertheless, more in-depth 
studies are necessary to determine the implications of genetic polymorphisms in these 
three candidate drug resistance loci, on in vivo and in vitro antimalarial drug susceptibility. 
Furthermore, the genetic background of the parasites appears to be critical in determining 
drug susceptibility, so further investigation is required to validate candidate polymorphism 
in pfubp1, pfap2-mu and pf26S-protSU genes as molecular markers of drug susceptibility in 
different geographical settings.  
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ABSTRACT  
The emergence of drug-resistant parasites is a serious threat faced by malaria control 
programmes. Understanding the genetic basis of resistance is critical to the success of 
treatment and intervention strategies. A novel locus associated with antimalarial 
resistance, pcap2-mu (encoding the mu chain of the AP2 adaptor complex), was recently 
identified in studies on the rodent malaria parasite Plasmodium chabaudi. Furthermore, 
analysis in Kenyan malaria patients of polymorphisms in the Plasmodium falciparum 
homologue pfap2-mu found evidence that differences in the amino acid encoded by codon 
160 are associated with enhanced parasite survival in vivo following combination 
treatments which included artemisinin derivatives. Here we characterize the role of pfap2-
mu in mediating the in vitro antimalarial drug response of P. falciparum by generating 
transgenic parasites constitutively expressing either the wild-type Ser160 or the 160Asn 
mutant form of pfap2-mu. Transgenic parasites carrying the pfap2-mu 160Asn allele were 
significantly less sensitive to dihydroartemisinin using a standard 48-hour in vitro test, 
providing direct evidence of an altered parasite response to artemisinin. Our data also 
provide evidence that pfap2-mu variants can modulate parasite sensitivity to quinine. No 
evidence was found that pfap2-mu variants contribute to the slow clearance phenotype 
exhibited by P. falciparum in Cambodian patients treated with artesunate monotherapy. 
These findings provide compelling evidence that pfap2-mu can modulate P. falciparum 
responses to multiple drugs. We propose that this gene should be evaluated further as a 
potential molecular marker of antimalarial resistance. 
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INTRODUCTION 
Antimalarial drugs remain indispensable tools in the fight against malaria. The potent 
artemisinin derivatives, combined with longer half-life partner drugs, are the only 
efficacious treatments left for multidrug-resistant P. falciparum, and thus form the 
cornerstone of antimalarial drug therapy. The emergence of drug resistance represents one 
of the most serious problems faced by malaria control programmes. Historically, parasite 
resistance to antimalarial medicines has emerged in Southeast Asia and eventually spread 
towards Africa and, alarmingly, there is already evidence of reduced susceptibility of P. 
falciparum to artemisinin derivatives in Southeast Asia, as evidenced by delayed parasite 
clearance times in vivo (1-4). For now, the delayed clearance phenotype appears to be 
confined to the Greater Mekong sub region (5); however, this reduced artemisinin 
sensitivity may spread to other regions or independently arise elsewhere, including Africa, 
where the burden of malaria is highest and where the emergence of resistance would have 
a terrible impact. A better understanding of mechanisms of artemisinin resistance would be 
a major advance in our ability to develop and validate new tools for resistance surveillance. 
These are essential tools to guide national treatment policies and help the design and 
deployment of new drug combinations that may deter the emergence and spread of 
resistance.  
Mutations within the k13 kelch propeller domain gene (pfk13) recently identified in 
Cambodian parasite populations have been proposed as a molecular marker of artemisinin 
resistance (6). Nevertheless, other genes acting together with pfk13 in Cambodia are likely 
to be involved in the slow clearance phenotype, and k13-independent mechanisms may 
have arisen in other settings. Other potential genetic markers of artemisinin resistance 
have previously been identified using genome-wide sequencing of drug-pressured mutants 
of the rodent malaria parasite Plasmodium chabaudi (7). One of these, the gene encoding 
the mu subunit of the adaptor protein 2 (AP2) complex involved in clathrin-mediated 
endocytosis, exhibits polymorphism in P. falciparum isolates from Africa (8). 
We recently reported a phenomenon of sub-microscopic persistent parasites at day 3 
following treatment with artemisinin combination therapy in Kenyan children. These 
persistent parasites were only detectable by qPCR but the children carrying these parasites 
had a higher mosquito transmission potential and were more likely to go on to classical 
treatment failure at day 28 or 42 post-treatment (9). Sequence analysis of these parasites 
revealed a particular genotype, combining variants of the pfcrt, pfmdr1, pfap2-mu and 
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pfubp1 candidate drug-resistance genes, which may modulate the responses to artemisinin 
combination treatments (10). This study specifically demonstrated that a Ser160Asn/Thr 
mutation in the P. falciparum ap2-mu gene was a modulator of in vivo responses to 
artemisinin derivatives in Kenyan malaria patients, being significantly more common 
among sub-microscopic parasites surviving combination treatment at day 3 than in the pre-
treatment population.  
To explore the role of this putative artemisinin resistance marker, we have generated 
transgenic P. falciparum parasites expressing an extra copy of either the wild-type (WT) 
pfap2-mu gene or the 160Asn form, driven by a heterologous promoter, in addition to their 
endogenous WT pfap2-mu gene. The susceptibility of these parasites to several 
antimalarial drugs (dihydroartemisinin, quinine, chloroquine, lumefantrine, mefloquine and 
atovaquone) was compared to the parental Dd2attB strain in a classical 48 hour growth 
inhibition assay. Dihydroartemisinin susceptibility of the parasites was further evaluated 
using two alternative assays, a 6 hour pulsing assay established specifically for this study 
and the recently described ring-stage survival assay (RSA) (11).  
 
MATERIALS AND METHODS 
Culture of Plasmodium falciparum 
The Dd2attB clone of P. falciparum was generated by integration of the acceptor attB 
site, derived from mycobacteriophage bxb1, into the non-essential glutaredoxin-like gene 
located within the cg6 locus of chromosome 7. Drug selection with 5nM WR99210 was 
applied throughout, to maintain the presence of this site as described (12). Parasite 
cultures were maintained in complete growth medium composed of RPMI 1640 growth 
medium supplemented with 2.5% (v/v) human AB serum, 147μM hypoxanthine, 5g/l 
Albumax II (Invitrogen), 10mM D-glucose and 2mM L-glutamine at 2% haematocrit in 5% 
CO2 at 37°C. Parasite cultures were synchronized at the ring stage using sequential 
D-sorbitol lysis treatment (13). Where not listed, reagents were obtained from 
Sigma-Aldrich. 
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Figure 1. Site specific integration of pfap2-mu gene (WT and 160Asn) into the P. falciparum Dd2
attB
 
line. (A) Schematic diagram of the integrase-mediated attB x attP recombination approach 
(Nkrumah et al., 2006). The top panel shows the cotransfected plasmids: plasmid pINT, carrying the 
integrase expression unit that catalyses the recombination, and the neomycin resistance cassette 
(neo); and the pDC2-CAM-pfap2-mu-bsd-attP plasmid carrying the WT or a mutant 160Asn pfap2-
mu gene sequence under the control of the calmodulin promoter, a blasticidin resistance cassette 
(bsd) and the attP site. The middle panel shows the recipient cg6-attB recombinant locus present in 
Dd2
attB
. The attB x attP recombination generates two sites, attL (left) and attR (right). The hDHFR 
represent the drug selection markers for WR99210. The lower panel represents the integration of 
the pDC2-CAM-pfap2-mu-bsd-attP plasmid into the cg6-attB locus of Dd2
attB
. The position and 
orientation of the PCR primers (P1 to P6) used in the analysis of the transgenic parasites are shown. 
(B) PCR monitoring of integration of pDC2-CAM-pfap2-mu-bsd-attP plasmid on the transfected 
parasites (two independent transfection experiments, A and B, for the Wt and the 160Asn mutant). 
The Dd2
attB 
DNA was used as a control. The top panel shows integration of the blasticidin cassette 
into the attB recombinant locus using the primers P1 and P2 (expected fragment size: 1700 bp). The 
middle panel shows the presence of the pfap2-mu-hsp86 3’UTR fusion (using the P3 and P4 primers; 
expected fragment size 800 bp). The bottom panel shows the PCR product used to confirm the 
presence of the 160Asn mutation by sequencing (using the P5 and P6 primers; expected fragment 
size: 840 bp). 
 
Generation of P. falciparum transfection constructs 
The open reading frames of both the wild-type and mutant (160Asn) allele of the pfap2-
mu gene (PlasmoDB identifier: PF3D7_1218300) were amplified, respectively, from 
genomic DNA of P. falciparum parasite line 3D7 and from a P. falciparum field sample 
previously shown to harbour the 160Asn mutation (10). The PCR primers used are 
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described in Supplementary Table S1. Plasmids pDC2-cam-pfap2-mu-attP and the pDC2-
cam-pfap2-mu160Asn-attP were then engineered (Fig. 1A). The pfap2-mu amplicons were 
cloned as AvrII/XhoI fragments between the calmodulin (PF3D7_1434200) promoter and 
the hsp86 (PF3D7_0708500) 3’ UTR in the pDC2 vector (14) which also encodes a 
blasticidin-S deaminase (bsd) selectable marker cassette. The resulting constructs were 
verified by sequence analysis and DNA for transfection was purified using the Qiagen 
CompactPrep Plasmid Maxi Kit.  
For each duplex transfection, 50µg of the plasmid containing the attP site together with 
the pfap2-mu gene (WT or the 160Asn copy) and 50µg of the pINT plasmid containing the 
integrase expression unit that catalyses the recombination, and the neomycin resistance 
cassette (each in 25µl TE buffer) were resuspended in 350µl cytomix [120mM KCl, 0.15mM 
CaCl2, 2mM EGTA (pH 7.6), 5mM MgCl2, 10mM K2HPO4/KH2PO4 (pH 7.6) and 25mM HEPES 
(pH 7.6)]. 
 
Plasmodium falciparum transfections 
Transfections of P. falciparum were carried out as described by Adjalley and colleagues 
(15), with slight modifications. Briefly, 250µL of synchronized ring stage Dd2attB infected 
erythrocytes at 6-9% parasitaemia, was added to 400µL of the duplex plasmid preparation 
in electroporation cuvettes (Bio-Rad). Parasites were transfected by electroporation (0.31 
kV, 950µF and infinite resistance; Bio-Rad Gene Pulser XCell) and then immediately 
transferred to culture flasks containing 10ml of complete medium and 500µl of newly 
harvested red blood cells. Transfectants were allowed to recover in drug-free medium for 
24 hours and then selected with 2.5µg/ml blasticidin (Sigma-Aldrich) and 125μg/ml of G418 
(Invitrogen, Life Technologies). Drug pressure with G418, selecting for the pINT plasmid, 
was applied for six days. The medium was changed daily for the first six days, and then 
every other day with fresh medium containing the blasticidin and WR99210 selection 
agents. Cultures were diluted 3:5 weekly (by the addition of 30% fresh blood cells) and 
monitored by Giemsa staining every 4-5 days for appearance of the transfected parasites. 
Drug pressure was maintained until the correct integration at the genomic attB locus was 
verified by PCR. Two independent transfections for each pfap2-mu plasmid were carried 
out.  
Correct integration was verified by PCR using the P1/P2 primer pair (Figure 1, Table 1). 
The presence of the pfap2-mu gene with the hsp86 3’UTR and the pfap2-mu gene was also 
monitored using the P3/P4 and the P5/P6 primer pairs, respectively (Figure 1, Table 1). 
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Sequence analysis of the mutation site G479A (160Asn) was performed using the P5/P6 
primer pair.  
 
Table 1. Primer sequences used in vector construction and integration confirmation 
Primer Sequence (5’ – 3’) Description 
C1 CGTAACTAGTATGATCGATGCGCTGTACAT Amplification of the pfap2-mu ORF (Forward) 
C2 ATGCCTCGAGCTATTTATACTGGTAGATGCC Amplification of the pfap2-mu ORF (Reverse) 
P1 
CCAGGATCCAAAAGAAGGAGGAGG Confirming integration of the bsd cassette into the attB 
recombinant locus (Forward) 
P2 
ATGCATGCCAAGCCTTTGTCTCAAG Confirming integration of the bsd cassette into the attB 
recombinant locus (Reverse) 
P3 
GCATATTTCATCATTGTGTTACC Confirming the presence of the pfap2-mu-Hsp86 3’UTR 
fusion (Forward) 
P4 
GGGGTGATGATAAAATGAAAGATA Confirming the presence of the pfap2-mu-Hsp86 3’UTR 
fusion (Reverse) 
P5 GATATCCACAAACATTAGAAGTG Confirming the presence of the pfap2-mu gene (Forward) 
P6 CCATCTGGTGGTGTGAAGG Confirming the presence of the pfap2-mu gene (Reverse) 
 
RNA extraction and cDNA preparation 
For total RNA isolation, parasitized red cells were rapidly lysed in TRI Reagent (Sigma-
Aldrich) and then stored at -80°C prior to RNA extraction, which followed the 
manufacturer’s protocol as previously described (16). Briefly, the TRI Reagent lysates were 
thawed at 37°C, 0.4ml of chloroform (Sigma-Aldrich) added, and the mixture was vigorously 
mixed and incubated 15 minutes at room temperature before centrifugation (12,000xg, for 
15 minutes at 4°C). The aqueous phase was precipitated with 0.5ml of isopropanol 
(Sigma-Aldrich), incubated for 10 minutes at room temperature and centrifuged (12,000xg, 
for 10 minutes at 4°C) to allow RNA precipitation, and the pellet washed with 75% ethanol 
(Sigma-Aldrich). The samples were stored at 4°C overnight and then centrifuged at 
12,000xg, for 10 minutes at 4°C. The ethanol was removed and the RNA pellet was air-
dried, before being resuspended in 20µl of nuclease free water (Promega).  
Extracted RNA was treated with RQ1 ribonuclease-free deoxyribonuclease (Promega) 
and reverse transcribed using gene specific primers (Q2 and Q3; Table 2) and the GoScript 
reverse transcriptase kit (Promega), as described by the manufacturer. Each 
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nuclease-treated preparation was then split in two. In the control tubes reverse 
transcriptase was replaced with water (DNA contamination control). 
 
Table 2. Primer sequences used in quantitative RT-PCR on P. falciparum mRNA 
Primer Sequence (5’ – 3’) Description 
Q1 GGAAAGGTAACCTTAAAATGTC pfap2-mu amplification (Forward)  
Q2 GTTACTACCGGCGAGAATATT 
pfap2-mu amplification (Reverse) and cDNA 
synthesis 
Q3 TGAAAGCAGCGTAGCTCAGA tRNA amplification (Forward)  
Q4 CGCGTGGTTTCGATCCACG tRNA amplification (Reverse) and cDNA synthesis 
 
Quantitative RT-PCR on ring stage and late stage samples of P. falciparum mRNA 
Quantitative RT-PCR (RT-qPCR) was performed using QuantiTect SYBR Green PCR Kit 
(Qiagen) in a Rotor-Gene RG3000 machine (Corbett Research). Transcripts of the pfap2-mu 
gene were amplified using the Q1/Q2 primer pair (Table 2) and the Plasmodium tRNA 
methionine (PgMET) gene was used as a reference source of RNA. Previously published 
primer sequences Q3/Q4 (Table 2) were used to amplify the pgmet gene as described (17). 
Reactions were carried out in 25µl volumes using QuantiTect SYBR Green PCR master mix 
according to the manufacturer's guidelines. The PCR cycles used were 95°C for 6 minutes 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute, for all reactions. Each 
parasite RNA sample was tested in triplicate in each experiment. Relative expression of 
pfap2-mu was calculated from the average threshold cycle (CT) values from two 
experiments, normalized to pgmet, using the Ct method, where the parental line was 
used as the comparator.  
 
Standard 48 hour drug susceptibility assays 
Standard 48 hour drug exposure assays were performed to determine the susceptibility 
of parasites to dihydroartemisinin (DHA), quinine, chloroquine, lumefantrine, mefloquine 
and atovaquone according to protocols using the intercalating dye PicoGreen to provide a 
fluorescent signal, as previously deployed in our laboratory (18). The resulting IC50
48h 
estimates were used as primary indicators of anti-malarial susceptibility, determined from 
a log-dose response analysis using the Prism v6.04 (GraphPad Software, Inc., San Diego, 
CA). Each assay was performed with two replicates on at least two (range 2 – 6) 
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independent occasions for each drug. For statistical analysis best-fit estimates of the IC50 
and their 95% confidence intervals were obtained by nonlinear regression fitting of the 
sigmoidal dose response curve for each drug across all experiments, after normalisation 
using control well fluorescent signals. For statistical comparison of each transgenic with the 
parental curve and comparison between the two transgenic curves, data were first fitted 
independently and then globally to find a shared best-fit value for the IC50
48h. Results were 
compared by a sum-of-squares F-test.  
 
Artemisinin 6 hour pulse assays 
To generate IC50
6h estimates for artemisinin, we devised an alternative in vitro drug 
susceptibility protocol. DHA was serially diluted in complete medium (250µl) in Eppendorf 
tubes, using the same ten concentrations generated for the standard 48 hour drug assays. 
250µl of ring stage culture was added to each drug dilution (2% final hematocrit and 0.5% 
final parasitemia) and incubated at 37°C for 6 hours. After the incubation time half of the 
culture was placed in a 96-well tissue culture plate (modified 48 hour assay) and the other 
half was washed three times with 1000μl of RPMI, to remove dihydroartemisinin, before 
being replenished with drug free medium and placed in the 96-well culture plate. The plate 
was then incubated at 37°C for 42 hours until growth assessment using the PicoGreen 
detection method, as described for the standard 48 hour assays, generating a measure of 
DHA sensitivity in the form of an IC50
6h estimate.  
 
Ring stage survival assays (RSA) 
The RSA was performed as described by Witkowski and colleagues (11) with minor 
modifications. The parasite cultures were tightly synchronized across two consecutive ring 
stage cycles with sorbitol treatment. Late schizont stage parasites cultures were enriched 
using MACS separation columns (Miltenyi Biotech GmbH) and were cultured for 3 hours at 
37°C with fresh erythrocytes, and again sorbitol-treated. This early ring stage (0-3 hours) 
parasite preparation, at 1% parasitaemia, 2% haematocrit in 2ml final volume, was then 
exposed for 6 hours to 700nM of dihydroartemisinin in 0.1% DMSO. After the 6 hour 
exposure the cultures were washed and resuspended in drug-free culture medium and 
cultured at 37°C for a further 66 hours. Dihydroartemisinin susceptibility was then assessed 
microscopically on thin films by estimating the percentage of viable parasites that had 
developed into a new generation of trophozoites, 66 hours after dihydroartemisinin 
exposure, compared to parasites exposed to 0.1% DMSO alone.  
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RESULTS  
Generation of transgenic parasites by integration of an additional copy of 
pfap2-mu in Dd2attB 
To investigate the potential role for the pfap2-mu 160Asn mutation in mediating 
reduced in vitro susceptibility of P. falciparum to antimalarial drugs, we generated 
transgenic parasites with an additional copy of either the wild-type Ser160 or the 160Asn 
mutant form of pfap2-mu gene. This was achieved using Bxb1 mycobacteriophage 
integrase-mediated recombination to deliver transgenes into the P. falciparum genome in a 
site-specific manner dictated by the presence in the parental line Dd2attB of the attB target 
sequence, replacing the cg6 locus (12). The pfap2-mu gene, with or without the 160Asn 
mutation, was cloned into the pDC2 plasmid under the control of the calmodulin promoter 
(Fig 1A), and cotransfected into Dd2attB strain with the pINT plasmid (encoding integrase) 
(12). After transfection the parasites were placed under drug selection with both blasticidin 
and G418, generating two transgenic lines termed Dd2attB::WT-pfap2-mu and 
Dd2attB::160Asn-pfap2-mu. Stably transfected parasites were obtained two to three weeks 
after transfection and diagnostic PCR using P1/P2 specific primers (Fig. 1 A; Table 1) 
revealed correct integration into the attB site. The presence of the pfap2-mu transgenes 
was confirmed by PCR analysis (Fig. 1 B; Table 1) and the presence of the 160Asn mutation 
in the Dd2attB::160Asn-pfap2-mu line was confirmed by sequencing.  
 
RT-qPCR analysis of pfap2-mu in transgenic lines 
Quantitative RT-qPCR analysis of cultures of the parental and transfected parasite lines 
provided evidence of constitutive blood-stage expression of the introduced transgenes. In 
ring stage cultures, 7.9-fold (160Asn-pfap2-mu) and 23.8-fold (WT-pfap2-mu) over-
expression of pfap2-mu mRNA was found in the transfectant lines compared to the 
parental, reflecting the known expression profile of the calmodulin promoter, but late 
stage cultures of both transfectant lines exhibited mRNA levels similar to those of Dd2attB 
(Fig. 2). For each sample, parallel reactions prepared without reverse transcriptase did not 
generate detectable amplicons within 35 cycles, demonstrating the absence of detectable 
genomic DNA contaminating the RNA (data not shown). Total RNA prepared from the 
peripheral blood of a malaria patient as part of a previous study (18) was also analysed, and 
confirmed transcription of pfap2-mu by circulating P. falciparum blood stages in vivo.  
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Figure 2. Expression levels of pfap2-mu transcripts on ring and late stage (trophozoites and 
schizonts) cultures of Dd2
attB
, Dd2
attB
::WT-pfap2-mu and Dd2
attB
::160Asn-pfap2-mu lines. Mean 
mRNA expression level of pfap2-mu in Dd2
attB
 and transfected lines from RT-qPCR analysis. The 
expression of pfap2-mu was normalized to the mRNA level of PgMET. Error bars indicate standard 
deviations. 
 
In vitro sensitivity of pfap2-mu transfectant parasites 
The growth inhibition curves for dihydroartemisinin, quinine, chloroquine and 
lumefantrine for both transgenic lines are presented in Figure 3. Table 3 shows the mean 
(± standard deviation) IC50
48h estimates calculated for the parental and transfected lines 
and the significance of any differences in sensitivity between the different lines. In four 
independent experiments, the transgenic parasite line harbouring the 160Asn copy of the 
pfap2-mu gene displayed a significantly reduced sensitivity to DHA (mean IC50
48h = 3.3 nM) 
when compared with both the parent line (mean IC50
48h = 2.7 nM) and WT-pfap2-mu (mean 
IC50
48h = 2.5 nM) lines (Table 3). Quinine IC50
48h increased significantly from 459.2 nM in the 
parental line and from 471.5 nM in the WT-pfap2-mu, to 671.2 nM in the 160Asn-pfap2-mu 
parasite line. The presence of 160Asn-pfap2-mu also led to reduced susceptibility to 
chloroquine, when compared with the parental line, whereas the WT transfected line 
exhibited an intermediate phenotype, not statistically different from either the parental or 
mutant transgenic lines. Thus decreased sensitivity to DHA, quinine and chloroquine was 
conferred in these experiments by the presence of the 160Asn pfap2-mu mutant allele 
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given that the overexpression of the WT allele had no effect on parasite susceptibility to 
these antimalarials. In contrast, the Dd2attB :: WT-pfap2-mu line showed significantly 
reduced susceptibility to lumefantrine, IC50 57.7 nM, when compared with the parental 
line, IC50 36.1 nM. No significant difference was found between the WT and the 160Asn 
lines, nor between the 160Asn and the parental lines. The presence of the 160Asn-pfap2-
mu did not significantly alter parasite susceptibility to atovaquone, a drug with a well-
known mitochondrial mode of action that is unrelated to that of the artemisinins and 
aminoquinolines, nor to mefloquine (Table 3).  
 
 
Figure 3. Dose response curves of the Dd2
attB
 (Parental), Dd2
attB
 :: WT-pfap2-mu and 
Dd2
attB 
:: 160Asn-pfap2-mu strains to dihydroartemisinin, quinine, chloroquine and lumefantrine. 
The drug sensitivity of the parasites was assessed using a standard 48h assay. Each point represents 
the mean of at least two independent experiments, with two replicates for each experiment. The 
error bars indicate ± standard errors of the means. Best-fit curves were generated by Prism v6.04. 
The X axis indicates the increasing concentration of the different drugs and the Y axis indicates the 
parasite viability.  
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Table 3: In vitro drug susceptibility of the Dd2attB (Parental), Dd2attB :: WT-pfap2-mu and Dd2attB :: 160Asn-pfap2-mu transfectant strains to six 
antimalarial drugs. The drug sensitivity of the parasites was assessed using a classic 48h growth inhibition assay. The best-fit curve for each drug was 
generated in Prism v6.04 and the best-fit estimate of the IC50 and their 95% confidence intervals are indicated in the table. 
 
 
a
N – Number of independent experiments, each experiment had two replicates;  
P-value
*
 – The sum-of-squares F-test was used to test the significance of difference among the IC50 values of the different parasites. The significant P-values are indicated in 
bold 
 Dd2attB (Parental) Dd2attB :: WT-pfap2-mu P-value* Dd2attB:: 160Asn-pfap2-mu P-value P-value 
Drug 
N
a 
IC50 (nM) 
[95% CI] 
N 
IC50 (nM) 
[95% CI] 
WT 
Vs 
Dd2
attB
 
N 
IC50 (nM) 
[95% CI] 
160Asn 
Vs 
Dd2
attB
 
WT 
Vs 
160Asn 
Dihydroartemisinin 4 
2.7 
[2.6-2.9] 
4 
2.5 
[2.0-3.1] 
0.371 4 
3.3 
[2.9-3.8] 
0.0057 0.0227 
Quinine 3 
459.2 
[413.3-510.3] 
3 
471.5 
[442.1-502.9] 
0.683 3 
671.2 
[582.3-773.6] 
<0.0001 <0.0001 
Chloroquine 4 
37.6 
[25.9-54.5] 
4 
48.0 
[29.6-78.0] 
0.445 3 
67.1 
[58.6-76.8] 
0.0028 0.1429 
Lumefantrine 2 
36.1 
[28.3-46.2] 
2 
57.7 
[43.0-77.4] 
0.0294 2 
44.8 
[32.3-62.1] 
0.3028 0.2517 
Mefloquine 6 
13.1 
[10.3-16.7] 
6 
16.7 
[13.9-19.9] 
0.1416 6 
17.0 
[13.6-21.2] 
0.1488 0.8829 
Atovaquone 4 
2.7 
[2.3-3.4] 
4 
2.8 
[2.3-3.5] 
0.923 4 
4.0 
[2.7-6.0] 
0.1014 0.1127 
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The 6 hour drug pulse assay, developed to better reflect the short exposure times to 
artemisinin that occur in vivo, was used to estimate DHA IC50
6h for parental and transgenic 
lines. Figure 4 shows the best-fit curves generated and IC50
6h estimates are indicated in 
table 4. The survival curves obtained in the 6 hour pulse assay showed a rightward shift 
towards higher dihydroartemisinin concentrations compared with the survival curves 
obtained in the modified 48 hour assay (ie with a 6 hour tube incubation prior to plating; 
see Methods). These curve shifts meant that DHA IC50
6h estimates were always higher than 
the IC50
48h, by approximately 2-fold. Nevertheless, no significant difference was found 
between the transfectant and the parental lines using either the IC50
48h or IC50
6h estimates 
(Table 4). The IC50 values obtained in the modified 48 hour assay were slightly higher 
(range: 3.9 to 4.1nM) than the ones obtained in the standard 48 hour assay (range: 2.5 to 
3.3nM), possibly due to differences in drug exposure arising from the initial 6 hour 
incubation in microcentrifuge tubes.  
The susceptibility of young ring stage (0-3 hour) cultures to a 6 hour pulse with 700nM of 
DHA was evaluated using the RSA of Witkowski et al. (11). Parasite viability was zero, 
defined as more than 99% of parasites recorded as dead at 72 hours, in all test wells (data 
not shown), indicating that parental and transgenic lines were fully susceptible to DHA by 
this test.   
Figure 4. Dose response curves of the Dd2
attB
 (Parental), Dd2
attB
 :: WT-pfap2-mu and 
Dd2
attB 
:: 160Asn-pfap2-mu transfectants to Dihydroartemisinin. The drug sensitivity of the 
parasites was assessed using a modified 48 hour assay (solid line) and 6 hour pulse assay (dashed 
line). Each point represents the mean of two independent experiments, with two replicates for each 
experiment. The error bars indicate ± standard errors of the means. Best-fit curves were generated 
by Prism v6.04. The X axis indicates the increasing concentration of dihydroartemisinin and the Y axis 
indicates the parasite viability.  
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Table 4  In vitro drug susceptibility of the Dd2attB (Parental), Dd2attB :: WT-pfap2-mu and 
Dd2attB :: 160Asn-pfap2-mu transfectant strains to dihydroartemisinin using a 6h pulse 
assay. The best-fit curves were generated in Prism v6.04 and the best-fit estimate of the IC50 and 
their 95% confidence intervals are indicated in the table. The sum-of-squares F-test did not show any 
significant difference between the IC50  
 
 
 
 
 
 
 
 
* The dihydroartemisinin susceptibilitiy of each parasite line was assessed in both assays by two 
independent experiments, with two replicates for each experiment.  
 
DISCUSSION 
In this study we aimed to better understand the role of the ap2-mu gene in mediating P. 
falciparum drug responses. Pfap2-mu was first implicated in artemisinin resistance in the 
rodent malaria parasite P. chabaudi through whole-genome sequencing of a parasite 
lineage resistant to artemisinin, which identified a novel Ile568Thr change as responsible 
for this phenotype by genome-wide association analysis (8). Several variants of this gene 
were identified in P. falciparum, but a polymorphism homologous to P. chabaudi Ile568Thr 
has not been detected in field isolates to date (8, 10). However, our recent work conducted 
in Kenya provides evidence that a Ser160Asn/Thr mutation can modulate the parasite 
response to artemisinin combination treatments in vivo (10). Consistent with these results, 
we now show that transgenic parasites carrying 160Asn pfap2-mu are significantly less 
susceptible to dihydroartemisinin in vitro, manifest as a 32% increase in DHA IC50, 
compared to transgenic parasites carrying an additional copy of the wild-type pfap2-mu 
locus, using a standard 48 hour drug susceptibility testing protocol (18). In addition, this 
study shows that changes in pfap2-mu sequence (for quinine and chloroquine) or 
expression level (for lumefantrine) also affect parasite sensitivity to other antimalarials in 
 
IC50  (nM) [95% CI]  
 
Modified 48h assay * 6h pulse assay * 
Dd2
attB
 (Parental) 
4.1 
[3.7-4.6] 
10.8 
[8.6-13.5] 
Dd2
attB
 :: WT-pfap2-mu 
3.9 
[3.8-4.1] 
8.8 
[8.1-9.4] 
Dd2
attB 
:: 160Asn-pfap2-mu 
3.9 
[3.6-4.2] 
9.1 
[6.3-13.1] 
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vitro. Further experiments are needed to confirm that the higher early stage mRNA 
expression measured here is accompanied by an increased expression of the corresponding 
protein, but await the development of suitable reagents (i.e. specific antibodies). 
Additionally, it will be important to compare in vitro  susceptibility of the transgenic 
parasites to that of Cambodian parasite lines with known clearance time phenotypes in 
both 48-hour exposure dose-response assessment, generating IC50 estimates, and in the 
RSA 0-3h  assay.  
The pfap2-mu gene is predicted to encode the mu (µ) subunit of the adaptor protein 2 
(AP2) complex. AP2 facilitates formation of clathrin-coated vesicles, for the trafficking of 
cargo from one membrane compartment of the cell to another, by recruiting a number of 
other proteins to the forming vesicle (19). AP2 is located at the parasite plasma membrane 
and also contributes to the selection of specific cargo (20). The mu subunit binds to the 
cytoplasmic side of cargo molecules through recognition of specific signals and is 
incorporated into the mature clathrin-coated vesicle (21), suggesting that AP2-mu variants 
may influence drug resistance by modulating cargo trafficking (8). The precise mechanism 
by which polymorphisms in pfap2-mu affect antimalarial drug response remains unknown. 
The P. chabaudi Ile568Thr mutation is predicted to lie in the C-terminus of the AP2-mu 
protein, whereas the Ser160Asn mutation in P. falciparum is positioned in the N-terminal 
domain. Both regions are highly conserved across the genus and, by analogy to studies of 
mammalian homologues, it is predicted that both codons contribute to -sheet structure 
lying within or adjacent to the hydrophobic pocket that binds to the recognition motif 
present in the cargo protein (8). These mutations may therefore mediate antimalarial drug 
response by reducing AP2-mu binding affinity to the membrane cargo, and thus decreasing 
the efficiency of endocytotic trafficking of membrane proteins. A better understanding of 
AP2 variants requires studies of structure and function of the adaptor complex protein in 
Plasmodium spp.  
The phenotype of reduced susceptibility to dihydroartemisinin described in this study is 
moderate, and unlikely to confer drug resistance in itself; the phenomenon also appears to 
be significantly different from the slow clearance phenotype described in Southeast Asia, 
which implicates mutations in the pfk13 kelch propeller domain. Firstly, the latter is 
associated with prolonged parasite clearance times in vivo and with increased survival in 
the ring stage parasite survival assay, but not with any change in vitro susceptibility to 
dihydroartemisinin using a standard 48 hour drug assay. Here, the transgenic population 
carrying the mutant pfap2-mu was shown to be significantly less susceptible to 
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dihydroartemisinin than the parental population, even though the IC50 was only marginally 
increased; however, this “tolerant” phenotype was not detected using the RSA, and is thus 
distinct from the phenotype described by Witkowski et al. (11). Secondly, contrary to the SE 
Asian isolates, the persistent Kenyan parasites carrying the Ser160Asn/Thr mutation also 
carry the chloroquine sensitive haplotype pfcrt CVMNK and were microscopically 
undetectable; to date the pfk13 genotypes associated with SE Asian reduction in 
susceptibility have not been seen in Kenyan parasites with the whole genome sequence 
data currently available (10). 
The modulation of artemisinin sensitivity in an African context clearly manifests as a 
different phenotype from the one described in Cambodia, with different genes and 
genotypes implicated. In fact, some African slowly clearing infections are not associated 
with polymorphisms in the kelch protein (4), suggesting the contribution of other genetic 
factors. Furthermore, drug resistance may not arise in a single step, but as a long and 
complex process during which parasites become gradually more and more tolerant to the 
drug. This is believed to be achieved through the stepwise accumulation of genetic changes 
in the same gene or in different genes (22). Therefore, it is possible that mutations in AP2-
mu are an early step during the development of artemisinin resistance, and that additional 
genetic changes would be required before a fully resistant parasite genotype has emerged. 
Alternatively, AP2-mu may contribute to a broad parasite heterogeneity that modulates 
the drug response to several antimalarial drugs, as seen for pfmdr1 and other members of 
the ABC transporter family in P. falciparum (23).  
A potential weakness of our study is the sole use of Dd2attB (a multidrug resistant line 
sensitive to artemisinin) as our parent isolate, one that propagates more rapidly than the 
few other lines available harbouring the attB site (14). The genetic background of the 
parasite can influence the acquirement of drug resistance, so the drug responses observed 
in this study may vary in isolates with a different pre-existing drug sensitivity background. 
For example, a significant increase in lumefantrine IC50
48h to 57.7 nM was observed in the 
Dd2attB ::WT-pfap2-mu transgenic parasites, which is well within the range we have 
observed in patient isolates tested ex vivo (18). However, the highest IC50
48h among these 
patient isolates occurred in those wild-type for the chloroquine-associated resistance 
marker pfcrt. Additionally, the Dd2attB clone of P. falciparum was generated by integration 
of the acceptor attB site, into the non-essential glutaredoxin-like gene located within the 
cg6 locus of chromosome 7. Glutaredoxin-like proteins are proteins involved in the redox 
homeostasis of the cell (24). Therefore, a parasite lacking the cg6 locus is probably not the 
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ideal parasite model to study artemisinin resistance given the involvement of this class of 
drugs on parasite oxidative stress (25, 26). In order to better understand the role of AP2-
mu in drug resistance it is important to perform further genetic studies by performing gene 
replacement experiments as well as using isolates with different backgrounds, including 
chloroquine-sensitive genotypes.  
In summary, this study shows that constitutive expression of 160Asn pfap2-mu in Dd2attB 
altered P. falciparum susceptibility to dihydroartemisinin, with transgenic parasites 
exhibiting significantly higher IC50
48h estimates. This confirms pfap2-mu as a locus of 
interest for studies of artemisinin susceptibility. Our data also provide evidence that pfap2-
mu variants can modulate parasite sensitivity to quinine, chloroquine and lumefantrine in 
vitro.   
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This chapter will be submitted to the Malaria Journal after further revisions: 
Henriques G., van Schalkwyk D.A, Burrow R., Baker D.A., Hallett R., Flueck C., 
Sutherland C.J. Localization of Adaptor Protein 2 mu-subunit in Plasmodium 
falciparum parasites.  
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Abstract 
Plasmodium falciparum is becoming increasingly more resistant to antimalarial drugs, 
and therefore insights into the mechanisms of drug action and resistance are critical. 
Recent studies have shown that naturally-occurring mutations in the P. falciparum mu 
subunit of the Adaptor protein 2 complex (AP2) can modulate artemisinin response in vivo 
and functional follow-up revealed that this gene can also modulate in vitro parasite 
sensitivity to multiple drugs. AP2 is part of a family of adaptor proteins that sort cargo into 
clathrin-coated vesicles for transport between membrane-bound compartments in the cell. 
By replacing the endogenous pfap2-mu gene with green fluorescent protein (GFP)-tagged 
transgene, we show for the first time that the pfAP2-mu fused with GFP is expressed in 
trophozoites and schizonts. These transgenic parasites will allow further studies into the 
molecular mechanisms of clathrin-mediated endocytosis and drug resistance in P. 
falciparum malaria.  
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INTRODUCTION 
Malaria is one of the most important infectious diseases in humans and remains a major 
public health and economic problem in developing countries. Antimalarial drugs remain as 
one of the most powerful tools in the fight against malaria with artemisinin derivatives now 
standing as the cornerstone of anti-malarial drug therapy. However, recent evidence of 
reduced susceptibility to artemisinins, manifesting itself by delayed in vivo parasite 
clearance (Noedl, Se et al. 2008; Dondorp, Nosten et al. 2009), is accumulating on the Thai 
Cambodian border and nearby countries (Carrara, Lwin et al. 2013; Kyaw, Nyunt et al. 
2013; WHO 2014). It will be a public health disaster if reduced susceptibility to artemisinins 
spreads to Africa where the burden of disease is high, and where the loss of drug efficacy 
would unquestionably lead to an increase in morbidity and mortality. Therefore, there is a 
crucial need to better understand the mechanisms of artemisinin action and the 
determinants of parasite susceptibility. 
Three lines of evidence indicate that components of the clathrin-mediated endocytosis 
pathway in Plasmodium spp. are among the determinants of parasite susceptibility to 
artemisinins. Firstly, whole genome sequencing in the rodent malaria parasite Plasmodium 
chabaudi led to the identification of a mutation in a gene encoding the mu chain of the 
Adaptor Protein complex 2 (AP2) that arose along with the experimental evolution of in 
vivo artemisinin resistance (Henriques et al., 2013; Chapter 4). Secondly, we have recently 
shown that naturally-occurring mutations in the P. falciparum homologue pfap2-mu 
modulate artemisinin response in vivo in a cohort of Kenyan children treated with ACT 
(Henriques et a.l 2014; Chapter 5). Finally, functional studies of transgenic P. falciparum 
carrying an additional copy of the pfap2-mu locus revealed that this gene can also 
modulate in vitro parasite sensitivity to multiple drugs (Henriques et al., submitted to AAC; 
Chapter 7).  
AP2 is one of a five member family of heterotetrameric clathrin-associated adaptor 
protein (AP1 5) complexes that mediate transport between membrane-bound 
compartments in eukaryotic cells by selecting the vesicle cargo and helping in the vesicle 
biogenesis (Robinson and Bonifacino 2001; Owen, Collins et al. 2004; Robinson 2004; Hirst, 
Barlow et al. 2011). Within this family, AP2 is specifically associated with the plasma 
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membrane and is involved in the internalization of extracellular molecules, cell surface 
receptors and other plasma membrane proteins (Le Borgne and Hoflack 1998; Traub 2003; 
Jackson, Kelly et al. 2010). Each adaptor protein complex is composed of four subunits: two 
large (beta 1-5, and either gamma, alpha, delta, epsilon or zeta), one medium (mu 1-5) and 
one small (sigma 1-5) (Figure 1). Each of these subunits fulfils a specific function within the 
complex. The mu subunit, in particular, is responsible for cargo selection by directly 
recognizing the YXXφ motif (where X is any amino acid and φ is a bulky hydrophobic 
residue), one of the most common sorting signals present in the cytosolic domains of 
transmembrane proteins (Ohno, Stewart et al. 1995; Owen and Evans 1998; Bonifacino and 
Traub 2003) 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of the AP complex. All four complexes consist of two large 
subunits: a β subunit and a more divergent subunit, either γ, α, δ, ε or ζ; a medium-sized (μ) subunit; 
and a small (σ) subunit. The specific divergent subunits depends on the particular AP complex (AP1: 
γ; AP2: α; AP3: δ; AP4: ε and AP5: ζ). 
 
Homologues of all 4 components of the AP2 complex were shown to be present in P. 
falciparum (Nevin and Dacks 2009). In this study we modified the endogenous pfap2-mu 
gene of the Dd2 P. falciparum parasite by fusing it to green fluorescence protein (GFP) to 
study its temporal and spatial expression patterns during the parasite life cycle. 
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Material and methods 
Parasite culture and transfection 
The Dd2 clone of Plasmodium falciparum was cultured in human A+ erythrocytes 
(National Health Blood & Transplant, UK) and in complete growth media composed of RPMI 
1640 growth medium supplemented with 147 μM hypoxanthine, 5 g/l Albumax II 
(Invitrogen), 10 mM D-glucose and 2 mM L-glutamine at 2% haematocrit in 5% CO2 at 37°C. 
Parasitaemia was monitored by Giemsa-stained thin blood smears and cultures were 
synchronized at the ring stage using sequential D-sorbitol lysis treatment (Lambros and 
Vanderberg, 1979). Where not listed, reagents were obtained from Sigma-Aldrich. For 
transfections, synchronized ring stage parasites were electroporated with 50 μg of plasmid 
DNA as described previously (Henriques et al., 2014). Transfected parasites underwent 
positive selection 24 h after transfection with 5 nM WR99210 (a kind gift from Jacobus 
Pharmaceuticals, New Jersey, USA) for five weeks with weekly replenishment of fresh red 
blood cells until resistant parasites were seen. Transformed parasites were selected by 
repeated drug on-off cycling (3 weeks off and 1 week on) to encourage loss of episomal 
transformants and selection of parasites in which integration had taken place.  
 
Molecular cloning, plasmid constructs 
A region encoding the 3’ end encompassing codons 146 – 621 (leaving out the stop 
codon) of pfap2-mu gene (PlasmoDB identifier: PF3D7_1218300) was PCR amplified from 
3D7 genomic DNA using the forward C1 and reverse C2 primers introducing a 5’ PstI and a 
3’ NotI (New England Biolabs) restriction sites, respectively (Table 1). The 1508 bp pfap2-
mu amplicon was digested with PstI and a NotI (New England Biolabs) and cloned into 
similarly digested pH-GFP transfection plasmid (Witmer, Schmid et al. 2012) before GFP 
coding sequence, to generate pH-pfap2-mu-GFP vector (Figure 2A). The transfection vector 
containing the fusion construct was verified by sequencing, transformed in E. coli. Plasmid 
DNA for transfection was prepared using the Qiagen Maxiprep kit (Quiagen). 
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Diagnostic PCR and characterization by Southern blot analysis of Dd2 
GFP-transgenic line 
Genomic DNA from Dd2::pH-pfap2-mu-GFP line and Dd2 (control) was harvested from 
schizonts at ≥5% parasitaemia. The cells were lysed with saponin and after centrifugation 
the pellet was resuspended in lysis buffer (500 mM Na Acetate pH 5.2, 100 mM NaCl, 1 mM 
EDTA, 3% SDS). DNA was isolated with phenol/chloroform extraction at room temperature 
(RT) and ethanol precipitation. Integration of the GFP-tag construct in the pfap2-mu locus 
was confirmed by a diagnostic PCR using primer pair P1/P2 (Figure 2A; Table 1). The 
presence of the pfap2-mu gene was also confirmed using the P3/P4 primer pairs (Figure 2A; 
Table 1).  
 
Table 1. Primer sequences used in vector integration, PCR confirmation and in probe 
amplification for Southern blot analysis 
Primer Sequence (5’ – 3’) Description 
C1 CGTACTGCAGGATATCCACAAACATTAGAAG
*
 Amplification of the 3’ end of pfap2-mu (Forward) 
C2 CGTAGCGGCCGCATTTATACTGGTAGATGCCCG
**
 Amplification of the 3’ end of pfap2-mu (Reverse) 
P1 CCGTATTAACAAGAAGCAATTC 
Confirming integration of the GFP-tag construct in the 
pfap2-mu locus (forward) 
P2 CCCTCTCCACTGACAGAAAAT 
Confirming integration of the GFP-tag construct in the 
pfap2-mu locus (reverse) 
P3 GATATCCACAAACATTAGAAGTG Confirming the presence of the pfap2-mu (Forward) 
P4 CCTTCACACCACCAGATGG Confirming the presence of the pfap2-mu (Reverse) 
S1 CGGGCAACTTCTGATACAAAG pfap2-mu probe (forward) 
S2 GTCCTATTATGTATATGTGGATC pfap2-mu probe (reverse) 
*
PstI restriction site is underlined; 
**
NotI restriction site is underlined. 
 
For Southern blot analysis, genomic DNA was digested with ClaI/NcoI (New England 
Biolabs) and the digested DNA was separated on a 0.8% agarose gel. The gel was 
depurinated in 0.25 M HCL and denaturated in 0.4 M NaOH before transferred overnight to 
a BrightStar®-Plus positively charged nylon membrane (Ambicon) by gravitational flow. The 
DNA was UV cross-linked to the membrane. 
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The integrants were screened using probes against the 5’-end of the pfap2-mu gene. 
The pfap2-mu probe was PCR amplified using the S1/S2 primer pair (Table 1) with the 
following conditions: 15 sec denaturation at 98°C, 30 sec annealing at 55°C, and elongation 
45 min at 68°C; the cycle was repeated 35 times. The PCR product was purified using a 
QIAquick PCR purification kit (Qiagen). 
The probe was 32P-labelled by random priming using the Redoprime-II random prime 
labelling system (GE Healthcare). The target DNA was denatured for 5 min at 96°C and 
cooled on ice for 5 min. Denatured DNA was added to the labelling reaction mix (Klenow 
fragments, dNTPs, random hexamers), then 32P dATP (3000 Ci/mM) was added and the mix 
was incubated for 15 minutes at 37°C and the reaction was stopped using TE buffer. 
Unincorporated nucleotides were removed using Ilustra Microspin G-25 columns (GE 
Healthcare) and hybridization was performed overnight at 60°C, in a solution containing 6x 
SCC buffer, 2xDenhardt’s, 0.1% SDS, 100 μg/ml of sheared herring DNA. Membranes were 
washed two times at 60°C, with 2×SSC buffer and exposed to an Amersham Hyperfilm MP 
(GE Healthcare) at −80°C. 
 
Fluorescence microscopy 
Localization of fluorescent protein-tagged pfAP2-mu in transfected parasites was 
analyzed through direct detection of the green fluorescence in paraformaldehyde fixed 
parasite samples and through imunofluorescence assays (IFA). For IFA, thin smears of 
parasite cultures were air dried and fixed using 100% methanol at -20°C for 2 minutes. The 
fixed cells were washed with PBS. After washing, the slides were incubated for 1 h at RT 
with mouse anti-GFP (1:20, Roche) antibody diluted in 3% bovine serum albumin (w/v) in 
PBS. Cells were washed three times with PBS and incubated with IgG-specific secondary 
antibody coupled with Alexa Fluor® 488 (1:400, Sigma) for 1 h at RT and then washed 3 
times with PBS. 
The smears were mounted for microscopic examination with vectashield mounting 
medium with 4’,6-diamidini-2-phenylindole (DAPI) (Vector). Images were acquired using a 
Zeiss LSM510 laser scanning confocal microscope (Carl Zeiss Jena GmbH, Germany) and 
images were processed using Zeiss LSM Image Browser software version 4.0.0.157. 
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Results 
To localize pfAP2-mu in the parasite, we have engineered P. falciparum Dd2 parasites 
stably expressing GFP fused to pfap2-mu gene under the control of its endogenous 
promoter, using a single-cross-over homologous recombination strategy (Figure 2A). To 
ensure authentic and functional expression of this chimaera, the gfp-coding sequence was 
appended to the 3-end of the endogenous pfap2-mu gene. WR99210 resistant parasites 
were obtained five weeks after transfection and the integration of the GFP-tag construct 
into the pfap2-mu locus was tested for by PCR and Southern blot analysis. Evidence that 
the plasmid had integrated was provided by the detection of PCR product that amplified 
the pfap2-mu-GFP fusion (expected fragment size: 2000) and the lack of a product for the 
Dd2 wild-type locus (Figure 2B). Southern blot analysis confirmed the correct integration of 
the GFP-tag construct into the pfap2-mu locus. A 2000 bp product corresponding to the 
pfap2-mu-GFP fusion was detected in schizont genomic DNA isolated from transgenic 
parasites but not in wild-type Dd2 parasites (Figure 2C). The transfected parasites did not 
show evidence of any growth defect as compared to the wild type Dd2 parasite (data not 
shown), indicating that the addition of a C-terminal GFP-tag did not affect asexual 
multiplication of the parasite in vitro.   
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Figure 2. GFP tagging of pfap2-mu. (A) Schematic representation of the single-cross-over 
homologous recombination strategy showing the wild type pfap2-mu locus (top panel); the pH-
pfap2-mu-GFP plasmid containing ~1500 bp of the 3’ end coding sequence of pfap2-mu fused in 
frame with the GFP sequence (middle panel); and the recombined pfap2-mu-GFP locus resulting 
from integration of the GFP-tag construct (lower panel). Transcription termination and 
polyadenylation of the pfap2-mu-GFP transgene are ensured by the presence of the Hrp2-3’ 
untranslated region (UTR) of P. falciparum histidine-rich protein 2. The human dihydrofolate 
reductase (hDHFR) represents the positive drug selection marker for WR99210. The positions of PCR 
primers (arrows), the enzyme digestion sites used to detect integration along with the expected 
fragment sizes and the pfap2-mu probe hybridization sites (blue bar) are indicated in the figure. (B) 
Agarose gel image showing integration of pH-pfap2-mu-GFP plasmid by PCR on the transfected 
parasites. The Dd2
 
DNA was used as a control. The top panel shows integration of the GFP-tag 
construct into the pfap2-mu locus using the primers P1 and P2 (expected fragment size: 2000 bp). 
The lower panel shows the presence of the pfap2-mu locus, using the P3 and P4 primers (expected 
fragment size: 800 bp). (C) Confirmation of integration by Southern blot analysis of transfected 
parasites. Genomic DNA from P. falciparum strain Dd2 and transgenic parasites was digested with 
ClaI and NcoI and separated on a 0.8% agarose gel. Lane 1: Molecular marker; Lane 2: 
pH-pfap2-mu-GFP plasmid; Lane 3: Dd2 (control) and Lane 4: Dd2::pH-pfap2-mu-GFP line. The blot 
was probed with a pfap2-mu probe (see panel A). The band expected from a single-site crossover 
integration of the GFP tag into the 3’end of the pfap2-mu gene (expected fragment size: 2000 bp) 
was observed. The band expected for the digested plasmid (expected fragment size: 8200 bp) was 
also seen. A single band was observed for the parental strain (expected fragment size: 3400 bp) that 
was absent in transgenic parasites. 
 
Chapter 8 – AP2-mu localization studies 
 
 198 
 
Figure 3. Localization of pfAP2-mu protein by direct fluorescent microcopy. The transgenic parasite 
population was examined by direct fluorescence microscopy to detect GFP (Green). Nuclei were 
labelled with DAPI stain (blue) prior to analysis. The merged image of the two is also shown together 
with the corresponding bright field image. 
 
Fluorescence images of fixed pfap2-mu–GFP parasites were taken at different 
intraerythrocytic stages. Although the fusion protein was seen in late trophozoite stage as 
a weak fluorescence signal (Figure 3), this result was not reproducible. On the other hand, 
the imunofluorescence microscopic examination of transgenic parasites using an anti-GFP 
antibody revealed that the pfap2-mu–GFP fusion protein was expressed during the schizont 
state (Figure 4). The AP2-mu-GFP chimeras appeared to localize throughout the cytoplasm 
in trophozoites (Figures 3 and 4). In schizonts GFP fluorescence was detected at multiple 
punctuated subcelluar structures (Figure 4).  
The lack of detectable fluorescence by direct observation can be due to improper folding or 
instability of the encoded chimeric GFP. Additionally, this result could be attributed to GFP 
expression having a lesser detection signal than immunocytochemistry using Alexa-
conjugated secondary antibodies, which can amplify the signal (Patterson, Knobel et al. 
1997). 
No expression was observed during the ring and trophozoite stages (data not shown). 
Fluorescent images shown in Figure 4 are representative of pfAP2-mu-GFP expression 
during the schizont stage. Fluoresecent signal was visibly concentrated over nucleated 
(infected) erythrocytes, as indicated by co-localised DAPI fluorescence (Figure 4, fourth 
column). P. falciparum wild type Dd2 parasites were tested as a control for the specificity 
of GFP localization (Figure 5). In the latter, low density fluorescent signal occurred 
sporadically in the preparation, but was not associated with nucleated (infected) 
erythrocytes. 
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Figure 4. Confocal microscopy using anti-GFP antibody in the pfap2-mu-GFP transgenic line. Four 
representative fields (rows) of labelled GFP transgenic parasites, showing the localization of pfAP2-
mu-GFP fusion protein in schizonts. The first column of images shows the bright field, the second 
column DAPI staining of parasite DNA, the third represents GFP fluorescence and the fourth column 
all images merged. In schizonts, small punctuated subcellular structures of GFP fluorescence were 
observed.  
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Figure 5. Confocal microscopy using anti-GFP antibody in P. falciparum wild type Dd2 parasites 
(negative control). Three representative fields (rows) of labelled Dd2 parasites. The first column of 
images shows the bright field, the second column DAPI staining of parasite DNA (blue), the third 
represents GFP fluorescence (green) and the fourth column all images merged. Only faint 
background fluorescence is visible and is not associated with nucleated (infected) erythrocytes.  
 
Discussion 
We have demonstrated that a GFP-tagged pfAP2-mu can be expressed and detected in 
the parasite. Expression of the pfAP2-mu-GFP protein was detected in trophozoites by 
direct observation and in schizonts using an anti-GFP antibody while protein expression 
was either expressed in undetectable amount or not expressed during ring stage. 
Additional experiments are necessary in order to determine the stage specific expression 
and exact localization of the AP2-mu protein in P. falciparum. These experiments should 
include the cloning of pfap2-mu–GFP parasites by limiting dilution, in order to obtain a pure 
parasite population expressing pfAP2-mu-GFP protein as a replacement for the chimaric 
population used in this study. Future studies will be needed to confirm the expression of 
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pfap2-mu–GFP fusion protein by western blot and to colocalize pfAP2-mu-GFP protein 
using different cell compartment markers.  
During the blood stage of malaria infection, the parasite internalizes and degrades 
massive amounts of haemoglobin in the digestive vacuole. One of the processes described 
for the delivery of haemoglobin into the digestive vacuole was the mechanism mediated by 
membrane-bound vesicles (clathrin coated vesicles) (Hong-chang et al. 2009). These 
membrane-bound vesicles have specific coat proteins (such as clathrin) that are important 
for cargo selection and direction of transport between donor and acceptor compartments. 
Clathrin coats contain both clathrin (acts as a scaffold) and adaptor proteins (AP), that link 
clathrin to receptors in coated vesicles. AP complexes connect cargo proteins and lipids to 
clathrin at vesicle budding sites, as well as binding accessory proteins that regulate coat 
assembly and disassembly (Edeling et al. 2006; Owen et al. 2004; Robinson et al. 2004). 
Interestingly, the pfap2-mu gene encodes a clathrin mu adaptor protein that is a subunit of 
the AP2 adaptor, associated with the plasma membrane and responsible for endocytosis. 
Consequently, mutations in this protein may alter the adaptor binding specificity affecting 
the transport of haemoglobin or other proteins by clathrin coated vesicles to the digestive 
vacuole. The implications of these mutations to artemisinin resistance phenotypes are 
unclear in the absence of further studies of structure and function of the adaptor complex 
protein in Plasmodium spp. 
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Chapter 9 – Discussion 
 
Malaria is a major public health problem which is further exacerbated by P. falciparum 
drug resistance. Over the last few decades the global spread of parasite resistance to 
almost every frontline antimalarial drug has challenged malaria control programs (WHO 
2010a; Petersen et al. 2011). To deal with this situation artemisinin based combination 
therapies have been introduced and widely deployed in malaria endemic regions (Lin et al. 
2010; WHO 2013f). The characteristic rapid antimalarial action of the artemisinins (White 
1997), combined with their extremely short elimination half-lives (Hastings et al. 2002; 
Stepniewska and White 2008) has led to the hope that resistance to artemisinin would 
never emerge or would be very slow to develop, since parasite exposure to subtherapeutic 
drug levels is thought to be very brief. Unfortunately, even the artemisinins seem to be 
losing efficacy in the Greater Mekong subregion (Ashley et al. 2014; WHO 2014). In order to 
preserve the most efficacious drug in controlling malaria infections in SE Asia it is crucial 
that we understand the underlying mechanisms giving rise to resistance to this class of 
drugs. 
 
9.1.ARTEMISININ RESISTANCE OR TOLERANCE DEBATE 
Artemisinin resistance/tolerance remains a controversial issue ever since the discovery 
of the first suspected cases of resistance. The standard definition of antimalarial resistance 
includes treatment failure; a parasite is considered resistant if is able to survive and/or 
multiply despite the administration of adequate drug dosage and confirmation of adequate 
antimalarial concentration present in the patient’s blood. Artemisinin resistance in the 
Greater Mekong subregion, characterized by a phenotype of delayed parasite clearance in 
the first few days after the treatment, does not fulfill this standard definition of resistance. 
Despite the lengthening of parasite clearance times, artemisinins still cure patients with 
malaria after the administration of artesunate monotherapy for 7 days (cure rates at day 28 
after treatment ranging from 92% to 100%) (Noedl et al. 2008; Noedl et al. 2010; Bethell et 
al. 2011; Kyaw et al. 2013). In any case, any sign of artemisinin decreased effectiveness is 
alarming. Due to its very high parasite killing rate (White 1997), a delay in the speed at 
which parasites are cleared after artemisinin treatment can be considered as an early sign 
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of resistance. Long-lasting infections increase the risk of transmission and as artemisinins 
become less effective, a higher number of parasites are exposed to the partner drug, thus 
increasing the probability that parasites resistant to both artemisinin and partner drug will 
emerge. 
Detecting early signs of drug resistance can be very challenging, particularly in the era of 
ACT treatment. First, the short elimination half-life of artemisinins (Duc et al. 1994; de Vries 
and Dien 1996) can lead to high recrudescence rates after artemisinin monotherapy 
(Meshnick et al. 1996; Giao et al. 2001). Second, since artemisinins are used in combination 
with other drugs a decrease in artemisinin susceptibility will not be directly reflected in a 
significant increase in clinical failures, which are strongly influenced by resistance to the 
partner drug. In fact, slower clearance phenotypes are associated with high cure rates after 
ACT treatment (Dondorp et al. 2009; Ashley et al. 2014). Resistance to CQ and SP was only 
recognized after it was already widespread and after treatment failure rates were already 
very high. Nowadays, we have better monitoring and surveillance methods so we are in a 
much better position to monitor the emergence of drug resistance in “real time”. For these 
reasons, we should not wait until artemisinin tolerance reaches the threshold at which 
artemisinins start to fail and become a clinical problem to try to understand how resistance 
to this class of drugs may evolve and spread.  
The delayed parasite clearance phenotype is now at the core of the current WHO 
working definition of artemisinin resistance; artemisinin resistance is confirmed if parasites 
persist for 7 days after treatment with artemisinin monotherapy therapy or the presence of 
parasites at day 3 followed by recrudescent infection during follow-up (WHO 2011a). Since 
news of artemisinin resistance emerged intense investigation in this subject led to the 
development of improved drug susceptibility assays and to identification of a potential 
genetic marker of resistance. Standard 48 h in vitro tests could not detect in vivo slow 
parasite clearance. New assays, which better simulates in vivo drug concentrations 
revealed the artemisinin tolerance phenotype to be associated with ring stage parasite 
susceptibility differences (Witkowski et al. 2013; Chotivanich et al. 2014). Additionally, the 
clinical slow clearance phenotype has recently been associated with several polymorphisms 
in the propeller region of a kelch protein (Amaratunga et al. 2014; Ariey et al. 2014; Ashley 
et al. 2014). These findings will improve the capacity for and utility of molecular and in vitro 
artemisinin resistance surveillance. 
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Nevertheless, we should not put “all eggs in one basket”. It is crucial that our efforts to 
quantify and track parasite susceptibility to artemisinins do not neglect the importance of 
the partner drugs, given that the high failure rates observed after ACT treatment can also 
be caused due to resistance to the partner drug. In fact, treatment failure rates with 
artesunate and mefloquine in combination have increased in the Thai-Cambodian border 
(Vijaykadga et al. 2006; Carrara et al. 2009; Rogers et al. 2009) and this high failure rate can 
be explained by solely the presence of mefloquine resistance, which was confirmed before 
the introduction of the artesunate-mefloquine combination therapy (Boudreau et al. 1982; 
Nosten et al. 1991). Furthermore, a recent trial conducted in Cambodia reported a high 
failure rate after dihydroartemisinin-piperaquine treatment suggesting that piperaquine 
resistance is also emerging (Saunders et al. 2014). Moreover, there is also a real risk that 
resistance can emerge de novo elsewhere, as a result of the same or a different set of 
genetic changes. Proper monitoring of P. falciparum susceptibility to both artemisinins and 
partner drugs across the entire malaria endemic world is imperative, but particularly in 
sub-Saharan Africa, since the emergence of resistance there should it occur, would 
undoubtedly lead to increased morbidity and mortality. 
In this context, the main aims of this thesis were to identify and characterize the genetic 
determinants responsible for the artemisinin resistant phenotype observed in a lineage of 
P. chabaudi drug-pressured parasites. Initially, we identified a unique mutation in a gene 
encoding the mu-chain of the AP2-adaptor complex in a P. chabaudi parasite displaying 
high level of artemisinin resistance. Afterwards we investigated the importance of this and 
two other molecular markers identified in the rodent model, in modulating susceptibility to 
artemisinins in P. falciparum natural populations.  
 
9.2.ARTEMISININ RESISTANCE PHENOTYPE IN RODENT MALARIA 
In Chapter 4 we have characterized a parasite resistant to artemisinin derived from a 
CQ resistant parasite after prolonged and progressive artemisinin selection (Afonso et al. 
2006b). Using whole-genome sequencing we identified one point mutation in a gene 
encoding an AP2 adaptor protein, a component of the endocytic machinery. AP2-mu 3D 
structure homology models indicate that the mutated residue interacts with a cargo 
recognition sequence, suggesting that the endocytosis and trafficking of membrane 
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proteins is modified in artemisinin resistant rodent malaria parasite. This provides new 
insights into possible mechanisms of resistance to artemisinin and its derivatives.  
 
9.3.CORRELATION OF IN VITRO PARASITE SUSCEPTIBILITY AND POLYMORPHISMS IN 
CANDIDATE MOLECULAR MARKERS 
The DNA sequence analysis of pfap2-mu gene in Brazil, São Tomé and Rwanda isolates 
revealed a total of 12 polymorphic sites, consisting of five non-synonymous and 4 
synonymous mutations and three insertions. A polymorphism similar to P. chabaudi I568T 
was not detected in any of the P. falciparum isolates. One non-synonymous mutation 
(160N) was weakly correlated with in vitro responses to dihydroartemisinin in isolates from 
Rwanda (Chapter 4).  
Association between the IC50 to QN, CQ, MDA, LUM, PIP and DHA and P. falciparum 
polymorphisms in pfubp1, pfap2-mu and pf26S-protSU was assessed in isolates obtained 
from a clinical trial of AL and AS + AQ in Burkina Faso. Data revealed that polymorphisms in 
pfubp1 and pf26S-protSU, can modulate in vitro responses to Lumefantrine. Additionally, 
this study is in agreement with the recent suggestion that polymorphisms in pfap2-mu may 
contribute to P. falciparum susceptibility to multiple drugs. Further studies are necessary to 
further confirm the importance of these new molecular markers in modulating P. 
falciparum antimalarial drug susceptibility. 
 
9.4.CORRELATION OF IN VIVO PARASITE SUSCEPTIBILITY AND POLYMORPHISMS IN 
THE CANDIDATE MOLECULAR MARKERS 
In Chapter 5 we genetically characterized the recently described Kenyan 
sub-microscopic persistent parasites. These parasites were significantly more likely to carry 
mutant alleles of the pfap2-mu and pfubp1 genes than the baseline population suggesting 
that the sub-microscopic persistency phenotype is genetically determined. These 
sub-microscopic parasites were also associated with a higher transmission potential and 
with an elevated risk of recurrent infections (Beshir et al. 2013). Taken together, these 
results point towards the necessity for further research on the public health impact of 
these sub-microscopic parasites and the role of these loci as in vivo markers of parasite 
survival after ACT treatment. 
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9.5.FUNCTIONAL ANALYSIS OF THE PFAP2-MU GENE 
In order to further evaluate the role of pfap2-mu gene in artemisinin susceptibility 
modulation and improve our understanding of the underlying biological mechanisms we 
functionally characterized this gene using transfection techniques (Chapters 7 and 8). The 
transgenic parasites carrying the 160Asn allele of pfap2-mu were significantly less sensitive 
to DHA, QN and CQ suggesting a general mechanism which modulates the drug response to 
different antimalarial drugs (Chapter 7). This broad mechanism can directly contribute for 
the emergence of artemisinin resistance but also indirectly, by sequentially decreasing the 
efficacy of the partner drugs, exposing the artemisinin component to selective pressure. 
This selective pressure could subsequently facilitate emergence of new foci of tolerance to 
artemisinins. Further experiments are needed to investigate the role of pfAP2-mu in 
modulating parasite susceptibility to other ACT partner drugs not evaluated in this study, 
namely amodiaquine, piperaquine and pyronaridine.  
 
We have generated a parasite stably expressing a GFP-fused pfap2-mu and we showed, 
for the first time, that the pfAP2-mu fused with GFP is expressed in trophozoites and 
schizonts stages (Chapter 8). These transgenic parasites will allow further studies into the 
molecular mechanisms of clathrin-mediated endocytosis and drug resistance in P. 
falciparum malaria. 
 
9.6. SE ASIA PHENOTYPE VS AFRICAN PHENOTYPE 
ACT efficacy in Africa remains high (Ashley et al. 2014; Zani et al. 2014) and until now, 
there are no signs of resistance in this continent. However, we recently reported 
persistency of sub-microscopic P. falciparum parasites until day 3 after ACT 
treatment in Kenyan children.  Children carrying such parasites were significantly more 
likely to be infectious to mosquitoes and experience late treatment failure (Beshir et al. 
2013). Interestingly, these persistent sub-microscopic parasites carry a specific genetic 
signature including the wild type CVMNK pfcrt haplotype, the NFD pfmdr1 haplotype and 
the 160N/T pfap2-mu and 1528D pfubp1 mutations (Henriques et al. 2014a). It is important 
to note that this phenotype appears to be significantly different from the slow clearance of 
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P. falciparum infections reported in Southeast Asia. Firstly, by microscopy all infections 
were cleared before day 3 after the ACT treatment. Secondly, the Southeast Asian isolates 
have a different genetic signature, as they are known to carry the K76T pfCRT 
mutation, and pfmdr1 polymorphisms are not associated with reduced artemisinin 
susceptibility (Imwong et al. 2010). As far as we know, slow clearing Cambodian isolates do 
not carry the 160N/T pfap2-mu polymorphisms (Henriques et al. 2014a), but this requires 
confirmation. On the contrary, slow parasite clearance of Southeast Asian parasites has 
recently been linked with point mutations in the pfk13 kelch propeller domain. We are 
currently evaluating this gene in P. falciparum isolates from eastern Kenya. Functional 
analysis of pfap2-mu in vitro revealed that transgenic parasites constitutively expressing 
the 160Asn mutant form of pfap2-mu were significantly less sensitive to dihydroartemisinin 
using a standard 48 hour drug assay, but did not demonstrate increased survival in the ring 
stage parasite survival assay (Henriques et al., submitted; Chapter 7). Taken together, these 
findings suggest that modulation of artemisinin sensitivity in an African context clearly 
manifests as a different phenotype from the one described in Cambodia with different 
genes and multi-locus genotypes implicated. In fact, some African slowly clearing infections 
described recently are not associated with polymorphisms in the kelch protein, suggesting 
the contribution of other genetic factors (Ashley et al. 2014). 
Our interpretation is that polymorphisms in pfap2-mu may not confer resistance per se 
but they could be in some way advantageous for the parasites, enhancing their likelihood 
of survival. This fitness enhancement could be explained by a gain in biological robustness. 
Biological robustness is a major evolutionary mechanism that allows mutations to 
accumulate in the organism background while maintaining a little changed-changed 
functional phenotype. The role of this mechanism during the acquisition of pyrimethamine 
resistance in P. falciparum was recently described. Amplification of the GTP cyclohydrolase 
I increased the robustness of the folate pathway allowing the fixation of subsequent 
mutations in DHFR that could be deleterious/disadvantageous in the absence of GTP 
cyclohydrolase I amplification (Kumpornsin et al. 2014). In a similar way, pfap2-mu 
polymorphisms can increase the robustness of the parasites by reducing the fitness cost 
associated with the acquisition of mutations in other genes directly involved in artemisinin 
resistance. 
Alternatively, AP2-mu could be directly involved in the mechanism of artemisinin 
resistance. Drug resistance may not arise in a single step, but as a long and complex process 
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during which parasites become gradually more and more tolerant to the drug. This is 
believed to be achieved through the stepwise accumulation of genetic changes in the same 
gene or in different genes (Mita et al. 2014). Therefore, it is possible that mutations in AP2-
mu are an early step during the development of artemisinin resistance, and that additional 
genetic changes would be required before a fully resistant parasite genotype is able to 
emerge.  
 
9.7.POSSIBLE MODEL OF ARTEMISININ RESISTANCE MEDIATED BY UBIQUITIN-
DEPENDENT ENDOCYTOSIS VIA CLATHRIN-COATED VESICLES 
Transmembrane proteins are a diverse group of proteins containing receptors, ion 
channels, transporters, anchors and pumps that are responsible for a variety of key cellular 
mechanisms. The availability and localization of these proteins is dynamically regulated by 
endocytosis. Transmembrane proteins destined for internalization are packaged into a 
vesicle, which is invaginated due to the action of various accessory adaptor proteins and 
clathrin (Kelly and Owen 2011). The AP-2 adaptor complex interacts with the internalization 
signal of the cargo protein and starts recruiting clathrin and other accessory proteins 
involved in the clathrin mediated endocytosis (Bonifacino and Traub 2003). After 
endocytosis, proteins enter the early endosome where they are sorted, and are either 
recycled back to the plasma membrane or targeted for destruction (Le Roy and Wrana 
2005). 
Here we suggest a speculative model (Figure 9.1) for the involvement of AP2-mu, UBP1 
and 26SPS in artemisinin resistance based on the ubiquitin-dependent endocytosis via 
clathrin-coated vesicles. Artemisinin resistance could conceivably have its foundation on 
one or a combination of the following molecular interactions: 
 
1 – Regulation of membrane protein abundance 
Several studies have shown that ubiquitination acts as a signal for internalization and 
sorting of certain membrane proteins (Kolling and Hollenberg 1994; Hicke 2001; Hicke and 
Dunn 2003). Together, ubiquitin and deubiquitinating enzymes provide a reversible 
modification that regulates the fate of target proteins (Bonifacino and Weissman 
1998).Ubiquitination is a process by which ubiquitin monomers form covalent bonds with 
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the target protein. Deubiquitinating enzymes play the antagonistic role, by removing the 
ubiquitin monomers from target substrates (Nijman et al. 2005). A poly-ubiquitin chain of 
at least four ubiquitin molecules can trigger degradation of the substrate by the 26S 
proteasome into peptides and free ubiquitin (Hicke and Dunn 2003; Komander and Rape 
2012). On the contrary, proteins modified by a single ubiquitin may escape proteasomal 
recognition and be recycled back to the plasma membrane through sorting and recycling 
endosomes (Hegde and DiAntonio 2002; Dupre et al. 2004). 
Modifications in AP2-mu (mu subunit of clathrin associated adaptor protein 2), UBP1 
(deubiquitinase enzyme) and 26S-protSU (subunit of the 26S proteasome) proteins may 
modulate artemisinin resistance by controlling the abundance of important membrane 
proteins, like MDR1, for example. Interestingly, it has been shown that a member of the 
ABC family of transporters accumulates in the plasma membrane of yeast mutants with a 
defective endocytosis pathway or ubiquitination-deficiencies (Kolling and Hollenberg 1994). 
Furthermore, changes in the clathrin-dependent endocytosis and trafficking of mdr1-
encoded P-glycoprotein (in human cancer cell lines) alter both its partition between cell 
membrane and intracellular pools, as well as drug resistance levels (Kim et al. 1997). 
Finally, P-glycoprotein distributions within cancer cells and their respective drug-resistance 
phenotypes are also mediated by ubiquitination (Zhang et al. 2004). Therefore, it is possible 
that mutations on the three candidate markers increase the half-life of MDR1 by 
preventing its degradation by the proteasome. 
 
2 - Regulation of stress responses 
The ubiquitin-proteasome pathway plays a critical role in stress response by degrading 
misfolded or damaged proteins, which would otherwise accumulate and harm the cell 
(Dantuma and Lindsten 2010; Shang and Taylor 2011). Artemisinin action has been linked 
to the generation of radicals, which damage the parasite (Meshnick et al. 1993; Meshnick 
1994a). Modifications on the ubiquitin-proteasome pathway could conceivably increase the 
probability of parasite survival despite the putative oxidative stress generated by 
artemisinin action. 
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3 – Dormancy  
Resistance to artemisinins has been related to general biological features like dormancy 
(Cheng et al. 2012; Teuscher et al. 2012). The parasite can enter a state of reversible 
quiescence by perhaps activating the autophagy-dependent survival mechanism, which 
allows the parasite to recycle both nutrients and energy during dormancy. Interestingly it 
was recently described that the autophagy-mediated degradation can be regulated by the 
ubiquitin-proteasome pathway (Korolchuk et al. 2010; Klionsky and Schulman 2014). 
Experimental studies on the molecular interactions between the ubiquitin-
proteasome system, and clathrin-mediated endocytosis may provide important insights 
regarding artemisinin action and resistance mechanisms. 
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Figure 9.1 – Possible model for the involvement of AP2-mu, UBP1 and 26SPS in artemisinin resistance based on the ubiquitin-dependent endocytosis via 
clathrin-coated vesicles 
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Chapter 10 – Future Perspectives 
 
Pharmaceutical research has not kept up with the growing resistance to antimalarials. P. 
falciparum develops resistance much faster than the rate of new pharmaceuticals is being 
developed and a loss of the artemisinins to resistance would have disastrous consequences 
for malaria control. Although it may not be possible to prevent the emergence and/or 
spread of artemisinin resistant parasites, understanding their mechanisms of action and 
resistance can provide crucial information to maximise the life expectancy of this important 
class of antimalarial drugs.  
 
The main hypothesis of this thesis, that the three loci that mediate ART resistance in 
experimentally selected in P. chabaudi will similarly modify ART response in natural 
parasite populations of P. falciparum, was partially supported by two of the three genes 
investigated, pfubp1 and pfap2-mu. Nevertheless, there are some gaps in evidence that 
should be addressed in future studies:  
 
 Directional selection of pfubp1 and pf26S-protSU polymorphisms should be 
investigated on day 3 after ACT treatments, and not only on day fail; 
 It will be important to compare in vitro susceptibility of the transgenic parasites to 
that of Cambodian parasite lines with known clearance time phenotypes;  
 Further work shoud include gene replacement experiments and explore the impact 
of pfap2-mu mutations in a chloroquine sensitive background 
 
This thesis has shed light on the complex issue of P. falciparum resistance to 
artemisinins and will foster new studies to understand its mechanisms. It also confirmed 
the feasibility of coupling the P. chabaudi model to validation in the P. falciparum parasite 
in vivo and in vitro for identifying novel drug resistance loci. 
 
Another weakness of our study was that some isolates of interest were not sequenced at 
all loci, mainly due to exhaustion of small, finite blood samples. Although the limited 
number of observations in each of the treatment arms precluded comparisons of effect 
estimates due to lack of power, an exploratory stratification was carried out, generating 
odds ratios with very wide confidence intervals (data not shown) 
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Further studies are needed to determine the public health impact of the  newly 
observed phenomenon of persisting sub-microscopic parasites and their relation with 
particular mutations in the pfap2-mu and pfubp1 genes. To achieve this we intend to 
analyse samples from a recent ACT clinical trial (ClinicalTrials.gov identifier: NCT01939886) 
conducted in 2013 in Mbita, Kenya, the same location where the first clinical trial was 
conducted, 4 years earlier (Beshir et al. 2013; Sawa et al. 2013; Henriques et al. 2014a).  
 
We also plan to extend the functional studies of P. falciparum pfap2-mu 
polymorphisms, using Zinc-Finger Nuclease (ZFN)-mediated gene editing, a new technology 
that allows the production of mutant parasites with much higher efficiency and reduced 
timelines. We intend to generate transgenic lines harbouring the P. falciparum 160Asn 
mutation and the P. chabaudi 592Thr resistant mutation using both laboratory adapted 
strains and one Kenyan clinical isolate (HL1204), recently adapted to in vitro culture (van 
Schalkwyk et al. 2013). Parasite clones expressing the variant alleles will then be tested for 
their susceptibility to a panel of antimalarial drugs including artemisinin derivatives and 
their partner drugs. An alternative approach for gene editing is the use of clustered, 
regularly interspaced, short palindromic repeat (CRISPR) technology. This new strategy 
takes advantage of a short RNA to guide the Cas9 endonuclease to cause a double strand 
breaks at any specific genomic loci and has been recently adapted in P. falciparum (Ghorbal 
et al. 2014). 
These allelic replacement studies would significantly improve our understanding on how 
polymorphisms in AP2-mu can modify ART sensitivity in isolates with different 
backgrounds, including chloroquine-sensitive genotypes.  
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